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Abstract 
Gangliosides are a family of membrane lipids enriched in the central nervous system (CNS) 
that play an important role in cell signaling processes on the membrane. Alterations in the 
homeostatic distribution of the a-series family of gangliosides has been observed in both pre-
clinical models and human patients with neurodegenerative diseases and injuries, such as 
Alzheimer’s disease (AD) and strokes. Ganglioside dysregulation has been implicated as an 
important mechanisms driving pathology in the aging brain, yet there is little information on 
where and when these lipid changes occur as well as the role of dysregulation during 
neurodegeneration. Matrix-Assisted Laser Desorption/Ionization (MALDI) imaging mass 
spectrometry (IMS) is a novel imaging technique that can map the distribution of ionizable 
molecules on a sample in a 2-dimensional format, making it the ideal tool for analyzing 
gangliosides on post-mortem brain tissue sections. A comorbid rat model of stroke and Aβ 
toxicity, using an endothelin-1 (ET-1) induced unilateral striatal stroke together with 
intracerebralventricular (icv) injections of Aβ(25-35), was used to examine ganglioside 
dysregulation in response to neurodegenerative injuries of varying severity. Results indicated 
that ganglioside dysregulation was correlated with the severity of the neurodegenerative 
injury and showed a characteristic pattern of depleted protective complex gangliosides with 
accumulated toxic simple gangliosides at the site of injury. Transgenic (Tg) rats with a 
mutation in the Alzheimer’s precursor protein (APP) demonstrated a similar characteristic 
shift in ganglioside distribution during aging compared to wild-type (Wt) rats in brain 
regions which are susceptible to damage in AD, such as the white matter and hippocampus. 
Finally, chloroquine (CQ), a pharmacological inhibitor of ganglioside catabolism, was used 
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as a treatment for ganglioside dysregulation after injury in the rat comorbid stroke model. CQ 
was found to prevent ganglioside dysregulation acutely after stroke and was correlated with 
reduced pathology and functional impairments. These results support the hypothesis of 
ganglioside dysregulation as an important mechanism of neurodegeneration in the aging and 
injured brain and highlights the benefits associated with the restoration of ganglioside 
homeostasis after stroke injury. 
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Chapter 1  
1 Introduction 
The following chapter contains a review of the literature pertaining to the topics discussed 
in this work. Ganglioside dysregulation was examined in the context of neurodegeneration 
and aging in rats using a novel imaging technique. Relevant background information on the 
pathogenesis of ischemic stroke, Alzheimer’s disease (AD), and the co-morbidity of stroke 
and AD are presented, followed by a detailed description of gangliosides and their role 
during aging, injury, and neurodegenerative disease. Next, the MALDI imaging mass 
spectrometry technique used to examine the distribution of gangliosides in the brain is 
described. Finally, background information on a pharmacological compound used to 
prevent ganglioside dysregulation is provided. 
1.1   Ischemic stroke  
A stroke is the abrupt development of neurological deficits due to an interruption of blood 
supply, and thus oxygen, to the brain. These injuries can be either hemorrhagic or ischemic 
in nature. Ischemic strokes are most common, accounting for roughly 80% of all strokes, 
and occur as a result of blood vessel occlusion (Fluri, Schuhmnn, & Kleinschnitz, 2015). 
The brain region surrounding the occlusion is starved of oxygen and energy, setting off a 
cascade of pathological events that can lead to irreversible tissue damage. Excitotoxicity in 
the early stages of the ischemic cascade is caused by a massive release of the excitatory 
neurotransmitter glutamate (Lai, Zhang, & Wang, 2014). Neural cells have a large number 
of glutamate receptors which makes the brain particularly susceptible to excitotoxic 
damage, and thus ischemic injuries (Lai et al., 2014). Glutamate stimulates N-methyl-D-
aspartate (NMDA) receptors on the cell surface mediate the influx of calcium (Ca²⁺) into 
the cell. The increased Ca²⁺ then triggers a secondary intracellular Ca²⁺ overload which 
promotes apoptotic cell death (Randall & Thayer, 1992; Szydlowska & Tymianski, 2010). 
When excessive intracellular Ca²⁺ is taken up by mitochondria, reactive oxygen species 
(ROS) and free radicals are produced leading to oxidative stress, further perpetuating 
neurodegeneration (Castilho, Ward, & Nicholls, 1999; Zoppo et al., 2000). The 
pathological events in the ischemic cascade are not linear, but rather circular in nature, with 
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one factor affecting downstream events and also feeding back to exacerbate the initial 
triggering event.  
The region immediately surrounding the ischemic occlusion is termed the necrotic 
core, where irreversible cellular damage often occurs. The ischemic penumbra is a peri-
lesion area surrounding the necrotic core which is vulnerable to damage but can also be 
prevented depending on a number of variables, such as autophagy and inflammation (C 
Iadecola & Anrather, 2011). Autophagy is a mechanism in which intracellular components 
are broken down and recycled and can be considered a pro-survival mechanism for the cell 
when it selectively degrades damaged or malfunctioning cellular components. However, 
prolonged exposure to stress, such as an ischemic stroke, can over-activate this process, 
leading to apoptotic cell death (Debnath, Baehrecke, & Kroemer, 2005; Mizushima, 
Levine, Cuervo, & Klionsky, 2009). Microglia and astrocytes, the brain’s inflammatory 
cells, arrive at the site of injury, leading to an upregulation of pro-inflammatory cytokines, 
such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, macrophage inflammatory 
protein (MIP)-1α, and monocyte chemoattractant protein -1 (MCP-1) (Hawkins et al., 
2017; C Iadecola & Anrather, 2011; Zoppo et al., 2000). When neuroinflammation spreads 
outside of the necrotic core, the upregulation of pro-inflammatory cytokines can become 
pathological, leading to phagocytic engulfment and pro-apoptotic/autophagic signaling of 
potentially viable cells (Hawkins et al., 2017).  
Currently, the only effective treatment for stroke is recombinant tissue plasminogen 
activator (rtPA), an anti-clotting agent, which must be administered within a very narrow 
therapeutic window (within 3 hrs of stroke) and excludes individuals over the age of 80, 
those who take anti-coagulant medications, those with mild or recurring strokes, and those 
with comorbidities (Fluri et al., 2015; X. Liu et al., 2013; The National Institute of 
Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995). A review of rtPA 
administration in 2165 stroke patients at a Canadian teaching hospital revealed that 73% of 
patients were excluded from treatment as they arrived at the hospital more than 3 hrs after 
stroke onset. Of the total patients with ischemic stroke who were present at the hospital 
within 3 hrs, only 26% received rtPA treatment once the exclusion criteria listed above was 
factored in (Barber, Zhang, Demchuk, & Hill, 2001). Patients who do receive this treatment 
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have a significantly decreased risk of severe neurological impairments but it is 
accompanied by a 10 fold increase in the risk of intracerebral hemorrhage (Liu et al., 2013; 
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 
1995). Due to the multifactorial nature of the ischemic cascade, it is unlikely that a single 
target approach will be sufficient to temper the complex interaction of pathogenesis after 
stroke (Fisher, 1997; Liu et al., 2013). Thus, a better understanding of the key mediators of 
ischemic damage would allow for a more effective approach to treatment. 
Ischemic stroke can be modelled in animals to study the mechanisms governing the 
pathogenesis and test possible therapeutic interventions. The most common animal model 
of stroke is middle cerebral artery occlusion (MCAO) (Fluri et al., 2015; Longa, Weinstein, 
Carlson, & Cummins, 1989; Tamura, Graham, McCulloch, & Teasdale, 1981). This 
technique involves sending a suture through the common carotid artery until the MCA is 
reached and occluded for a predetermined period (generally 60-120 min in rats), after 
which time the occlusion is released and reperfusion begins. Different strains of rats were 
found to have distinct responses to MCAO injuries, making the choice of rat strain an 
important variable to consider in experimental stroke research. For example, Sprague-
Dawley rats were found to have considerable variability in stroke size in response to 
MCAO injuries while Wistar rats exhibited the most consistent results (Howells et al., 
2010; Ström, Ingberg, Theodorsson, & Theodorsson, 2013). Injection of the potent 
vasoconstrictive peptide Endothelin-1 (ET-1) is another common model of ischemic stroke. 
It is less invasive and results in lower mortality rates than MCAO, and can be administered 
directly into discrete brain regions (Fluri et al., 2015). ET-1 is generally administered 
topically or to the desired brain region via a stereotaxic injection, where cerebral blood 
flow is reduced up to 90% in the surrounding focal region, followed by reperfusion over 
several hours (Bogaert, Scheller, Moonen, Sarre, & Smolders, 2000; Fuxe et al., 1997). 
Thus, the ET-1 stroke model can be used to simulate smaller, “lacunar” infarcts that are 
common in the human aging brain. 
1.2  Alzheimer’s disease 
Age-related dementia has emerged as one of the biggest health problems of our time, 
affecting roughly 35.6 million people world-wide, with that number expected to triple by 
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2050 (Costantino Iadecola, 2013; The World Health Organization, 2012). It presents a 
devastating societal burden for caregivers and taxpayers alike, as it has become more costly 
to manage than both cancer and heart disease in the US (Hurd, Martorell, Delavande, 
Mullen, & Langa, 2013). Alzheimer’s disease (AD) is a neurodegenerative disease 
characterized by progressive cognitive decline and represents the most common form of 
dementia. Alois Alzheimer described four major neuropathological features of the disease 
including senile plaques, neurofibrillary tangles, hardening of arteries, and lipid granule 
accumulation (Chan et al., 2009; Foley, 2010; Iadecola, 2013). Patients with AD exhibit 
altered sensory perceptions most commonly manifesting as memory loss which 
progressively worsen leading to a wide array of behavioural deficits as the disease 
progresses. The cause of AD remains unclear; however, several genetic and non-genetic 
factors have been implicated.  
The amyloid cascade hypothesis was one of the most prominent theories of AD 
pathogenesis. Generally, it states that the accumulation and deposition of amyloid beta 
(Aβ) plaques in the brain lead to neuronal dysfunction and cell death (Goate et al., 1991). 
This theory posited that Aβ accumulation was the driving factor in the development of AD-
related symptoms and associated pathologies such as neurofibrillary tangles, inflammation, 
neuronal loss, and cognitive decline (Hardy & Higgins, 1992). However, increasing 
evidence has countered this hypothesis as the total amyloid burden was not found to be 
correlated with cognitive decline or even the manifestation of AD symptoms (Haass & 
Selkoe, 2007; McLean et al., 1999; Snowdon et al., 1997). Although Aβ is still considered 
an important factor in the pathogenesis of AD, attention has shifted from solid Aβ plaques 
to soluble oligomers of Aβ, in conjunction with other predisposing factors, as a major 
driver of the disease (Ferreira, Vieira, & Felice, 2007; Li et al., 2009; Tomiyama et al., 
2010). 
AD can present in either an early onset form (familial) or late onset form (sporadic). 
Genetic factors are thought to be the main cause of familial AD cases. Mutations in several 
genes regulating the cleavage and processing of amyloid precursor protein (APP) have 
been shown to upregulate the production of Aβ. APP is cleaved by proteases, β- and γ-
secretase, to form Aβ. Presenilin (PSEN) regulates the activity of γ- secretase to increase 
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the ratio of long chain Aβ42 to Aβ40, a toxic fragment of the Aβ protein. The presence of 
the apolipoprotein E4 (APOE4) gene has been found to increase the risk for familial AD 
and remains the most common genetic screening marker for individuals with a family 
history of early-onset AD (Bandaru et al., 2009; Carrieri, Bonafè, Luca, Rose, & Varcasia, 
2001; Sanan et al., 1994).  The main risk factor for the sporadic form of AD is age, which 
is hypothesized to interact with certain environmental and lifestyle factors along with 
existing conditions, such as stroke and diabetes, to initiate AD (Purnell, Gao, Callahan, & 
Hendrie, 2009; Reitz, 2012).  
The vascular system of the brain is thought to play a major role in the development 
and progression of AD. Roughly 90% of AD patients present with cerebral amyloid 
angiopathy (CAA), which occurs when Aβ (mostly Aβ40) deposits and accumulates in 
blood vessels, leading to narrowing of blood vessels and cognitive decline (Attems, 
Jellinger, Thal, & Van Nostrand, 2011). The narrowing of cerebral blood vessels increases 
the risk for ischemic stroke injuries and impedes the clearance of solutes from the brain 
(Jellinger, 2002; Soontornniyomkij et al., 2010). The occipital lobe is the most frequently 
and severely affected part of the brain for CAA, followed by the frontal lobe (Attems, 
Jellinger, & Lintner, 2005). As the disease progresses, accumulated Aβ leads to 
degeneration of vessel smooth muscle, leading to a thinning of vessel walls, making them 
more vulnerable to “mini aneurysms” and dysphoric, or structurally abnormal, vessel 
formation (Attems et al., 2011). Carriers of the APOE4 gene who develop late-onset 
dementia are at a higher risk of developing CAA (Trembath et al., 2007). Thus, the 
interaction of Aβ with the brain’s vasculature is a critical component of the pathogenesis of 
AD. 
Vascular dementia is the second most common form of dementia. It is characterized 
by the presence of vascular lesions and is commonly associated with the appearance of 
white matter lesions which can accumulate over time in a condition referred to as 
leukoaraiosis (Hachinski & Potter, 1987; Iadecola, 2013). This form of dementia is highly 
associated with cardiovascular risk factors such as stroke, hypertension, diabetes, 
hyperlipidemia and smoking. Many of the symptoms of vascular dementia overlap with 
those of AD, often being differentiated solely on the severity or location of 
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neurodegenerative or vascular lesions. White matter lesions can grow over time and are 
correlated with the evolution of cognitive impairments (Maillard, Carmichael, Fletcher, & 
Reed, 2012). Indeed, vascular risk factors are known to play a major role in the initiation 
and progression of dementia (Hachinski, Bowler, & Loeb, 1993; Steingart, Hachinski, & 
Lau, 1987; Thiel, Cechetto, Heiss, Hachinski, & Whitehead, 2014). 
 
1.3  Comorbidity of AD and Stroke 
A number of variables have been shown to correlate and/or increase the risk of developing 
AD such as atherosclerotic disease, atrial fibrillation, hypertension and adult-onset diabetes 
mellitus (Cechetto, Hachinski, & Whitehead, 2008; Cifuentes et al., 2015). In fact, the 
incidence of “pure” dementia is relatively rare, while a mixed vascular-degenerative 
presentation is quite common (Dodge, Chang, Kamboh, & Ganguli, 2012; Iadecola, 2013). 
Epidemiological evidence is particularly strong pertaining to the relationship between the 
incidence of stroke and the development of dementia. Approximately 25% of stroke 
survivors develop dementia (Jin, Østbye, Feightner, Di Legge, & Hachinski, 2008). 
Patients with both minor cerebral infarcts and AD lesions are more likely to develop the 
clinical manifestations of dementia with synergistic effects on dementia related pathology 
(Hachinski & Munoz, 2000; Snowdon et al., 1997). Elderly individuals are at a particularly 
high risk of “silent strokes”, or lacunar infarcts, which are ischemic lesions in small vessels 
that often do not produce observable deficits but can lead to accumulated damage over time 
(Masuda, Nabika, & Notsu, 2001). Patients with lacunar infarcts in the basal ganglia, 
thalamus, or white matter regions have demonstrated a high prevalence of dementia (Gold 
et al., 2005; Prins et al., 2004; Schmidt et al., 2005; Snowdon et al., 1997), therefore, the 
location of stroke injury is also a determining factor in the development of subsequent 
dementia. 
The interaction between stroke and AD has also been shown to be bidirectional, 
with increases in Aβ being associated with compromised vascular function (Grammas, 
Yamada, & Zlokovic, 2002). For example, Aβ plaques have been observed to accumulate 
around cerebral blood vessels leading to vascular degeneration (Kalaria, 2002). On the 
7 
 
other hand, APP protein has been observed to accumulate around the site of infarcts in rats 
(Kalaria et al., 1993). Additionally, hypoxia caused by hypoxia inducible factor 1α (HIF-
1α) was associated with increased Aβ production and cleavage by β-secretase (BACE1), 
which the authors suggest may contribute to triggering the amyloid cascade (Zhang et al., 
2007). Thus, a complex interaction exists between stroke and AD that can synergistically 
overlap to produce exacerbated pathology. 
Clinical findings of interaction and synergism between stroke and AD have been 
recapitulated in a number of animal models which have been useful in teasing apart the 
mechanisms involved. Synergistic interactions of pathology have been observed in rats 
who have received both icv injections of the toxic Aβ peptide 25-35 in addition to a focal 
ET-1 induced striatal stroke (Amtul et al., 2014; Whitehead, Cheng, Hachinski, & 
Cechetto, 2007; Whitehead, Hachinski, & Cechetto, 2005). These rats displayed increased 
neuroinflammation, progressive increases in infarct size, and performed worse on cognitive 
memory tasks than rats with just ET-1 stroke or Aβ toxicity alone. Another study using 
transgenic (Tg) APP rats with or without ET-1 stroke injuries, demonstrated that Tg rats 
with increased Aβ production displayed increased cognitive inflexibility on an operant set 
shifting task compared to Tg rat without a stroke or wild type (Wt) rats with stroke, 
suggesting a synergistic effect on cognitive impairment in the comorbid rats (Levit et al., 
2017).  
A correlation has been observed between individuals who carry the APOE4 gene 
and cerebrovascular disease (Kalmijn, Feskens, Launer, & Kromhout, 1996). The Canadian 
Study of Health and Aging examined the joint effect of stroke and APOE4 in 954 
participants and found that individuals who had both a stroke and were positive for the 
APOE4 gene displayed the highest prevalence of dementia (Jin et al., 2008). However, it 
was found that the effect of stroke on the incidence of dementia was not affected by the 
presence of the APOE4 gene, suggesting that stroke and APOE4 may increase the risk for 
dementia via independent mechanisms (Jin et al., 2008). Conversely, the PSEN1 gene has 
been shown to render neural cells vulnerable to hypoxia-induced apoptosis in vitro and was 
correlated with increased intracellular levels of Ca²⁺ (Mattson, Zhu, Yu, & Kindy, 2000). In 
vivo, PSEN1 knock-in mice display increased brain damage in response to a focal ischemic 
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reperfusion injury and worsened behavioural outcomes (Mattson et al., 2000). These 
studies suggest that the interaction between AD and stroke may be partially governed by 
specific genetic markers.  
Common neuropathological features are present in both AD and stroke, with vascular 
dysfunction being the most prevalent. Vascular cognitive impairment (VCI), an umbrella 
term which encompasses all cognitive disorders associated with cerebrovascular disease 
and injury, is thought to occur primarily due to reduced cerebral blood flow and damage to 
myelin, leading to cerebral atrophy and dysfunctions in connectivity within the brain 
(Appelman et al., 2009; Dichgans & Leys, 2017; Lawrence et al., 2013). VCI is a very 
common feature of senile dementia, making up roughly 75% of cases (Gearing et al., 1995; 
Hachinski, 2008). Another common neuropathological feature is neuroinflammation. The 
activation and proliferation of microglia and astrocytes, increased ROS, upregulation of 
inflammatory cytokines and nuclear factor kappa B (NFκB) are all neuroinflammatory 
events that are synergistically activated in the presence of both AD and stroke (Bales, Du, 
Holtzman, Cordell, & Paul, 2000; Cheng et al., 2006; Stoll, Jander, & Schroeter, 1998; S. 
N. Whitehead et al., 2005). The neuroinflammatory response after stroke is exacerbated by 
the presence of Aβ toxicity and is implicated as mechanism which can mediate the severity 
of cognitive impairments (Amtul et al., 2014; Li et al., 2011; Whitehead, Cheng, 
Hachinski, & Cechetto, 2007; Whitehead, Hachinski, & Cechetto, 2005). Indeed, anti-
inflammatory treatment has shown beneficial effects in reducing the exacerbated 
neuroinflammatory response and cognitive impairments associated with stroke and Aβ 
comorbidity (Whitehead, Cheng, Hachinski, & Cechetto, 2005). However, anti-
inflammatory agents alone are not sufficient to prevent the pathogenesis of either stroke or 
AD further investigate factors which may be mediating the synergistic interaction between 
stroke and AD. 
1.4  Gangliosides 
Over 60% of the mass of our brains are made up of lipids (Chang, Ke & Chen, 2009) yet 
their precise role in the development and pathogenesis of neurodegenerative diseases and 
injuries remains unclear. Changes in brain lipids are correlated with the progression of 
diseases, such as AD (Ariga, McDonald, & Yu, 2008). Indeed, lipid biomarkers may hold 
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the key to identifying individuals at risk of developing neurodegenerative diseases. 
Mapstone et al, used a lipidomics approach to identify several plasma phospholipids in 
peripheral blood samples that could predict, with 90% accuracy, the conversion from a 
cognitively normal phenotype to mild cognitive impairment or AD within a 2-3 year 
timeframe (Mapstone et al., 2014). These findings are particularly important given the 
disappointing results from biomarkers that target other AD-associated proteins in cerebral 
spinal fluid such as Aβ42 and Tau (Irizarry, 2004). Thus, a better understanding of the role 
of lipids in the aging brain may reveal important mechanistic clues as to the development 
of neurodegenerative diseases and the brain’s response to injury. One group of membrane 
lipids, called gangliosides, are of particular interest in the context of neurodegeneration as 
they have been shown to be altered in response to a number of neurodegenerative diseases 
and injuries. The following section provides background on ganglioside structure, function, 
as well as a review of the literature of their role in neurodegenerative diseases and injuries. 
 
1.4.1 Ganglioside Structure 
Gangliosides are part of a glycosphingolipid family that contain sialic acid residues. They 
have a wide variety of biological functions due to their location on the outer leaflet of 
plasma membranes (Lopez & Schnaar, 2009). They make up a crucial component of lipid 
rafts, or ganglioside-enriched microdomains (GEMs), where they effect the physical 
properties of the membrane as well as their function (Daniotti & Iglesias-Bartolomé, 2011; 
Sandro Sonnino & Prinetti, 2010). Lipid rafts are complexes made up of cholesterol, 
glycosphingolipids, and proteins which play an important role in signal transduction. The 
specific functions of lipid rafts varies depending on their composition which can lead to the 
segregation of rafts within the lipid bilayer based on, for example, the type of gangliosides 
present (Sonnino, Mauri, Ciampa, & Prinetti, 2013). Lipid rafts cluster molecules with 
similar properties together in order to facilitate the molecular interactions required for 
specialized cellular functions (Hooper, 1998). Gangliosides play an important role in 
stabilizing lipid rafts due to their physical structure, both within the phospholipid bilayer 
and on the outer leaflet of the membrane (Sonnino & Prinetti, 2010).  
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The hydrophobic portion of the ganglioside molecule is made up of the ceramide 
domain which contains a sphingosine moiety with a carbon chain of variable length 
attached to a fatty acid (Fig. 1.1). The ceramide domain acts to provide structural integrity 
on the membrane but is also suggested to play a more critical role in determining 
ganglioside function. Gangliosides with 18 carbons (d18:1) in their sphingosine moiety are 
most common in the CNS, however, gangliosides can also have shorter or longer carbon 
chains. The length of the carbon chain in the sphingosine moiety can alter the fluidic 
properties of the membrane which has functional consequences for glycoprotein 
interactions at the cell surface (Masserini, Palestini, & Freire, 1989; Sonnino & Chigorno, 
2000). Indeed, gangliosides with varying carbon lengths are thought to have unique 
functional roles in the brain (Sonnino & Chigorno, 2000), however, technical challenges in 
detecting and visualizing gangliosides with varying carbons lengths has made it difficult to 
examine this hypothesis. Alterations in the length of the carbon chain in the ceramide 
domain are thought to occur during ganglioside degradation and recycling processes, 
however the precise mechanisms remain unclear (Palestini, Masserini, Sonnino, & 
Tettamanti, 1990).  
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Figure 1.1: Ganglioside Structure. Gangliosides are composed of both a hydrophilic 
domain which extends into the extracellular space, and hydrophobic ceramide anchor 
(highlighted) embedded within the lipid bilayer. The hydrophilic portion contains an 
oligosaccharide chain of variable length with is composed of 3 types of sugar units 
(glucose, galactose, N-acetyl galactosamine) as well as sialic acid residues (NeuAc). The 
number and type of sugar units along with the number of sialic acid residues attached to 
galactose units determines the type of ganglioside (i.e. GM1, GM2, GM3). The 
hydrophobic portion of the molecule is made up of a fatty acid, usually stearic acid, and a 
sphingosine LCB tail with varying numbers of carbons. The most common form of 
ganglioside contains 18 carbons (d18:1) within the sphingosine moiety with the second 
most common form having a slightly longer carbon tail with 20 carbons (d20:1). Figure 
modified from Weishaupt et al., 2015. 
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Ceramide forms the hydrophobic backbone of the ganglioside molecule and is 
synthesized in the endoplasmic reticulum (Bisel, Pavone, & Calamai, 2014). The 
hydrophilic domain contains an oligosaccharide chain made up of a variable amount of 
glucose (Glc), galactose (Gal), and N-acetylgalactosamine (GalNAc), as well as one or 
more sialic acid residues. Glycosylation occurs in the golgi apparatus where only a limited 
number of oligosaccharides (Glc, Gal, GalNAc) are assembled to form gangliosides. The 
number and sequence of sugar units in the oligosaccharide domain act as a coding unit 
which are selective to specific glycoprotein interactions, giving each ganglioside species a 
unique regulatory function on the membrane (Ledeen & Wu, 2015). The combination of 
lactose and ceramide, or LacCer, forms the main lipid core of all gangliosides (Prokazova, 
Samovilova, Gracheva, & Golovanova, 2009). GM3 is produced when a sialic acid residue 
is added to LacCer by the enzyme GM3 synthase (also known as ST I, ST3Gal V, or CMP-
NeuAC) (Fig. 1.2). This ganglioside forms the basis upon which all other gangliosides are 
synthesized. Oligosaccharide units and/or sialic acid residues are added to GM3 by various 
glycosyltransferases and sialyltransferase enzymes to produce the over 200 identified 
species of gangliosides (Bisel et al., 2014). Berselli et al., proposed that the activity of 
GM3 synthase may be related to the location within the golgi apparatus and can dictate 
assembly of either simple gangliosides, such as GM3 or GD3, or more complex 
gangliosides, such as GM1 and GD1a (Berselli et al., 2006). 
Hydrolysis of sialic acids by Neu3 in lysosomes and on the plasma membrane is the 
first step of ganglioside degradation (Ha, Lee, Cho, Kim, & Kim, 2004; Prokazova et al., 
2009). Gangliosides with a sialic acid residue on a terminal chain galactose unit or 
polysialic gangliosides are the first to be catabolized and can be degraded directly in the 
membrane, while gangliosides with a single sialic acid residue located on a middle chain 
galactose unit, such as GM1, are degraded only in the lysosome (Miyagi et al., 1999). 
Gangliosides are transported to endosomes and eventually lysosomes where they are 
sequentially degraded by hydrolytic enzymes such as sialidase, β-galactosidase (βGal), and 
β-hexosaminidase (βHex) (Bisel et al., 2014). 
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Figure 1.2: Schematic of A- and B-series ganglioside metabolism. Gangliosides are 
synthesized (green) from the conversion of Lactosylceramide (LacCer) to GM3 by the 
addition of a sialic acid residue to the galactose unit of LacCer by the SAT I enzyme (or 
GM3 synthase). Thus, GM3 is the structural precursor of all other ganglioside species with 
more complex species being synthesized from GM3 by various transferase enzymes that 
add sugar units (GalNAcT, GalT II) and sialic acids (SAT IV, SAT II). Gangliosides are 
catabolized (red) by sialidase as well as sugar cleaving enzymes β-Galactosidase (βGal) 
and β-Hexosaminidase (βHex). Catabolism of gangliosides generally occurs within 
endosomes and lysosomes, however, there are membrane-bound sialidases which can 
directly catabolize gangliosides with sialic acids on terminal galactose units, such as GD1a 
and GT1b, directly on the membrane. GM3 is catabolized by a specialized sialidase 
enzymes called Neu3, which can only break down GM3. 
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1.4.2 GM3 
Ganglioside GM3 is the first and simplest member of the ganglioside family and is the 
metabolic precursor of more complex gangliosides and thus plays a determining role in the 
abundance of all upstream ganglioside species. GM3 is the main ganglioside in extra-neural 
tissues, but is present only in small amounts in the CNS (Dawson, Matalon, & Dorfman, 
1972; Muthings & Cacic, 1997; Negroni, Chigorno, Tettamanti, & Sonnino, 1996; Nilsson 
& Svennerholm, 1982; Ohashi, 1978; Prokazova et al., 2009; Rauvala & Finne, 1980; 
Seyfried, Ando, & Yu, 1978). GM3 synthase, which synthesizes GM3 from LacCer, is a 
unique sialyltransferase enzyme that is specific only to the GM3 lipid substrate, whereas 
other sialyltransferases can sialylate various lipid substrates (Harduin-lepers, Mollicone, 
Delannoy, & Oriol, 2005). Therefore, GM3 plays an important regulatory role for the 
synthesis of all other downstream gangliosides. 
GM3 was identified as a molecule that regulates cell growth leading to interest in its 
potential role in the field of oncology. Numerous mechanistic studies examining the effects 
of GM3 in various cancer-based in vitro cell lines and in vivo rodent tumor models have 
identified important regulatory functions of GM3 including the inhibition of cell growth, 
proliferation, migration, adhesion, cell motility, angiogenesis, as well as the upregulation of 
apoptotic pathways (Chung et al., 2014; Fujimoto et al., 2005). Additionally, GM3 
accumulation can increase the expression of TNF-α, a pro-inflammatory cytokine which 
modulates immunity and apoptosis (Kabayama et al., 2005). Exogenous administration of 
GM3 to B16 cells and cultured mouse melanoma cells resulted in a drastic increase in 
TNF-α mRNA, while cells treated with D-1-threo-1-phenyl-2-decanoylamino-3-
morpholino-1-propanol (D-PDMP), an inhibitor of GM3 synthesis, resulted in decreased 
TNF-α mRNA expression (Péguet-navarro et al., 2017; Prokazova et al., 2009; Wang et al., 
2007). The ability of GM3 to modulate a major pro-inflammatory cytokine suggests that it 
may play a role in the development of pathological inflammation. Angiogenesis, a critical 
factor for tumor growth, is suppressed when GM3 levels are increased through autocrine 
and paracrine effects on vascular-endothelial growth factor (VEGF)  and by blocking 
VEGF receptor 2  (Choi et al., 2006; Mukherjee et al., 2008; Seyfried & Mukherjee, 2010). 
However, when complex gangliosides GM1 and GD1a were increased as well, 
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angiogenesis was restored suggesting that the balance between GM3 and complex 
gangliosides was an important factor in determining GM3’s anti-angiogenic properties 
(Abate, Mukherjee, & Seyfried, 2006). In the mouse brain, astrocytomas expressing high 
levels of GM3 were found to be less vascularized and grow slower than those expressing 
low levels of GM3 (Seyfried & Murkhejee, 2010). GM3’s interaction with TNF-α and 
VEGF have also led to interest for researchers in the field of metabolic disease as GM3 
accumulation is correlated with insulin resistance in type 2 diabetes (Inokuchi, 2007; 
Sasaki et al., 2003; Veillon et al., 2015; Vukovic, Bozic, Markotic, Ljubicic, & Kurir, 
2015; Wang et al., 2013; Zador et al., 1993). TNF-α appears to have a bidirectional 
relationship with GM3, with increases in the pro-inflammatory cytokine also being linked 
to an increase in GM3 synthase in animal models of metabolic disease (Tagami et al., 
2002). Indeed, increases in GM3 have been shown to play a pathological role in animal 
models of metabolic disease through suppression of insulin-sensitive glucose transport and 
impaired wound healing (Randeria et al., 2015; Tagami et al., 2002). Reducing GM3 levels 
was shown to improve wound healing by increasing angiogenesis when applied to the 
lesion site and was also associated with increased insulin sensitivity and glucose tolerance 
in the liver of mice (Randeria et al., 2015; Yoshizumi et al., 2007). Overall, GM3 
accumulation appears to be tied to the inflammatory response and impairs healing by 
blocking angiogenesis. 
In order to examine the function of GM3 within the CNS, several in vitro and in 
vivo knock-out models have been developed. Studies in GM2/GD2 and GM3 synthase 
single and double KO mice, which lack complex gangliosides and accumulate simple 
ganglioside GM3, have demonstrated severe behavioural deficits that are exacerbated with 
aging leading to increased neurodegeneration, severe white matter pathology, and disrupted 
axon-glial interactions (Niimi et al., 2011; Sugiura et al., 2005; Tajima et al., 2009; 
Yamashita et al., 2005). Single KO GM2/GD2 synthase mice, which lack complex 
gangliosides and accumulate both simple gangliosides GM3 and GD3 developed 
progressive behavioural neuropathies including deficits in reflexes, strength, coordination 
and balance (Chiavegatto, Sun, Nelson, & Schnaar, 2000). Sheik et al., used the same 
single KO mouse model and found that the KO mice had reduced expression of myelin-
associated glycoprotein (MAG) along with severe deficits in white matter including 
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decreased central myelination, axonal degeneration in both the central and peripheral 
nervous system, and demyelination of peripheral nerves (Sheikh et al., 1999). These studies 
not only suggest that complex gangliosides are essential to maintain the integrity of the 
nervous system throughout life but also point to potential toxicity associated with GM3 
accumulation in the brain.  
A number of in vitro neural models have confirmed many of the findings from 
oncology-based studies with regards to the accumulation GM3. Sohn et al., examined the 
effect of glutamate toxicity on GM3 levels and GM3 toxicity in HT22 hippocampal cells 
and found that glutamate toxicity led to an increase in GM3 in a time dependent manner, as 
assessed by high performance thin layer chromatography (HPTLC). GM3, GD3, and GT1 
were then exogenously administered to HT22 cells but only GM3 was found to 
significantly decrease cell viability (Sohn et al., 2006). HT22 cells transfected with GD3 
synthase siRNA to increase GM3 levels showed similar results on cell viability, further 
supporting the hypothesis that GM3 accumulation leads to cell death. The authors suggest 
that GM3 may be directly connected to toxic events such as the production of ROS and 
Ca²⁺ influx by stimulating the oxidative pathway (Sohn et al., 2006). Nakatsuji & Miller 
administered GM3, GM1, and GD3 to rat primary astrocyte cultures and found that only 
GM3 administration resulted in a significant decrease in cell proliferation, as assessed by 
BrdU staining, and led to an increase in apoptosis, as measured by TUNEL staining 
(Nakatsuji & Miller, 2001). The authors further examined the effects of GM3 accumulation 
in-vivo through icv injections of GM3 into the right ventricle of Sprague-Dawley rats and 
examined cell proliferation and apoptosis. BrdU staining was decreased 30% in the lateral 
and dorsolateral ventricular regions in GM3 injected rats while there was an increase in 
TUNEL positive staining in the same regions in addition to the subventricular zone and 
striatum. The authors demonstrate that the inhibition of cell proliferation by exogenous 
GM3 is correlated with the increased expression of cell cycle inhibitor p27KIP1 and 
suggest that proliferating neural precursors may be more susceptible to GM3 toxicity than 
mature, non-proliferating cells (Nakatsuji & Miller, 2001). Thus, GM3 accumulation may 
play an important mechanistic role in the development and progression of 
neurodegeneration in the brain. 
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1.4.3 GM2 
Ganglioside GM2 is a minor component of brain gangliosides. It is formed through the 
addition of a glucose sugar unit to the oligosaccharide chain of GM3 by GM2 synthase. 
There is little direct evidence detailing the functions of GM2. It is thought to be involved in 
the process of insulin resistance through interactions with insulin receptors, however, the 
precise function of GM2 remains unclear (Higashi et al., 2011). GM2, like GM3, has also 
been shown to play a role in oncogenesis. It has been suggested that GM2 plays a 
protective role and that its depletion is correlated with greater cancer malignancy (Bisel et 
al., 2014). Accumulations of GM2 have been observed in the brains of several pre-clinical 
and clinical manifestations of neurodegenerative diseases such as AD and Hunter’s disease 
(Bisel et al., 2014; Dufresne et al., 2017; Pernber, Blennow, Bogdanovic, Månsson, & 
Blomqvist, 2012). 
Studies of GM2 gangliosidosis, wherein an inherited genetic defect in the catabolic 
enzyme βHex leads to an accumulation of GM2, have revealed important clues as to its role 
in the brain. Patients with GM2 gangliosidoses are characterized by progressive 
deterioration of motor, cerebral, and spinocerebellar function caused by a deficiency in 
lysosomal enzyme βHex (Maegawa et al., 2007). β-Hex has two main gene variants, HexA, 
and HexB. Genetic mutations of a specific gene variant lead to the development of unique 
neuropathies. For example, mutation in the HexA gene variant leads to the development of 
Tay Sachs disease, while mutations in both HexA and HexB lead to Sandhoff’s disease. 
The infantile versions of GM2 gangliosidoses are the most severe, and generally result in 
death during infancy. Late-onset forms include juvenile, sub-acute, adult, and chronic 
subtypes with the severity and progression being correlated with the level of HexA activity 
(Conzelmann & Sandhoff, 1983). Therefore, treatments aimed at increasing the activity of 
HexA, and subsequently β-Hex activity, should lead to functional benefits. Pyrimethamine 
(PYR), an anti-malarial compound, was found clinically to act as a pharmacological 
chaperone that increases HexA levels, thereby decreasing GM2 levels and restoring 
ganglioside homeostasis. PYR was administered to several human Tay Sachs and 
Sandhoff’s disease cell lines which resulted in an increase of HexA levels (Maegawa et al., 
2007). In 2011, a phase I/II clinical trial of PYR in patients with Tay Sachs or Sandhoff’s 
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disease showed a 4-fold increase in HexA levels and is currently moving forward to further 
examine the clinical effects in patients (Clarke et al., 2011). These studies demonstrate the 
efficacy of targeting the ganglioside metabolic pathway as a treatment for ganglioside 
accumulation. 
GM2 levels are transiently increased in response to neurodegenerative injuries such 
as stroke and traumatic brain injuries (Whitehead et al., 2011; Woods et al., 2013). In a 
crucial mechanistic study of a mouse model of fetal alcohol spectrum disorder, Saito et al., 
describe GM2’s potential role in neurodegeneration. Mice were subcutaneously injected 
with ethanol on post-natal day 7, which led to a severe apoptotic neurodegenerative 
response. GM2 levels were increased in the brain following ethanol injection and peaked at 
24 hrs, followed by a decrease at 72 hrs, similar to the GM2 response after a 
neurodegenerative injury. The authors examined the abundance of GM2, GM1, and GD1a 
using HPTLC and found accumulation patterns which suggest GM2 may be a degradation 
product of more complex species. GM2 accumulation was found to occur primarily in 
lysosomes, mitochondrial membranes, and activated microglia, and also co-localized with 
caspase-3 positive (apoptotic) neurons. The authors hypothesized, based on their results, 
that GM2 was involved in mitochondrial-mediated apoptosis and increased in microglia 
due to phagocytic functions, as GM2 staining in microglia partially overlapped with 
staining for a late endosomal/lysosomal marker LAMP1 (Saito et al., 2013). Overall, 
evidence from the literature suggests that GM2 accumulation is correlated with 
neurodegeneration and apoptosis. 
 
1.4.4 GM1 
GM1, along with GD1a/b and GT1a/b make up the main gangliosides found in the brain. 
GD1 and GT1 contain the same oligosaccharide units as GM1 but have additional sialic 
acid residues. These additional sialic acids are susceptible to degradation from membrane-
bound sialidase enzymes, however, GM1 is resistant to most forms of sialidase (Miyagi et 
al., 1999; Sonnino et al., 2011). GM1 can be found throughout the CNS but has been 
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reported to be particularly enriched in the white matter (Vajn, Viljetic, Degmecic, Schnaar, 
& Heffer, 2013). 
GM1 has numerous signaling and regulatory functions compared to other 
ganglioside species (Ledeen & Wu, 2015). It is involved in the maintenance of lipid raft 
integrity and modulation of calcium (Ca2⁺), sodium (Na⁺), and potassium (K⁺) ions across 
the plasma membrane to maintain homeostasis and promote neurite outgrowth (Rodriguez, 
Piddini, Hasegawa, Miyagi, & Dotti, 2001; Suzuki et al., 2007; Gusheng Wu, Lu, Andre, 
Gabius, & Ledeen, 2016). Contrary to GM3’s anti-angiogenic properties, complex 
gangliosides such as GM1 and GD1 are pro-angiogenic (Gullino, 2017; Margheri et al., 
2015; Ziche, Alessandri, & Gullino, 1989). GM1 can also promote neuritogenesis by 
modulating the binding activity of several cell adhesion molecules including neural cell 
adhesion molecule, N-cadherin, and laminin which promotes Ca²⁺ influx and tropomyosin-
related kinase A (TrkA) mediated activation of nerve growth receptors (Laitinen, 
Leppiinen, Merenmies, & Rauvala, 1987; Ledeen & Wu, 2015; Mutoh, Tokuda, & 
Miyadai, 1995; Walsh, Skaper, & Doherty, 1994). GM1 can further modulate neurotrophic 
factors through association with trkB receptors to promote the release of brain-derived 
neurotrophic factor (BDNF) and the Ret/GFRα complex to promote glial cell-line derived 
neurotrophic factor (GDNF), which functions to preserve the viability of catecholaminergic 
neurons (Pascual, Hidalgo-Figueroa, & Piruat, 2008; Pitto et al., 1998). Together, these 
functions highlight the crucial neuroprotective role of GM1 in the brain. 
GM1 began gaining interest as a therapeutic for neurodegeneration after exogenous 
administration of mixed brain gangliosides were found to improve peripheral sympathetic 
regeneration and re-innervation in cats (Ceccarelli, Aporti, & Finesso, 1976). Since then, 
GM1 has demonstrated neuroprotective and restorative effects in a number of 
neurodegenerative disease and injury models, as well as in human clinical trials (discussed 
below). An important development in the use of GM1 as a therapeutic was the creation of 
semisynthetic analogs of GM1 called lysogangliosides (LIGAs) which have identical 
biological functions to GM1 but have demonstrated increased membrane permeability in 
some cases (Kharlamov et al., 1994; Ledeen & Wu, 2015). While the oligosaccharide 
domain and sphingosine moiety are identical in LIGAs to GM1, the fatty acid chain in the 
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ceramide domain is often modified to shorter versions to facilitate permeability across the 
blood brain barrier and cellular membranes.  
Although there is ample evidence supporting the protective role of GM1 in the 
brain, an accumulation can be problematic as well, highlighting the importance of tight 
homeostatic regulation. Similar to GM2 gangliosidosis, a genetic defect in the β-Gal 
enzyme, which catabolizes GM1 to GM2, results in the accumulation of GM1 in the brain, 
a condition termed GM1 gangliosidosis. GM1 gangliosidosis is characterized by 
progressive psychomotor deterioration and seizures and has both a severe infantile version 
and several late-onset forms. A GM1-mediated mechanism that is thought to contribute to 
the symptoms of GM1 gangliosidosis is excessive neurite outgrowth leading to cellular 
abnormalities such as “ectopic” growth of dendritic spines and neuro-axonal dystrophy 
(Walkley, 2003). These structural abnormalities lead to impaired signal transduction. 
Overall, there is ample evidence supporting the neuroprotective functions of GM1, 
however, homeostasis appears to be a key factor in dictating its ability to carry out these 
functions. 
 
1.4.5 GD1a 
GD1a is formed by the addition of a sialic acid residue to the terminal galactose unit of the 
GM1 oligosaccharide chain by sialyltransferase. GD1a is highly abundant throughout the 
brain but has been reported to be particularly enriched in the olfactory bulb, neocortex, 
amygdala, substantia nigra, thalamic nuclei and in myelinated commissural fibers (Vajn et 
al., 2013). 
GD1a is an endogenous ligand for myelin associated glycoprotein, or MAG, a 
ganglioside-binding protein expressed selectively on myelin membrane on axon surfaces 
which functions to maintain the long-term integrity of axons and myelin (Pan et al., 2005; 
Sheikh et al., 1999). MAG is known to be an inhibitor of axon outgrowth that can limit 
recovery after CNS injury, therefore, increasing GD1a is associated with inhibition of axon 
outgrowth and regeneration, a process which can be reversed through administration of 
sialidase or GM1 (Rubovitch, Zilbe, Chapman, Schreiber, & Pick, 2017; H. J. Yang et al., 
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2011). Although increasing GD1a levels after CNS injury can inhibit regeneration, a 
depletion of GD1a can also have deleterious effects on recovery as it is essential in 
maintaining appropriate axon-myelin interactions and ensuring the long-term stability of 
axons (Suzuki et al., 2007). It is important to note that not all MAG receptors bind GD1a, 
therefore the degree of MAG modulation by GD1a may be brain region dependent 
(Schnaar, 2010). 
Ganglioside GD1a also been extensively studied in the field of Oncology and has 
been shown to enhance VEGF induced cell proliferation and migration of endothelial cells 
(Lang, Guerrera, Li, & Ladisch, 2001; Mukherjee et al., 2008). Additionally, it has been 
observed to enhance epidermal growth factor (EGF) when upregulated in fibroblasts (Liu, 
Li, & Ladisch, 2004). Anti-GD1a antibodies are significantly elevated in motor neuron 
diseases and syndromes such as Guillain-Barre syndrome (GBS) and Amyotrophic lateral 
sclerosis (ALS) (Ho et al., 1999; Kaji et al., 2000; Pestronk et al., 1989). Interestingly, anti-
GD1a antibodies were only found to be elevated in the axonal form of GBS and not the 
demyelinating form, pointing to the important role of GD1a in axon stability (Ho et al., 
1999; Yuki, Yoshino, Sato, Shinozawa, & Miyatake, 1992). 
Because of GD1a’s susceptibility to membrane-bound sialidase, one of its hypothesized 
roles in the brain is to act as a reserve pool for GM1 (Riboni, Prinetti, Bassi, & Tettamanti, 
1991). This has led many to believe that GD1a and GM1 act as one functional unit, in 
conjunction with membrane-bound sialidase, to maintain GM1 levels in the brain (Ledeen 
& Wu, 2015; Miyagi & Yamaguchi, 2012; Sonnino et al., 2011). Indeed, due to the many 
important neuroprotective functions of GM1 and the inhibitory role of GD1a in recovery 
from injury, the breakdown of GD1a on the membrane may be an essential neuroprotective 
mechanism. 
 
1.4.6 Gangliosides in neurodevelopment and aging 
During pre-natal development, GM3 and GD3 are highly abundant in the brain (Yu, Tsai, 
& Ariga, 2012). GD3 has been observed to be the major ganglioside in neural stem cells, 
making up about 80% of the total ganglioside content (Nakatani, Yanagisawa, Suzuki, & 
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Yu, 2010). This finding suggests that the activity of GD3 synthase, which convert GM3 to 
GD3, may be highly active during prenatal development. The tight regulation of 
gangliosides during development support the hypothesis that the abundance of each species 
is related to the unique functional roles they play during specific stages of development 
(Yu et al., 2012). Elevated GM3 and GD3 levels are observed during neural tube formation 
and neural cell differentiation (Yu, Nakatani, & Yanagisawa, 2009). GM3 has also been 
observed to increase during cell contact formation (Hakomori, 2002). Studies in 
mammalian brains have shown that GM1 and GD1 levels are low during the early phases 
of neuron migration and mitosis but are rapidly upregulated during process outgrowth, 
synaptogenesis, and myelination (Yu et al., 2009; Yu et al., 2012). Complex ganglioside 
content increases in postnatal development leading to a shift from structurally simple 
gangliosides to complex (Piccinini et al., 2010). Simple gangliosides GM3 and GM2 are 
downregulated, while complex species GM1, GD1 and GT1 are upregulated (Ngamukote, 
Yanagisawa, Ariga, Ando, & Yu, 2007; Yu, Macala, Taki, Weinfield, & Yu, 1988). This 
shift is correlated with an increase in expression of ganglioside synthase genes (Ishii et al., 
2007). Mice lacking complex gangliosides through knock-out (KO) of GM1 synthase 
develop progressive, age-dependent neurodegeneration, particularly with regards to axon-
myelin interactions (Allende & Proia, 2002; Yao et al., 2014). A rare human disorder has 
been identified which results in the congenital loss of function of GM3 synthase, and thus, 
of all gangliosides. The disorder is characterized by severe neuromuscular and cognitive 
impairments, blindness, and seizures (Simpson et al., 2004; Vajn et al., 2013). These 
findings point to the important role of complex gangliosides in maintaining the functional 
integrity of nervous tissues in the developed brain. 
During aging, the physical and chemical properties of the membrane are altered 
resulting in a shift in the balance and/or changed ratios of many lipid species, including 
gangliosides (Ariga, McDonald, & Yu, 2008). Barrier et al., 2007 used HPTLC to examine 
ganglioside changes during aging in the cortex of mice and found an increase in GM3 
between 12 and 24 months, a decrease in GM2 between 6 and 24 months, and a minor 
decrease in GD1a between 3 and 6 months (Barrier et al., 2007). Total ganglioside content 
has been reported to decrease with age (Aydin, Cengiz, Ag, & Han, 2000; Ohsawa & 
Shumiya, 1991). Interestingly, an increase in simple ganglioside GM3 has been found to be 
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correlated with cell senescence in vitro (Patschan et al., 2008), a finding which was 
recapitulated in a senescence-accelerated mouse model. Oshawa & Shumiya used 
senescence-accelerated mice (SAM-P/8), which show earlier onset of irreversible 
advancement of senescence, shorter life span, age-related deterioration in learning abilities, 
and spongi-form degeneration, and found that they had decreased levels of complex 
gangliosides GD1 and GT1 along with a progressive increase in GM3 levels compared to 
control mice, as measured by HPTLC (Ohsawa & Shumiya, 1991). These studies indicate 
that ganglioside dysregulation, resulting in the depletion of complex gangliosides and the 
accumulation of GM3, may occur during the natural aging process. 
Interestingly, the ceramide moiety has also been shown to be altered during aging. 
Sugiura et al., found an increase in the proportion of d20:1 species of GD1 compared to 
d18:1 species in the molecular layer of the mouse hippocampus during aging (Sugiura, 
Shimma, Konishi, Yamada, & Setou, 2008). Indeed, previous evidence has also suggested 
that the accumulation of 20 carbon species of complex gangliosides is correlated with aging 
(Mansson, Vanier, & Svennerholm, 1977; Palestini, Masserini, Sonnino, & Tettamanti, 
1990; Palestini, Masserini, Fiorilli, Calappi & Tettamanti, 1993). These studies also 
provide evidence that significant anatomical heterogeneity in the age-dependent 
accumulation of d20:1 species may be present, however, a comprehensive examination of 
these species across the brain during aging has yet to be completed. 
 
1.4.7 Gangliosides in stroke 
Ganglioside dysregulation has been observed in the murine brain following 
neurodegenerative injuries such as stroke and traumatic brain injuries (TBI). Following 
TBI, mice were found to have significant increases in simple ganglioside GM2 in 
periventricular, hippocampal, and thalamic brain regions 2 hrs after injury which peaked at 
24 hr then returned to control levels by 72 hrs (Woods et al., 2013). A similar transient 
increase of simple gangliosides was observed in response to stroke damage. Whitehead et 
al., examined the abundance and distribution of both complex and simple gangliosides in a 
mouse model of MCAO ischemic stroke. Following MCAO, a significant increase in GM2 
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and GM3 species were observed in the ipsilateral hemisphere 3 d post-stroke, which 
peaked at 7 d then returned to control levels by 14 d (Whitehead et al., 2011). The authors 
further demonstrated that the degree of simple ganglioside accumulation varied depending 
on the anatomical brain region, with the striatum and hippocampus showing a more severe 
accumulation than the cerebral cortex. Taken together, these studies provide evidence that 
simple ganglioside accumulation may be involved in neurodegeneration after injury and 
that certain brain regions may be more susceptible than others to dysregulation. 
Increasing GM1 levels has been examined as a potential treatment for stroke due to 
its neurotrophic and pro-angiogenic properties and was found to be effective in reducing 
stroke-induced pathology both pre-clinically and in human patients. Several functions of 
GM1 have been described as being particularly important in protecting neural cells from 
the damage caused by the ischemic cascade including: 1) protecting against excitotoxicity 
by regulating Ca²⁺ influx into the cell (Wu & Ledeen, 1994; Zhang et al., 2015), 2) 
protecting cellular membranes by maintaining ion balance (Na⁺- K⁺) and reducing edema in 
neurons (Karpiak, Li, & Mahadik, 1987); 3) inhibiting nitric oxide production, lipid 
peroxidation, excessive activation of glutamate receptors, excitatory amino acids, and free 
radical production (Avrova et al., 1998; Carolei, Fieschi, & Bruno, 1991); 4) improving 
survival of neurons by increasing blood flow and axonal growth (Rabin, Bachis, & 
Mocchetti, 2002; Rong, Zhou, Xiao-Wen, Tao, & Tang, 2013); and 5) enhancing 
neurotrophic activity to strengthen neural remodeling and promote recovery after injury 
(Ferrari & Greene, 1996; Marconi et al., 2005). Another mechanism in which GM1 is 
thought to confer neuroprotection through inhibition of autophagy. Li et al., administered 
GM1 to rats for 3 consecutive days following MCAO and found that a dose of 50 mg/kg 
was associated with a decrease in infarct volume and increased neuro-behavioural scores. 
The authors found that GM1 treatment after MCAO led to a decrease in autophagy markers 
Beclin-1 and LC3-II, suggesting that GM1 may exert a neuroprotective effect through 
inhibition of excessive autophagy that would otherwise lead to cell death. Administration 
of tat-Beclin-1 to increase autophagy after MCAO in addition to GM1 treatment abolished 
in the protective effects of GM1 on infarct size and neuro-behavioural deficits, further 
supporting the existence of a neuroprotective GM1-mediated mechanism of autophagy 
inhibition (Li, Tian, Long, Chen, & Lu, 2016).  
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GM1 is a major component in cerebral white matter and increasing GM1 levels has 
been shown to reduce damage to white matter regions after a hypoxic injury. Rong et al., 
used a neonatal rat model of hypoxia-induced white matter damage to show that GM1 
treatment for 5 consecutive days reduced structural damage in the brain (edema, apoptosis, 
and necrosis around the ventricles), protected against white matter damage (increased 
myelin basic protein staining while also decreasing APP and GFAP staining), and reduced 
behavioural impairments (Rong et al., 2013).  
Despite very promising evidence of a potential GM1-derived treatment for stroke in 
pre-clinical models, results of human clinical trials have demonstrated mixed results. 
Several human clinical trials failed to demonstrate a significant therapeutic benefit of GM1 
treatment in stroke patients (Braune, 1991; Candelise, 2002; Hoffbrand, Bungley, 
Oppenheimer, & Sheldon, 1988), while others have shown that significant neurological and 
pathological improvements were associated with the treatment (Argentino et al., 1989; 
Bassi, Albizzati, Sbacchi, Frattola, & Massarotti, 1984). More studies are needed which 
examine the role of ganglioside dysregulation in stroke to address the controversial 
findings of these studies. 
 
1.4.8 Gangliosides in neurodegenerative diseases: Parkinson’s disease, 
Huntington’s disease, Prion diseases 
The accumulation of GM3 and GM2 has been described as characteristic of diseased 
neurons (Walkley, 2003). Indeed, it is considered a central feature of diseases such as 
Niemann-Pick type C, Gaucher’s disease, and Hunter’s disease (Kreutz et al., 2013; 
Dufresne et al., 2017). Ganglioside dysregulation has also been reported in a number of 
neurodegenerative diseases including Parkinson’s disease (PD), Huntington’s disease 
(HD), Prion diseases, and AD. In each case, despite the varying mechanisms involved, a 
depletion of complex gangliosides in the brain is observed which is often accompanied by a 
concomitant increase in simple species. Ganglioside dysregulation has been linked to the 
abnormal aggregation of proteins that is a central hallmark of the aforementioned 
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neurodegenerative conditions: α-synuclein in PD, Huntington in HD, Prion protein in 
Creutzfeldt-Jakob disease, and Aβ in AD. 
PD is characterized by the progressive loss of dopaminergic neurons in the 
substantia nigra pars compacta leading to impairments in motor function (Sulzer & 
Surmeier, 2013). Human patients were found to have a depletion of GM1 in the occipital 
cortex, an area that is generally thought to not be largely affected in the disease, as 
compared to age-matched controls, which the authors suggest could be indicative of a 
systemic deficit of GM1 (Wu, Lu, Kulkarni, & Ledeen, 2012). This was associated with 
lower levels of phosphorylation of proteins in glial cell line-derived neurotrophic factor 
(GDNF) receptors of nigral neurons, which are critical for the survival of 
catecholaminergic neurons. These findings were recapitulated by the same group in a 
mouse model lacking complex gangliosides which developed symptoms reminiscent of 
human PD patients including motor impairments, depletion of striatal dopamine, and 
aggregation of α-synuclein protein (Gusheng Wu et al., 2012). GDNF Signaling could be 
restored using the semisynthetic GM1 analog LIGA20 (Hadaczek et al., 2015; Gusheng 
Wu et al., 2012). Indeed, increasing GM1 levels in the brain through exogenous 
administration has shown great promise in pre-clinical PD mouse and primate models, 
which eventually led to human clinical trials (Herrero, Perez-Otan, Oset, Kastner, & 
Hirsch, 1993; Pope‐Coleman, Tinker, & Schneider, 2000; Schneider, Kean, & DiStefano, 
1995).  
Ganglioside dysregulation in HD is characterized not only by a depletion of 
complex species but also by an increase in GD3. Simple ganglioside GD3 has, similar to 
GM3, been linked to toxicity through stimulation of reactive oxygen species, leading to 
apoptosis (Scorrano, Petronilli, Lisa, & Bernardi, 1999), and has been implicated as a 
mechanism of neurodegeneration in HD (Desplats et al., 2007). Desplats et al., 2007, used 
microarray analysis, qPCR, and Western blot to examine changes in lipid gene expression 
in a Tg mouse model of HD as well as human caudate post-mortem samples. The authors 
found a 38% reduction in GM1 content in the Tg HD mice as compared to Wt along with a 
significant upregulation the St8sial gene, which encodes GD3 synthase, in the caudate of 
human HD patients (Desplats et al., 2007). Di Pardo et al., examined two different models 
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of HD mice (YAC128 and R6/2) and found that both Tg mouse models had significant 
deficiencies in complex gangliosides GM1, GD1a, and GT1b in the corpus callosum. 
Importantly, the authors found that these changes in gangliosides could be detected in the 
early stages of the disease. Taken together, these results suggest that ganglioside 
dysregulation may play a mechanistic role in the development of neurodegenerative 
diseases, such as HD, and that the white matter may be particularly susceptible to damage 
(Di Pardo, Amico, & Maglione, 2016). 
Prion diseases, or spongiform encephalopathies, such as Creukfeldt-Jakob’s disease 
(CJD), are characterized by a shift in complex and simple gangliosides. In a guinea pig 
model of CJD, a marked decrease in total ganglioside content was observed in brain 
regions highly affected by the disease such as the cerebral cortex, basal ganglia and 
thalamus, and brain stem. When the abundance of each individual ganglioside species in 
the brain was quantified using TLC, an increase in simple gangliosides GM3, GD3, and 
GD2 were observed along with a decrease in GM1, GD1a, GD1b, and GT1b (Yu & 
Manuelidis, 1978). In human CJD patients, a similar trend is observed but with a more 
severe depletion of multisialylated complex species GD1a, GD1b, and GT1b along with a 
particularly high accumulation of simple ganglioside GD3 (Ando, Toyoda, Nagai, & Ikuta, 
1984; Ohtani, Tamai, Ohnuki, & Miura, 1996; Tamai et al., 1979). Di Martino et al., found 
a similar shift in complex and simple gangliosides in a Scrapie-infected hamsters, another 
type of prion disease (Martino, Safar, Callegaro, Salem, & Gibbs, 1993). Overall 
ganglioside content is reduced in the brains of patients with neurodegenerative diseases, 
potentially owing to a shift in ganglioside content leading to neuronal loss in affected 
regions (Desplats et al., 2007). 
 
1.4.9 Gangliosides in neurodegenerative diseases: Alzheimer’s disease 
The role of gangliosides in AD remains unclear as a number of studies point to seemingly 
contradictory results. For example, while there is a large amount of evidence implicating 
GM1 as major driver of toxic Aβ accumulation in the brain, there is also evidence 
demonstrating that GM1 acts in a protective manner against AD pathology (Fantini, Yahi, 
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& Garmy, 2013; Grimm et al., 2012; Kreutz et al., 2013; Yanagisawa, Odaka, Suzuki, & 
Ihara, 1995; Yang et al., 2013). Regardless of the precise function, ganglioside 
dysregulation has been identified as a hallmark of the disease (Ariga et al., 2008). 
Proteolytic processing of APP is influenced by the lipid composition of cellular 
membranes, with gangliosides having an important role in interacting with Aβ in 
membrane rafts (Wolozin, 2004). In particular, gangliosides GM3 and GM1 have a high 
affinity for interaction with Aβ. Cholesterol has been shown to promote the binding of Aβ 
to GM1 enriched rafts to form what is termed ganglioside-bound Aβ (GAβ), a structure 
hypothesized to act as a seed for toxic Aβ fibrilogenesis (Ariga et al., 2008; Fantini, Yahi, 
& Garmy, 2013; Yanagisawa, Odaka, Suzuki, & Ihara, 1995). Several studies have 
reported that the formation of GAβ can induce conformational changes in Aβ from a 
random coiled structure to an ordered structure rich in β sheets when environmental factors, 
such as the pH, are favourable (Choo-Smith, Garzon-Rodriguez, Glabe, & Surewicz, 1997; 
Matsuzaki, Kato, & Yanagisawa, 2010; Mclaurin & Chakrabartty, 1996, 1997). This 
process is thought to occur mostly in early endosomes and leads to increased aggregation 
of Aβ in the brain (Kimura & Yanagisawa, 2007; Yamamoto, Nostrand, & Yanagisawa, 
2006; Yanagisawa et al., 1995). Toxic Aβ fibrillation has also been shown to be amplified 
through binding with GM3 enriched lipid rafts, leading to further dysregulation of 
ganglioside activity. In a study by Grimm et al., Aβ binding to GM3 led to a reduction in 
the activity of GD3 synthase, and thus decreased turnover from a to b-series gangliosides 
(Grimm et al., 2012) 
Human AD patients, similar to patients with other neurodegenerative diseases, 
show a significant decrease in total ganglioside content as compared to controls which is 
suggested to be related to the loss of the more abundant complex gangliosides (Molander-
melin, Blennow, Bogdanovic, Dellheden, & Fredman, 2005; Svennerholm & Gottfries, 
1994). The degree and location of ganglioside loss varies depending on the time of onset, 
with early onset, or familial AD patients having demonstrated a 58-70% decrease compared 
to controls in grey matter regions and 81% in frontal white matter, while late-onset patients 
appeared to show severe depletions only in the temporal lobe, hippocampus, and frontal 
white matter (Ariga et al., 2008; Svennerholm & Gottfries, 1994). Accumulations of simple 
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gangliosides GM2 and GM3 have also been observed in brain regions highly susceptible to 
neurodegeneration in AD. In a study by Kracun et al., gangliosides were found to be 
perturbed in early-onset AD patients such that there was a decrease in complex 
gangliosides GM1 and GD1a in the frontal and temporal cortices of the brain. These same 
regions were found to have a significant increase in simple gangliosides GM3 and GM2 
compared to control brains (Kracun, Kalanj, Talan-hranilovic, & Cosovic, 1992). Gottfries 
et al., found a similar ganglioside distribution pattern in the brains of early-onset AD 
patients (Gottfries, Jungbjer, Karlsson, & Svennerholm, 1996). Significant accumulations 
of GM3 were observed in the entorhinal cortex of late-onset AD patients, a brain region 
particularly susceptible to neurodegeneration in AD (Chan et al., 2012). These results point 
to the possibility of ganglioside degradation as a mechanism of pathology in AD brains. 
Indeed, Pitto et al., observed an upregulation of the GM1 catabolic enzyme β-Gal in 
cultured fibroblasts from AD patients compared to controls, leading to the accumulation of 
simple gangliosides GM2 and GM3 (Pitto et al., 2005). Overall, the severe depletion of 
complex gangliosides and accumulation of simple gangliosides in brain regions which are 
highly susceptible to neurodegeneration are consistent with the neuronal loss and 
cortical/hippocampal thinning considered the pathological hallmarks of the disease (Ariga 
et al., 2008). 
Understanding the role of ganglioside dysregulation in AD may not be as 
straightforward as a simple shift in the homeostatic distribution, rather, the unique 
functional properties of each species may lead to specific interactions with certain types of 
Aβ that are more or less favorable depending on various environmental factors. Pre-clinical 
animal models of AD have revealed important mechanistic information on the interaction 
of gangliosides with Aβ and specific mutations of various genes involved in the 
pathogenesis of human AD. Yamamoto et al., showed that different species of gangliosides 
reacted to specific types of hereditary Aβ and led to their accumulation. For example, the 
authors report that GM1 interacted with the Arctic variant of Aβ, GD3 with the Flemish Aβ 
variant, and GM3 with the Dutch and Italian Aβ variants. Interestingly, GM3, and GM2 to 
a lesser extent, were found to be the major gangliosides in human cerebrovascular smooth 
muscle cells, which the authors suggest may contribute to the accumulation of the Dutch 
Aβ variant in vascular walls. The authors further proposed that this differential interaction 
30 
 
of gangliosides with various hereditary variants of Aβ may contribute to the region-specific 
deposition of Aβ fibrils in the brain (Yamamoto, Hirabayashi, Amari, & Yamaguchi, 
2005). A follow up study by the same group used a Tg mouse model of AD with double 
Swedish/London mutations of the APP gene in addition to a knock out of the GM2 
synthase gene, resulting in the accumulation of GM3 and a reduction in complex 
gangliosides. The authors found that the Tg KO mice developed a severe dyshoric-form 
amyloid angiopathy in which amyloid deposition extended from blood vessel walls into the 
surrounding parenchyma and suggests, according to the authors, an important role of GM3 
in the development of vascular Aβ pathology in the brain (Oikawa et al., 2009). Barrier et 
al., examined several transgenic mouse models of AD and found that the degree and type of 
ganglioside perturbation observed was associated with the specific genetic modifications of 
the mice. Transgenic APP mice with Swedish and London mutations (APPSL) showed a 
significant decrease in all b-series gangliosides within the cortex at 24 m along with a 2-3 
fold increase in simple a-series gangliosides GM2 and GM3 compared to controls. Double 
transgenic mice with APPSL and PS1 mutations showed a slightly different pattern at 24 
m, with a less severe depletion of complex a and b-series gangliosides and an accumulation 
of simple ganglioside GD3. However, like the APPSL only mice, the APPSL/PS1 mice 
showed a significant increase in simple gangliosides GM3 and GM2 compared to age-
matched controls. In the double Tg APPSL/PS1 mice, an accumulation of simple 
gangliosides could be observed as early as 3 m, which, the authors suggest, implicates 
ganglioside dysregulation as an early driver of pathology in AD (Barrier et al., 2007). Thus, 
ganglioside dysregulation resulting in the accumulation of toxic simple gangliosides along 
with a depletion of protective complex gangliosides is region-specific and is linked to the 
proteolytic processing of Aβ, making the restoration of ganglioside homeostasis a 
potentially critical point of intervention. 
The ceramide domain of gangliosides may also play an important role in the 
development and progression of AD as ceramides with longer carbon chains have not only 
be observed to increase during the natural aging process, but also accumulate in brain 
regions susceptible to neurodegeneration in AD. Cutler et al., examined the distribution of 
several lipids in normal aging human subjects and AD patients. Long chain ceramides 
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(d24:1) were not only found to accumulate during normal aging in control subjects, but 
showed a significant increase in the middle frontal gyrus of AD patients compared to 
controls, an area highly susceptible to neurodegeneration. Examination of long chain 
ceramide levels in the cerebellum of AD patients, an area generally spared from 
neurodegenerative damage, showed no such increase in long chain ceramides, indicating 
that there are regional differences in long chain ceramide accumulation that may be 
correlated to neurodegeneration in AD. Additionally, the degree of accumulation of long 
chain ceramides was found to be correlated with the severity of AD pathology. The authors 
further examined the interaction of long chain ceramides with Aβ in hippocampal neurons 
and saw an increase in long chain ceramides in response to the exogenous administration of 
Aβ1-42. The increase in long chain ceramides was correlated with an increase in oxidative 
stress, as measured by lipid peroxidation product 4-hydroxynenonal (HNE), further 
supporting the possibility of mechanistic interaction between long chain ceramides and 
neurodegeneration (Cutler et al., 2004). Overall, the accumulation of these ganglioside 
species represents a potential mechanism of toxicity in the AD brain and is worthy of 
further investigation. 
Restoring ganglioside homeostasis in the early and later stages of AD progression is 
gaining interest as a therapeutic intervention for AD. Contrary to the hypothesized 
pathological role of GM1 in toxic Aβ fibril formation, exogenously administered GM1 has 
demonstrated therapeutic benefits both pre-clinically and clinically in AD. GM1 
administration in the presence of Aβ1-40 or Aβ1-42 injected into the ventricles of rats led 
to reduced memory impairments on the novel object recognition (NOR) task and Morris 
water maze and was associated with a decrease in oxidative stress and the maintenance of 
K⁺-Na⁺ ATPase activity (Kreutz et al., 2013; Yang et al., 2013). In a human clinical trial, 
several AD patients were treated with GM1 through continual ventricular injections for a 
period of 12 m. The progression of neural deterioration ceased in treated patients while 
increases in cerebral blood flow were observed. GM1-treated patients showed 
improvements in motor skills and cognitive performance in reading, writing, and 
comprehension (Svennerholm et al., 2002). These studies highlight the potential therapeutic 
interactions of GM1 in AD. Treatments targeting the accumulation of simple gangliosides 
have also demonstrated promise in pre-clinical models of AD. When Dutch APP mice were 
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treated with a small molecule pharmacological chaperone that increases the activity of β-
Hex, resulting in a decrease of GM2 levels, anxiety was reduced and learning behaviours 
improved on the novel object recognition task (NOR) which was associated with a 
reduction in GAβ in the subiculum and perirhinal cortex (Knight et al., 2014). Thus, 
targeting ganglioside dysregulation has shown therapeutic benefits in AD models and is 
worthy of further investigation.  
 
1.5  Chloroquine 
The ideal intervention for the prevention of ganglioside dysregulation in the brain would 
block both the degradation of protective complex gangliosides and the accumulation of 
toxic simple gangliosides in the brain. While there is currently no known compound which 
can selectively accomplish this task, it is possible to transiently block lysosomal activity, 
thus disrupting ganglioside catabolism. N-(7-chloroquinolin-4-yl)-N,N-diethyl-pentane-
1,4-diamine, or Chloroquine (CQ), is best known as an anti-malarial agent. 
Pharmacologically, CQ is a weak base leading to its accumulation in acidic cellular 
organelles, such as lysosomes. The accumulation of CQ in lysosomes leads to an increase 
in vacuolar pH and the subsequent disruption of acidic lysosomal enzymes (Poole & 
Ohkuma, 1981; Wang et al., 2016). CQ is characterized by its ability to inhibit autophagy, 
act as an anti-inflammatory agent, and alter lipid composition through disruption of 
metabolic enzymes.  
The autophagy-blocking properties of CQ have demonstrated utility as a therapeutic 
agent in oncology, revealing another important function of the compound. CQ can improve 
sensitivity of tumours to chemotherapy and prevent metastasis (Zhang et al., 2015). One 
mechanism with which it has been shown to exert these effects is through stabilization and 
normalization of tumor vasculature by modulating Notch-1 activity, pointing to its vasculo-
protective properties (Maes et al., 2014). Indeed, systemically-administered CQ has 
demonstrated a neuroprotective effect against damage to the blood brain barrier in mice 
(Mielke, Murphy, Maritz, Bengualid, & Ivy, 1997). These protective effects of CQ on the 
vasculature may be particularly useful as a therapeutic for vascular injuries, such as strokes. 
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The anti-inflammatory properties of CQ garnered interest in the compound as a 
therapeutic for inflammatory disorders including rheumatoid arthritis. A series of human 
clinical trials led to the conclusion that CQ acts as an effective anti-rheumatic compound in 
roughly 90% of patients, although treatment was most effective when paired with 
immunosuppressive medications (Ferraz et al., 1994; Freedman & Steinberg, 1960; Popert, 
Meijers, Sharp, & Bier, 1961).  Pathological inflammation is also a hallmark of the 
ischemic cascade and CQ has been shown to downregulate pro-inflammatory cytokines and 
mediate inflammatory responses through inhibition of toll-like receptor (TLR)-3 after 
stroke (Cui et al., 2013). CQ further confers protection after a neurodegenerative injury by 
reducing ROS and inhibiting autophagy (Hirata et al., 2011). The inhibition of autophagy, 
as previously mentioned, is of particular relevance to stroke therapies due to prolonged 
environmental stressors which can promote the over-activation of autophagy pathways, 
leading to cell death (Li, Tian, Long, Chen, & Lu, 2016). Thus, CQ has a number of 
neuroprotective effects that make it a promising therapeutic intervention for strokes. 
CQ also exhibits a strong interaction with lipids (Pfau et al., 1997) and has been 
used to inhibit the degradation of gangliosides both in vitro and in vivo, leading to the 
accumulation of complex gangliosides (Marchesini, Benaglia, Piccinotti, Bresciani, & 
Preti, 1998; Pfau et al., 1997). CQ disrupts the activity of lysosomal enzymes β-Gal and β-
Hex leading to an increase in GM1 levels and a decrease in GM1 degradation products 
GM2 and GM3 (Riboni, Caminiti, Bassi, & Tettamanti, 1995; Yuyama, Yamamoto, & 
Yanagisawa, 2006). Pfau et al., administered a low dose of CQ both pre-natally and post-
natally in rat pups in order to examine intrauterine effects of CQ on dendritic maturation in 
the hippocampus and found that CQ increased GM1 and decreased GM3 levels in pre-natal 
rats with an increase in GM1 levels also observed post-natally. Low dose CQ resulted in a 
significant elongation of apical and basilar dendrites of CA3 neurons and early formation 
of dendridic spines in the CA1 region of the hippocampus, however, the functional 
consequences of this altered dendridic architecture remains unclear (Pfau et al., 1997). 
Overall, CQ’s ability to transiently block the degradation of complex gangliosides makes it 
a useful tool to examine the potential therapeutic benefits of preventing ganglioside 
dysregulation in stroke and AD. 
34 
 
 
1.6  MALDI IMS 
Mass spectrometry (MS) is an analytical technique that detects the mass-to-charge ratio 
(m/z) of ionized molecules (Zaima, Hayasaka, Goto-Inoue, & Setou, 2010). The imaging 
component of MS technologies is a fairly recent development and has opened the door to 
previously unattainable spatial distribution information. This is particularly true in the area 
of lipidomics, where visualization of lipids in tissue sections previously relied upon 
techniques such as Immunohistochemistry (IHC). These techniques are especially 
problematic where membrane lipids are concerned due to their hydrophobic core being 
embedded within the plasma membrane and thus inaccessible for antibody-epitope binding. 
Antibodies for the various ganglioside species, if they exist, can only differentiate between 
ganglioside species based on their hydrophilic oligosaccharide domain. While this 
information may provide a general idea of ganglioside distribution patterns, it lacks the 
required specificity to reach meaningful biological conclusions on its own. Alternatively, 
ganglioside expression has been quantified using thin layer chromatography techniques, 
however these techniques require homogenization of tissue samples for lipid extraction 
which can be problematic when examining ganglioside distribution in discrete brain 
regions. 
There are three main ionization platforms which can be paired with an imaging 
modality for imaging MS experiments, each with its own advantages and disadvantages 
(Barceló-coblijn & Fernández, 2015; Chaurand, 2012): Matrix-Assisted Laser 
Desorption/Ionization (MALDI) uses a laser to ablate laser-absorbing matrix-coated 
samples under vacuum to achieve ionization of intact analytes of a wide molecular weight 
range from metabolites to proteins, Secondary Ion Mass Spectrometry (SIMS) uses a 
primary ion beam to sputter the surface of the sample then collects and analyses secondary 
ions, producing primarily fragmented ions in most cases (Guerquin-Kern, Wu, Quintana, & 
Croisy, 2005), Desorption Electrospray Ionization (DESI) requires minimal sample 
preparation and takes place under atmospheric pressure but has diminished sensitivity for 
larger molecular weight analytes (Wiseman & Laughlin, 2005). Adaptations and evolution 
in technologies are leading to increasing variations and complementary pairings in 
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ionization sources to maximize the specific advantages of each and customize the 
technology to suit the desired experimental paradigm (Monroe et al., 2008; Trimpin & 
Deinzer, 2007; Zhang, Wang, Liu, Han, & Xiong, 2016). Most importantly, IMS 
technology is capable of simultaneously detecting and imaging the ionic distribution of 
numerous molecules in a label-free manner from a variety of biological samples such as 
animal and human tissues, plants, and bacteria. MALDI IMS can detect a wide range of 
molecules, from very small molecules (m/z < 1000) to large molecules (m/z > 100 kDa), 
making it very versatile in experimental applications (Svatos, 2010; Yates, 1998; Zaima et 
al., 2010). Because the mass range of a-series gangliosides falls within an m/z of 1000 – 
2500 and high spatial resolution is required to examine discrete brain structures, MALDI 
IMS provides the ideal imaging platform for the detection and visualization of gangliosides 
in the brain.   
Sample preparation, including tissue freezing, sectioning, matrix selection, and 
method of matrix deposition all play a critical role in determining the quality of MALDI 
IMS data (Chaurand, 2012). It is preferable that samples for MALDI IMS remain 
chemically unmodified for analysis, which is why flash freezing, using either dry ice or 
liquid nitrogen, are generally used during sample preparation as opposed to chemical 
fixation. Further, chemical fixation using formaldehyde is generally avoided due to cross-
linking of proteins which can disrupt and/or distort MALDI data (Zaima et al., 2010). 
Ionization efficiency, which refers to the number of ions generated relative to the total 
number of molecules consumed, is a critical factor to consider during sample preparation 
and is influenced by the thickness of the tissue section (Murray et al., 2013; Sugiura, 
Shimma & Setou, 2006). Molecules with a lower molecular weight can be imaged from 
sections between 5 – 20 μm thick while it is recommended that thinner sections (2 – 5 μm) 
be used for molecules with a higher molecular weight (Zaima et al., 2010).  
MALDI IMS requires the coating of a matrix to facilitate ionization of analytes in 
the sample. The matrix can have several important roles in MALDI IMS depending on the 
solvent system used including: 1) extraction of molecules from the sample based on their 
chemical properties, 2) absorbing laser energy and transferring of the energy to analyte 
molecules, and 3) influencing spatial imaging resolution. Homogenous deposition of the 
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matrix on the sample and minimization of analyte delocalization during matrix deposition 
are crucial for achieving high spatial resolution. Gangliosides have a negative charge due 
the sialic acid residues on their structure, which means they are primarily imaged in 
negative polarity ion mode when analyzed via MALDI IMS. This negative charge also 
influences the types of matrices that will be used during sample preparation, as some 
matrix-solvent mixtures have a greater affinity for extracting negatively charged lipids than 
others (Thomas, Charbonneau, Fournaise, & Chaurand, 2012). The method of matrix 
deposition is a factor which is particularly important when imaging lipids, such as 
gangliosides. While wet matrix application techniques, wherein a solvent is used to 
dissolve a powdered matrix, are most common, they present an increased likelihood of 
large crystals forming on the surface of the sample as well as an increased risk of molecular 
delocalization, both of which can greatly reduce detection and imaging quality. Dry matrix 
application techniques, such as sublimation, can circumvent these limitations. Additional 
factors such as solvent rinses and incubation times may also lead to improvement in 
ganglioside signals at the expense of possible analyte delocalization (Angel, Spraggins, 
Baldwin, & Caprioli, 2012; Appendix 1).  
Once in the MALDI MS instrument, MS spectra are acquired through a series of 
repetitive laser pulses at predefined x-y coordinates. Broadly, the sample surface is 
irradiated using laser energy wherein protonation or deprotonation of molecules leads to 
the formation of either positively or negatively charge ions. Time-of-flight (TOF) analyzers 
are most common for MALDI IMS applications and allow ions to separate based on their 
m/z ratio (Dreisewerd, 2003; Zaima et al, 2010). The ions are finally quantified by a 
detector and MALDI MS data is then represented as peaks on a mass spectrum that 
indicates the relative abundance of each ion within the sample. This analytical data is 
accompanied by a “molecular map” of the ionic distribution of each peak across the intact 
tissue section formed by the numerous laser acquisition points. Because of the variability 
that is inherent in the sample preparation process and run-to-run variation related to 
ionization efficiency and background matrix suppression, MALDI IMS is considered a 
semi-quantitative technique. Various normalization and statistical approaches can be 
implemented to reduce errors caused by between-scan variability in order to pool data from 
multiple imaging experiments. 
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MALDI IMS has already been used to address various fundamental questions 
regarding the localization and biological role of gangliosides in the brain, including in pre-
clinical models of neurodegenerative disease and injury (Colsch, Jackson, Dutta, & Woods, 
2011; Dufresne et al., 2017; Hirano-Sakamaki et al., 2015; Whitehead et al., 2011; Woods 
et al., 2013). For example, recent evidence using a combination of MALDI IMS and IHC 
examined ganglioside distribution in a Tg mouse model of AD. Tg Arc/Sw mice, which 
develop Aβ plaques, contained significantly increased levels of simple gangliosides GM2 
d18:1 and GM3 d18:1 and d20:1, but not GM1 in cortical and hippocampal Aβ plaques 
(Kaya et al., 2017). The authors suggest that this increase in simple gangliosides are likely 
a result of complex ganglioside degradation or inhibition of lysosomal storage and 
degradation. Because of the semi-quantitative nature of MALDI IMS, pairing the technique 
with another form of ganglioside detection has become common and can aide in 
interpreting findings (Jones et al., 2017; Kaya et al., 2017). 
 
1.7 Rationale and objectives 
Gangliosides belong to a large family of glycosphingolipids enriched in the CNS that have 
important regulatory functions on the cell plasma membrane. Their abundance is tightly 
regulated by lysosomal enzymes in order for each species to carry out their unique 
functions (Yamamoto et al., 1996; Yu, Nakatani, & Yanagisawa, 2009). Alterations in 
ganglioside homeostasis is hypothesized to play an important role in the pathogenesis of 
neurodegenerative diseases and injuries (Ariga et al., 2013; Cutler et al., 2004; Whitehead 
et al., 2011; Woods et al., 2013), however, the nature of the relationship between 
neurodegeneration and ganglioside dysregulation remains unclear. 
 Novel imaging technologies, such as MALDI IMS, can be used to examine the 
distribution and abundance of gangliosides with greater sensitivity and specificity than 
traditional lipid imaging techniques, making it the ideal tool for a comprehensive and 
detailed analysis of a-series gangliosides in the brain. 
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The overarching hypothesis of these studies was that ganglioside dysregulation 
occurs in the aging brain and in response to neurodegenerative injuries and that restoring 
ganglioside homeostasis will result in functional benefits after injury in rats. 
The main objectives of this study were: 1) Examine ganglioside dysregulation in 
response to neurodegenerative injuries of varying severity to determine if specific patterns 
of alteration are associated with the neurodegenerative response (Chapter 2); 2) Examine 
changes in the ganglioside long chain base throughout the brain during aging in a-series 
gangliosides (Chapter 3); 3) Determine if a-series gangliosides are altered differently in the 
normal aging rat brain versus a rat model of prodromal AD to identify specific patterns of 
dysregulation which may be tied to the development of neurodegeneration in the aging 
brain (Chapter 4) and; 4) Examine the potential pathological and functional benefits 
associated with preventing ganglioside dysregulation after stroke (Chapter 5). 
  In Chapter 2, the degree of toxic simple ganglioside accumulation was found to be 
correlated with the severity of the neurodegenerative insult, with the d20:1 species often 
showing a more severe alteration in response to the injury than the d18:1 species. Little is 
known on the role of d20:1 versus d18:1 species of gangliosides, however, the d20:1 
species are hypothesized to accumulate in an age-dependent manner relative to the d18:1. 
In chapter 3, the ratio of d20:1 to d18:1 species of A-series gangliosides was examined 
during aging in Fischer rats. Interestingly, only complex gangliosides were observed to 
have an age-dependent increased in the d20:1/d18:1 ratio whereas this ratio decreased for 
simple gangliosides across the brain, with the exception of white matter regions. In chapter 
4, A-series gangliosides were examined individually in Wt and Tg APP rats in order to 
better understand the age-dependent alterations of simple and complex gangliosides during 
normal aging and in the prodromal stages of AD. Interestingly, an age-dependent depletion 
of complex ganglioside GD1 d18:1 was observed in the white matter of the brain. 
Additionally, Tg APP21 rats were found to have increased levels of toxic ganglioside 
species GM2 and GM3 than their Wt counterparts, pointing to a toxic pattern of 
ganglioside dysregulation in Tg APP rats. Finally, in chapter 5, an intervention using a 
pharmacological compound (chloroquine) aimed at preventing ganglioside dysregulation 
was examined after a severe stroke injury. Restoration of ganglioside homeostasis after 
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stroke was associated with reduced motor and cognitive impairment in Wistar rats. This 
work highlights the important role of ganglioside dysregulation in the rat brain during 
aging and neurodegeneration and the therapeutic benefits associated with maintaining 
ganglioside homeostasis after stroke injury. 
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Chapter 2 : Increased expression of simple ganglioside species GM2 
and GM3 detected by MALDI Imaging mass spectrometry in a 
combined rat model of Aβ toxicity and stroke 
  
2.1  Abstract 
The aging brain is often characterized by the presence of multiple comorbidities resulting 
in synergistic damaging effects in the brain as demonstrated through the interaction of 
Alzheimer’s disease (AD) and stroke. Gangliosides, a family of membrane lipids enriched 
in the central nervous system, may have a mechanistic role in mediating the brain’s 
response to injury as their expression is altered in a number of disease and injury states. 
Matrix-Assisted Laser Desorption Ionization (MALDI) Imaging Mass Spectrometry (IMS) 
was used to study the expression of a-series ganglioside species GD1a, GM1, GM2, and 
GM3 to determine alteration of their expression profiles in the presence of beta-amyloid 
(Aβ) toxicity in addition to ischemic injury. To model a stroke, rats received a unilateral 
striatal injection of endothelin-1 (ET-1) (stroke alone group). To model Aβ toxicity, rats 
received intracerebralventricular (icv) injections of the toxic 25-35 fragment of the Aβ 
peptide (Aβ alone group). To model the combination of Aβ toxicity with stroke, rats 
received both the unilateral ET-1 injection and the bilateral icv injections of Aβ₂₅₋₃₅ 
(combined Aβ/ET-1 group). By 3 d, a significant increase in the simple ganglioside species 
GM2 was observed in the ischemic brain region of rats who received a stroke (ET-1), with 
or without Aβ. By 21 d, GM2 levels only remained elevated in the combined Aβ/ET-1 
group. GM3 levels however demonstrated a different pattern of expression. By 3 d GM3 
was elevated in the ischemic brain region only in the combined Aβ/ET-1 group. By 21 d, 
GM3 was elevated in the ischemic brain region in both stroke alone and Aβ/ET-1 groups. 
Overall, results indicate that the accumulation of simple ganglioside species GM2 and 
GM3 may be indicative of a mechanism of interaction between AD and stroke. 
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2.2   Introduction 
As we age, our brains become more vulnerable to diseases and injuries. Elderly patients 
often simultaneously experience two or more medical conditions which complicates the 
study of age-related neurodegenerative diseases such as Alzheimer’s disease (AD). When 
multiple conditions are present simultaneously (comorbidity), synergistic effects on 
pathology and cognitive outcomes can be observed as demonstrated in the case of AD and 
stroke. A key study which examined the incidence of dementia among a group of elderly 
nuns diagnosed with AD found that only 57% of those diagnosed with AD developed 
dementia, while 93% of those who had suffered small subcortical infarcts plus a 
pathological diagnosis of AD developed dementia (Snowdon et al., 1997). AD and stroke 
comorbidity has also been observed in carriers of the APOE4 gene. Data from the Canadian 
Study of Health and Aging (CSHA) showed that prevalence of dementia was increased 
among those who had a history of stroke and were also APOE4 carriers (Jin et al., 2008). 
Furthermore, another study demonstrated that APOE4 carriers with a history of stroke were 
five times more likely to develop dementia than APOE4 carriers without such a history 
(Jonston et al., 2000). Although the clinical evidence for the interaction between AD and 
stroke has been well documented, the mechanism(s) for this interaction remains unclear. A 
potential mediator for this interaction may lie within a family of cellular membrane lipids 
known as gangliosides. 
Gangliosides are glycosphingolipids characterized by the presence of sialic acid 
residues. Being embedded within the plasma membrane, gangliosides perform a wide 
variety of biological functions by interacting with signaling molecules both within and 
outside of the cell. Some of these biological functions include cell signaling, proliferation, 
differentiation, embryogenesis, oncogenesis, neurodegeneration, and apoptosis (Prokazova 
et al., 2009; Yu, Suzuki & Yanagisawa, 2010). Ganglioside metabolism is controlled by the 
activities of several enzymes, which can add or remove sialic acid residues and/or 
oligosaccharide units to form the various derivatives that make up the ganglioside 
molecules. A-series gangliosides are the first, structurally simplest group of gangliosides 
derived from the addition of a sialic acid residue to lactosylceramide and contain the most 
abundant ganglioside species in the mammalian central nervous system, GM1, as well as 
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GD1a, GM2, and GM3 (Ando, Chang & Yu, 1978) (Fig 2.1). Every form of ganglioside is 
hypothesized to have unique functions within the cell and a normal homeostatic 
distribution of each species is maintained within healthy organisms (Yamamoto et al., 
1996; Yu, Nakatani & Yanagisawa, 2009; Sekigawa et al., 2011). Complex gangliosides 
GM1 and GD1a are more abundant in the brain than the simple species GM2 and GM3 and 
have been shown to be beneficial for recovery when exogenously administered in a number 
of in vitro, animal, and human disease and injury studies (Schneider et al., 2013; Kreutz et 
al. 2011). 
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Figure 2.1: Chemical Structure and Metabolic Pathways Involved in Ganglioside 
Synthesis and Catabolism. Gangliosides are composed of a hydrophobic domain called 
ceramide (Cer) and a hydrophilic domain made up of a series of sugar units (glucose – Glc, 
galactose – Gal, and N-acetylgalactosimine –GalNAc) with a sialic acid residue (Sia) 
attached to a galactose sugar unit. The number and type of sugar units and sialic acids 
present in the hydrophilic domain determines the type of ganglioside species (GM3, GM2, 
etc.). A group of transferase enzymes adds either a sugar unit (GalNAcT, GalT) or a sialic 
acid residue (sialyltransferase - SAT) to synthesize different ganglioside species. A 
different set of catabolic enzymes within the lysosome can also break down these 
components, thus a homeostatic abundance of each ganglioside species is maintained in a 
healthy organism. 
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Little is known of the functions of ganglioside GM2 in the adult mammalian brain. 
However, GM2 gangliosidosis, a group of autosomal recessive disorders caused by 
dysfunction in enzyme metabolic pathways, such as Tay Sachs and Sandhoff’s disease, can 
lead to accumulation of GM2 in neuronal cells resulting in a broad spectrum of 
neurological disorders (Bley et al., 2011). More recently, GM2 expression has been found 
to be elevated within the mouse brain at the injury site after a focal brain injury such as a 
traumatic brain injury or stroke (Whitehead et al., 2011; Woods et al., 2013). GM3, an 
essential component of the plasma membrane and lipid rafts (Prokazova et al., 2009), is 
structurally the simplest member of the ganglioside family and acts as a metabolic 
precursor to the other more complex ganglioside species (Fig 2.1). As such, GM3 plays a 
crucial role in regulating the level of expression of all other ganglioside species in cells. 
Although GM3 is one of the main gangliosides expressed in extra-neural tissues of 
vertebrates, it is generally expressed only in very small quantities in the healthy adult 
mammalian brain (Prokazova et al., 2009). Accumulation of GM3 in neural tissue has been 
shown to lead to toxic effects and apoptosis (Nakatsuji & Miller, 2001; Prokazova et al., 
2009; Sohn et al., 2006). GM3 has been successfully used as a treatment for tumors due to 
its potent anti-angiogenic and apoptotic effects (Abate, Mukherjee & Seyfried, 2006; 
Chung et al., 2009; Seyfried & Mukherjee, 2010). An increase in GM3 expression has also 
been observed in both human and animal models of AD (Chan et al., 2012), as well as in 
mouse models of stroke—reperfusion injury (Whitehead et al., 2011). Finally, additional to 
the sugar chains, the functions of gangliosides may also be determined by ceramides. In 
particular, certain gangliosides differ only by the length of their sphingosine backbone, 
d18:1 and d20:1 (18 carbon and 20 carbon species), and have been suggested to have 
unique roles within the cell (Angel, Spraggins, Baldwin & Caprioli, 2012; Kotani et al., 
1994; Whitehead et al., 2011; Woods et al., 2013).  
Labelling and visualizing gangliosides within tissue using immunohistochemistry 
(IHC) is a commonly used technique for identifying different species of gangliosides. 
However, the efficacy of antibody labelling on lipids in general is controversial and the 
availability of specific ganglioside antibodies for certain species can be very limited or 
non-existent (Richards et al., 2012). Moreover, immunolabelling is also incapable of 
distinguishing between the d18:1 and d20:1 species as the ceramides are hidden within the 
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cell membrane, inaccessible to antibodies for labelling. An alternative approach is the 
detection of gangliosides based on their molecular mass through spectrometry. Matrix-
Assisted Laser Desorption/Ionization Imaging Mass Spectrometry (MALDI IMS) can 
detect ganglioside molecules directly within tissue sections without any kind of 
immunological labelling. The masses and intensities of all ganglioside ions are recorded 
simultaneously within an anatomical reference point (Fig 2.2). 
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Figure 2.2: MALDI IMS Workflow. Following surgery, rats are euthanized via anesthetic 
overdose and decapitated. Fresh brains are isolated and sectioned at 10μm on a cryostat 
onto MALDI plates. Sections sprayed with CMBT matrix using an airbrush are processed 
on a MALDI mass spectrometer (Sciex 4700). Regions of interest (ROIs) are chosen with 
reference to the rat brain atlas by Paxinos and Watson. Stroke regions are identified and 
mass spectra are averaged from the infarct as well as from the corresponding non-injured 
striatum on the contralateral hemisphere. Mass spectra are generated from each ROI, and 
the peak height for the species of interest is calculated. Quantified data are represented as 
the ratio of the peak height between the ipsilateral (stroke) and contralateral ROIs. 
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Perturbations in the normal homeostatic expression of gangliosides have been 
observed in several models of neurodegeneration such as AD (Barrier et al., 2007; 
Svennerholm & Gottfries, 1994), Huntington’s disease (Desplats et al., 2007), Parkinson’s 
disease (Schneider et al., 2013), and prion diseases (Martino et al., 1993); however, this has 
not yet been reported within the context of comorbidities. Previous work using the same 
animal model as this study, has demonstrated that a synergistic relationship exists between 
animal models of stroke and AD both pathologically and behaviourally (Cechetto, 
Hachinski & Whitehead, 2008; Whitehead, Cheng, Hachinski & Cechetto, 2007), however 
the mechanism of this interaction remains unclear. This study utilizes both the novel 
MALDI IMS technique and, where possible, traditional IHC to examine changes in a-series 
ganglioside expression in rats who underwent either surgical striatal endothelin-1 (ET-1) 
injection (stroke alone group), bilateral icv injections of beta-amyloid (Aβ25–35) (Aβ alone 
group), or ET-1 with bilateral icv injections Aβ25–35 (combined Aβ/ET-1 group). The ET-
1 subcortical stroke model was chosen as it produces subcortical lacunar type infarcts that 
resemble those typically seen in patients who, upon post-mortem examination, have been 
identified as having pathological correlates of both AD and stroke (Snowdon et al., 1997). 
In addition, previous studies have demonstrated that targeted injections of ET-1 produced a 
transient focal ischemia-reperfusion injury in rats (Jiwa, Garrad & Hainsworth, 2010; 
Whitehead, Hachinski & Cechetto, 2005; Whitehead, Cheng, Hachinski, & Cechetto, 
2005). 
2.3   Materials and Methods 
2.3.1 Animals Models 
Rats were weighed before being anaesthetized in a Harvard anesthesia box with 3% 
isoflurane in 2 L/min oxygen and placed in a Kopf stereotaxic apparatus. Using an 
operating microscope, an incision was made in the scalp and the skull was exposed. 
Bregma was used as a reference point for all injection sites: Injections were administered 
with a Hamilton glass syringe at a rate of 1 μL over 30 sec. The syringe was left in place 
for 3 min after each injection then slowly removed. Rat body temperature was maintained 
at 37°C on a heating pad during the surgical and recovery periods before being returned to 
a cage. To induce Aβ toxicity, rats received 15 μL bilateral icv injections of the toxic Aβ 
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fragment, Aβ25–35 (50 nmol), at coordinates -0.8 mm (anterior/posterior), ±1.4 mm 
(medial/lateral) and -4.0 mm (dorsal/ventral). Aβ25–35 (Sigma-Aldrich Co., St. Louis, 
USA) was dissolved in saline and stored at -80°C in 30 μL aliquots and kept on dry ice 
prior to injection to prevent aggregation and allow better diffusion throughout the 
ventricles (Whitehead, Hachinski & Cechetto, 2005; Whitehead, Cheng, Hachinski, & 
Cechetto, 2005). To induce stroke, rats received a 3 μL unilateral injection of the potent 
vasoconstrictor ET-1 (60 pmol) into the right striatum, at coordinates +0.5 mm 
(anterior/posterior), -3.0 mm (medial/lateral) and -5.0 mm (dorsal/ventral). ET-1 (Sigma-
Aldrich Co., St. Louis, USA) was dissolved in sterile water and stored at -80°C in 8 μL 
aliquots and kept on dry ice prior to injection. To induce the comorbid Aβ/ET-1 model, rats 
received bilateral icv injections of Aβ25–35 followed by a unilateral ET-1 injection into the 
striatum at the same concentrations and coordinates as above. Sham surgery group animals 
underwent the same surgical procedure as the combined Aβ/ET-1 group rats but did not 
receive any chemical injections, only needle insertion to the appropriate brain regions. The 
mortality rate was slightly (but not statistically significantly) higher in ET-1 groups but was 
less than 10% of the total animals used and was attributed to the effects of the interaction 
between ET-1 and anesthesia. 
2.3.2 Euthanasia 
For histochemical and IHC analysis, rats were euthanized at 3 or 21 d post-surgery via 
Euthanyl overdose (0.5 mL, i.p.). Animals were then perfused transcardially with 0.01 M 
phosphate buffered saline (PBS) (pH 7.4) followed by 4% paraformaldehyde (PFA) (pH 
7.4). Brains were removed and kept in the same PFA solution for 24 hr, then cryoprotected 
in 30% sucrose until they were fully submerged. Brains were sectioned coronally on a 
Cryo3 Cryostat (TissueTek, Dublin, USA) into 35 μm thick sections and were stored in 
cryoprotectant at 4°C until used for immunohistochemistry. For MALDI IMS analysis, rats 
were euthanized via Euthanyl overdose (0.5 mL i.p.) at either 3 or 21 d post-surgery. Rats 
were decapitated and fresh whole brains were carefully removed and immediately frozen 
on dry ice. Frozen brains were stored at -80°C until used for MALDI IMS analysis. 
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2.3.3 Immunohistochemistry 
Sections from each experimental group were processed simultaneously to reduce variability 
between groups. Sections were washed in 0.1 M PBS (3 x 15 min each), then quenched for 
15 min in 1.5% hydrogen peroxide. Sections were washed in PBS (3 x 5 min each), then 
blocked in 1.5% bovine serum albumin (BSA) (Serological Research Institute, Richmond, 
USA) diluted in PBS with Triton-X (PBST) for 30 min. Sections were incubated with 
primary antibodies diluted in 1.5% BSA (PBST) for 48 hr at 4°C on a shaker. IHC 
procedure was similar for: mouse anti-rat OX-6 (1:1000, BD Biosciences, Mississauga, 
Canada), NeuN (1:1000, EMD Millipore, Billerica, USA), GFAP (1:1000, EMD Millipore, 
Billerica, USA) GM3 (1:500, Seikagaku Corporation, Tokyo, Japan), GM1 and GD1b 
(1:500, Ronald Schnaar, Johns Hopkins University, USA); however Triton-X was not used 
for GM3, GM1 or GD1b staining due to its membrane delocalizing effects (Lopez & 
Schnaar, 2009). Sections were then washed in PBS (3x 15 min each) then incubated with 
HRP-conjugated secondary antibodies diluted in 1.5% BSA (PBST) for 1 hr. HRP-
conjugated (anti-mouse IgG) (1:200, Vector Laboratories, Burlington, Canada) and anti-
rabbit IgG secondary antibodies (1:200, Vector Laboratories, Burlington, Canada) were 
used for the appropriate primary antibodies. Sections were washed in PBS (3 x 15 min 
each) then incubated in avidin-biotinylated complex (ABC) reagent (Vector Laboratories, 
Burlington, Canada) for 1 hr. Sections were then washed in PBS (3 x 5 min each) and 
developed in fresh 0.001% diaminobenzidine (DAB) (Vector Laboratories, Burlington, 
Canada) at 10 mg in 20 mL PBS with 300 μL 3% H2O2, Sigma for 5 min. Sections were 
washed in PBS (3 x 15 min each) then mounted onto VWR microscope slides coated in 
0.3% gelatin, dehydrated, cleared with xylene and then cover-slipped with Depex (Fisher 
Scientific). 
2.3.4 Immunofluorescence 
Free-floating sections were washed in PBS (3 x 10 min) then blocked in 1.5% BSA for 1 hr 
at room temperature. Sections were incubated with antibodies to GM3 [1:500] and either 
NeuN (1:1000, Millipore, Billerica, USA), GFAP (1:1000, Millipore, Billerica, USA) or 
IBA-1 for activated microglia/macrophages (1:1000, Santa Cruz Biotechnology Inc., Santa 
Cruz, USA) in 1.5% BSA for 48 hrs at 4°C. Sections were washed in PBS (3 x 10 min 
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each) then incubated with FITC conjugated anti-mouse IgG (1:300, Santa Cruz 
Biotechnology Inc., Santa Cruz, USA) and TR-conjugated anti-rabbit IgG (1:300, Santa 
Cruz Biotechnology Inc., Santa Cruz, USA) for 1 hr at room temperature in the dark. 
Sections were washed in PBS (3 x 10 min) and mounted onto microscope glass slides and 
cover-slipped with Fluoroshield mounting media (Sigma-Aldrich, Toronto, Canada). 
Fluoro Jade B. FJB is commonly used as a marker of neurodegeneration in the brain. 
Sections were washed in PBS (6 x 10 min each) then mounted onto microscope slides with 
0.3% gelatin and allowed to dry overnight. Slides were placed in 1% sodium hydroxide and 
in 80% ethanol for 5 min. Slides were then rehydrated in 95% ethanol for 3 min; 70% 
ethanol for 3 min; 50% ethanol for 2 min, and finally distilled water (3 x 1 min each). 
Slides were then incubated in 0.06% potassium permanganate (KMnO4) for 15 min on a 
shaker, in the dark. Slides were washed in distilled water (3 x 1 min each), then placed in 
fresh 0.0004% FJB (Millipore, Billerica, USA) in 0.1% acetic acid for 20 min on a shaker 
in the dark. Slides were washed in distilled water (3 x 1 min each) then allowed to dry in 
the fume hood before a xylene clearance step (1 min) and cover-slipped with Depex.  
Microscopy Imaging. Images were taken on a Leica DC300 (Leica Microsystems, 
Concord, Canada) microscope camera. Analysis and quantification was carried out using 
Image J (Wayne Rasband, National Institute of Health, Bethesda, USA) by one observer 
who was blinded to the experimental groups. 
2.3.5 MALDI Imaging Mass Spectrometry 
Fresh frozen rat brains were sliced on a CM 1850 cryostat and 10 μm coronal sections were 
taken from the striatum (stroke injury site) for MALDI IMS analysis. Sections were thaw 
mounted onto a MALDI target plate and dried in a desiccator for 10 min. An artist’s 
airbrush (Iwata HPBH, Japan) was used to apply 2 mL of 15 mg/mL 5-Chloro-3-
mercaptobenzothiazol (CMBT) (Sigma-Aldrich, Toronto, Canada) matrix dissolved in a 
4:4:1 mixture of chloroform: ethanol:water solvent, allowing each layer to dry completely 
before spraying the next layer thus minimizing delocalization of molecules within the 
tissue. Once the matrix was uniformly applied to the plate surface and dried, the plate was 
inserted into a Sciex MALDI 4700 TOF/TOF mass spectrometer (Sciex, Foster City, CA, 
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USA). Prior to acquiring an image, the instrument was calibrated using five peptide 
standards (4700 Calibration Mixture, Sciex) at 50 ppm mass tolerance. Reflectron and 
negative ion modes were used for all image acquisitions. During the scanning process, a 
laser beam is directed across the selected tissue sections at 100 μm steps and a mass 
spectrum is collected for each x,y coordinate. The laser ablates the tissue and causes the 
desorbed molecules in the tissue to ionize. These ions travel down a flight tube where they 
separate based on their mass-to-charge (m/z) ratio to a detector which records this data and 
compiles it into both a mass spectrometry data plot and a molecular image. The instrument 
took approximately 2 hr for acquisition of each image. The region of interest (ROI) for this 
MALDI IMS study included both the core of the infarct and the periphery in order to assess 
general changes in ganglioside metabolism after stroke and Aβ toxicity within the site of 
stroke injury. Representative MALDI IMS images were selected for the ET-1 group and 
Aβ/ET-1 combined group for each species of ganglioside in order to better visualize the 
changes in expression. Representative IMS images from the Aβ alone and control groups 
were not included as there were no significant alterations in ganglioside expression in any 
of these groups. The location of stroke injury within the striatum is highlighted with a 
green arrow in the MALDI IMS images. Three day (d) and 21 d time points were examined 
for each a-series ganglioside. The appropriate m/z ratio for each ganglioside species was 
confirmed using the Lipidmaps database (www.lipidmaps.org). Data was collected and 
analyzed as previously described (Fig 2.2). 
2.3.6 Data Analysis 
A single MALDI IMS image scan contains molecular information on the expression of 
each type of a-series ganglioside, the d18:1 and d20:1 species, as well as some unknown 
metabolic species. The molecular image can be used to locate a specific region of interest 
(ROI) such as the stroke region in the striatum where a mass spectrometry data plot is 
produced for that specific region for quantification. Multiple ROIs can be selected for 
comparison purposes. In this case, the injury site in one hemisphere was compared to the 
same location on the contralateral side of the brain. The peak height of each a-series 
ganglioside was quantified in both ROIs and, after baseline subtraction, a ratio was 
calculated for the differences in expression in the injured and non-injured tissue. The ratios 
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for multiple brain tissue scans in each group were compiled and a one way ANOVA was 
performed followed by a post-hoc Tukey’s multiple comparisons test to determine if there 
were any differences in expression between the surgical groups and the controls at both 
time points. Error bars represent the standard error of the mean (SEM) for each group. A p-
value of <0.05 was considered to be significant, n = 4 for each surgical group. 
2.4  Results 
2.4.1 Increased GM3 expression within infarcted region of combined Aβ/ET-1 
group persists at 21 d 
MALDI IMS results indicated a persistent perturbation in GM3 expression following stroke 
within the stroke region. Even though the MALDI MS instrument was capable of 
differentiating between the d18:1 and d20:1 species of GM3, signals from the d20:1 species 
fell below the threshold of detection and only signals from the d18:1 species were detected 
and quantified. At 3 d following surgery, MALDI IMS analysis demonstrated that GM3 
expression did not change following ET-1 injection alone or Aβ injections alone, however 
did increase in the combined Aβ/ET-1 group (Fig 2.3 A and 2.3 B) within the stroke 
region. By 21 d after surgery, GM3 expression remained at control levels in the Aβ alone 
group while GM3 significantly increased in the ET-1 alone group and remained elevated in 
the combined Aβ/ET-1 group within the stroke region (Fig 2.3 A and 2.3 B). To 
complement the MALDI IMS data, GM3 was detected by IHC 3 and 21 d following 
surgery. There was no GM3 signal detected in control treated animals (data not shown), as 
expected due to the low abundance of this species in the healthy adult brain. By 3 d 
following surgery, GM3 signal was detected within the stroke region of both ET-1 alone 
and combined Aβ/ET-1 groups (Fig 2.3 C and 2.3 D). By 21 d following surgery, GM3 
expression decreased within the infarct region of the ET-1 alone group compared to 3 d 
levels, whereas GM3 expression increased in the combined Aβ/ET-1 group over 3 d levels 
(Fig 2.3 C and 2.3 D). Similar to control and sham treated rats, there were no differences in 
GM3 expression (and all other gangliosides evaluated) within the right and left striatum of 
Aβ alone rats. 
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Figure 2.3: Increased GM3 expression within infarcted region of combined Aβ/ET-1 
group persists at 21 d. (A) Representative MALDI IMS images of ganglioside GM3 d18:1 
in stroke (ET-1 alone) and combined Aβ/ET-1 animals 3 and 21 d following surgery. 
Arrows indicate region of stroke induced infarct. Light regions in images represent areas of 
high expression while dark regions represent low levels of expression as indicated by 
intensity bar. (B) MALDI IMS quantification of ROIs from the striatum of control, sham 
surgery, Aβ alone, ET-1 alone, and combined Aβ/ET-1 animals at 3 d and Aβ alone, ET-1 
alone, and combined Aβ/ET-1 animals at 21 d. Data are expressed as the ratio of ipsilateral 
to contralateral ROIs. * indicates statistical significance +/- SEM over control and sham 
surgical groups, one-way ANOVA, Tukey’s post-hoc, p<0.05 (n = 4 for each group). There 
was an increase in expression observed in both the ET-1 alone and combined Aβ/ET-1 
groups from 3 to 21 d, however this was only statistically significant in the ET-1 alone 
group as the expression at 3 d was at control levels. (C,D) IHC detection and quantification 
of GM3 within the infarct region. Panel (C - right) is a higher magnification image of panel 
(C - left). * indicates statistical significance +/- SEM between groups, one-way ANOVA, 
Tukey’s post-hoc, p<0.05 (n = 6 for each group). 
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2.4.2 GM3 accumulation is associated with increased neurodegeneration and 
decreased cell survival at 21 d at the site of injury 
To evaluate the consequence of elevated GM3 expression within the stroke region, levels 
of cellular degeneration and neuronal loss were assessed. FluoroJade B (FJB) staining, a 
non-specific marker of cell death, was used to assess cellular degeneration at both 3 and 21 
d after surgery. Extensive FJB positive staining was observed within the borders of the 
infarct in both the ET-1 alone and combined Aβ/ET-1 groups (Fig 2.4 A). Quantification of 
FJB positive cells revealed no significant difference between the ET-1 alone and combined 
Aβ/ET-1 groups at 3 d following surgery (Fig 2.4 B). At 21 d post-surgery, the number of 
FJB-positive cells were lower in both ET-1 alone and combined Aβ/ET-1 groups compared 
to 3 d, however the combined group had significantly more degenerating cells (35% 
reduction from 3 d levels) within the ischemic region compared to the ET-1 alone group 
(65% reduction from 3 d levels). NeuN, a marker for mature neurons was used to assess the 
number of neurons that survived between 3 and 21 d within the infarcted striatum. At 3 d 
following stroke, there were equal numbers of NeuN positive neurons between ET-1 alone 
and combined Aβ/ET-1 groups. However, by 21 d, there were fewer NeuN positive 
neurons within the infarcted striatum in the combined group compared to the ET-1 alone 
group. Taken together with the FJB results, this suggests that the combined Aβ/ET-1 group 
experienced greater neuronal degeneration within the damaged striatum following stroke. 
To assess if GM3 expression was localized within neurons and if these neurons underwent 
degeneration, dual immunofluorescence labeling was performed (Fig 2.4 D). There was a 
high level of co-localization between NeuN and GM3 as well as between FJB and GM3, 
indicating that GM3 was expressed in degenerating neurons following stroke. 
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Figure 2.4: Effects of GM3 accumulation on neurodegeneration following stroke. (A) 
Photomicrographs of fluorojade-B immunofluorescence staining within the infarcted 
striatum of ET-1 and combined Aβ/ET-1 coronal rat brain sections. (B and C) 
Quantification of cell counts of FJB and NeuN cell counts. At 21 d following surgery, there 
was more FJB positive cells and less NeuN positive cells in the combined Aβ/ET-1 group 
compared to the ET-1 group according to one-way ANOVA and Tukey’s post-hoc, p<0.05 
(n = 6 for each group). (D) Photomicrographs of immunofluorescence dual labelling 
showing co-localization between NeuN and GM3 (shown individually and overlayed) and 
FJB and GM3 (shown individually and overlayed) in the infarct region of a 21 d combined 
Aβ/ET-1 animal. 
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2.4.3 Elevated GM2 at 3 d remains elevated at 21 d only in combined Aβ/ET-1 
group 
Since GM3 levels were differently expressed between surgical groups, we next evaluated 
the levels of GM2. Interestingly, GM2 expression levels were slightly different than the 
observed changes in GM3. The expression patterns of both the d18:1 and d20:1 species 
were profiled and quantified by MALDI IMS (Fig 2.5). By 3 d following surgery, both 
GM2 d18:1 and GM2 d20:1 expression in the combined Aβ/stroke group was found to be 
significantly elevated compared to Aβ alone and control groups (grey bars in Fig 2.5 B and 
2.5 D). Although GM2 expression in the ET-1 alone group also showed a very strong trend 
of increased expression in the GM2 d18:1 species, it was not found to be statistically 
significant (black bars in Fig 2.5 B). It was, however, found to be significantly elevated in 
the GM2 d20:1 species compared to Aβ alone and control groups (black bars in Fig 2.5 D). 
At 21 d post-surgery, GM2 expression returned to control levels in the ET-1 alone group 
for both the d18:1 and d20:1 species, but remained increased in the combined Aβ/ET-1 
group compared to Aβ alone and control groups (grey bars in Fig 2.5 D), though this 
increased expression was only statistically significant in the d20:1 species. 
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Figure 2.5: Elevated GM2 Expression at 3 d Remains Increased only in Combined 
Aβ/ET-1 Group. (A and C) Representative MALDI IMS images of GM2 d18:1 (A) and 
d20:1 (C) in stroke (ET-1 alone) and combined Aβ/ET-1 animals 3 and 21 d following 
surgery. Arrows indicate region of stroke induced infarct. (B and D) MALDI IMS 
quantification of ROI’s from the striatum of control, sham surgery, Aβ alone, ET-1 alone, 
and combined Aβ/ET-1 animals at 3 d and Aβ alone, ET-1 alone, and combined Aβ/ET-1 
animals at 21 d. Data are expressed as the ratio of ipsilateral to contralateral ROIs. Light 
regions in images represent areas of high expression while dark regions represent low 
levels of expression as indicated by intensity bar. There was no statistical increase in GM2 
expression between 3 and 21 d in any group, however, GM2 expression in the ET-1 group 
decreased significantly from 3 to 21 d (back to control levels). * indicates statistical 
significance +/- SEM over control and sham surgical groups, one-way ANOVA, Tukey’s 
post-hoc, p<0.05 (n = 4 for each group). 
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2.4.4 Elevated GM1 expression in combined Aβ/ET-1 group. 
Analysis of GM1 d18:1 expression was performed and data indicated no statistical 
difference between the ET-1 alone, Aβ alone, and control groups 3 d following surgery, 
however, GM1 expression in the combined Aβ/ET-1 group was significantly elevated 
compared to the other surgical and control groups (Fig 2.6 B). At 21 d, GM1 d18:1 
expression showed the same expression profile between experimental groups with no 
statistical differences (Fig 2.6 B). Analysis of the d20:1 species of GM1 demonstrated 
significantly increased expression in the combined Aβ/ET-1 group compared to all surgical 
and control groups at both 3 and 21 d post-surgery (Fig 2.6 D). 
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Figure 2.6: Elevated GM1 Expression in Combined Aβ/ET-1 Group. (A and C) 
Representative MALDI IMS images of GM1 d18:1 (A) and d20:1 (C) in stroke (ET-1 
alone) and combined Aβ/ET-1 animals 3 and 21 d following surgery. Arrows indicate 
region of stroke induced infarct. (B and D) MALDI IMS quantification of ROI’s from the 
striatum of control, sham surgery, Aβ alone, ET-1 alone, and combined Aβ/ET-1 animals at 
3 d and Aβ alone, ET-1 alone, and combined Aβ/ET-1 animals at 21 d. Data are expressed 
as the ratio of ipsilateral to contralateral ROIs. Light regions in images represent areas of 
high expression while dark regions represent low levels of expression as indicated by 
intensity bar. There were no statistically significant changes in GM1 expression between 3 
and 21 d in any of the groups. * indicates statistical significance +/- SEM over control and 
sham surgical groups in panel (B) and statistical significance over control, sham and ET-1 
alone surgical groups in panel (D), one-way ANOVA, Tukey’s post-hoc, p<0.05 (n = 4 for 
each group). 
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2.4.5 Increased GD1a [Na+] expression at 3 d in combined Aβ/ET-1 group 
All MALDI IMS experiments presented in this work were performed using negative ion 
mode. The most intense signals observed for GM1, GM2, and GM3 were their singly 
charged anions, [M - H+]1- (M minus H+ ions). Given that sialic acid is the most acidic site 
of these gangliosides, and each GM1, GM2, and GM3 has one sialic acid, the 
deprotonation site is likely the sialic acid. GD1a on the other hand is the only ganglioside 
studied in this work having two sialic acid groups. However, the doubly charged GD1a 
anion, [M - 2H+]2-, was not observed by MALDI MS. Instead, the sodium and potassium 
adducts were observed as two distinct peaks, [M - 2H+ + Na+]1- and [M - 2H+ + K+]1-, likely 
due to its considerable presence in tissue. Interestingly, GD1a showed very different 
patterns of expression for the sodium and potassium adduct ions. (Figs 2.7 and 2.8). At 3 d 
post-surgery, GD1a [Na+] d18:1 showed significantly increased expression in the combined 
Aβ/ET-1 group compared to controls (Fig 2.7 B and 2.7 D).  
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Figure 2.7: Increased GD1a [Na+] Expression at 3 d in Combined Aβ/ET-1 Group (A 
and C) Representative MALDI IMS images of GD1a [Na+] d18:1 (A) and d20:1 (C) in 
stroke (ET-1 alone) and combined Aβ/ET-1 animals 3 and 21 d following surgery. Arrows 
indicate regions of stroke induced infarct. (B and D) MALDI IMS quantification of ROI’s 
from the striatum of control, sham surgery, Aβ alone, ET-1 alone, and combined Aβ/ET-1 
animals at 3 d and Aβ alone, ET-1 alone, and combined Aβ/ET-1 animals at 21 d. Data are 
expressed as the ratio of ipsilateral to contralateral ROIs. Light regions in images represent 
areas of high expression while dark regions represent low levels of expression as indicated 
by intensity bar. GD1a [Na+] expression significantly decreased from 3 to 21 d in the d18:1 
species. There were no other significant changes in expression between 3 and 21 d in any 
of the groups. * indicates statistical significance over control and sham surgical groups 
one-way ANOVA, Tukey’s post-hoc, p<0.05 (n = 4 for each group). 
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2.4.6 Decreased expression of GD1a [K+] at 3 d in ET-1 alone group 
The d18:1 species expression in the combined Aβ/ET-1 group decreased at 21 d and was no 
longer different from the other groups. The potassium adduct of GD1a, (GD1a [K+]) (Fig 
2.8) showed a completely different pattern of expression from the GD1a [Na+]. At 3 d post-
surgery, the ET-1 alone group demonstrated a significantly decreased expression of GD1a 
[K+] compared to Aβ alone and control groups, but this returned to control levels by 21 d, 
whereas no statistical difference was observed at either time point in the combined Aβ/ET-
1 group, although there was a trend of decreased expression as well (Fig 2.8 A and 2.8 B). 
A similar trend was observed for the GD1a [K+] 20:1 species (Fig 2.8 C and 2.8 D). 
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Figure 2.8: Decreased expression of GD1a [K+] at 3 d in ET-1 alone group. (A and C) 
Representative MALDI IMS images of GD1a [K+] d18:1 (A) and d20:1 (C) in stroke (ET-1 
alone) and combined Aβ/ET-1 animals 3 and 21 d following surgery. Arrows indicate 
regions of stroke induced infarct. (B and D) MALDI IMS quantification of ROI’s from the 
striatum of control, sham surgery, Aβ alone, ET-1 alone, and combined Aβ/ET-1 animals at 
3 d and Aβ alone, ET-1 alone, and combined Aβ/ET-1 animals at 21 d. Data are expressed 
as the ratio of ipsilateral to contralateral ROIs. Light regions in images represent areas of 
high expression while dark regions represent low levels of expression as indicated by 
intensity bar. There were no statistically significant changes in expression between 3 and 
21 d in any of the surgical groups. * indicates statistical significance over control groups, 
one-way ANOVA, Tukey’s post-hoc, p<0.05 (n = 4 for each group). 
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2.5  Discussion 
Based on evidence from the literature (Chung et al., 2009; Nakatsuji & Miller, 2001; 
Prokazova et al., 2009; Sekigawa et al., 2011; Sohn et al., 2006; Woods et al., 2013; Yu, 
Suzuki & Yanagisawa, 2010; Yamamoto et al., 1996), the observed increase in simple 
ganglioside species GM2 and GM3 in the stroke region of the Aβ/ET-1 combined group at 
both 3 and 21 d after surgery is indicative of a more severe pathological response compared 
to ET-1 or Aβ alone. GM2 has been shown to be elevated immediately after TBI (Woods et 
al., 2013) and GM3 accumulation has been shown to increase toxicity and induce apoptosis 
in cells (Chung et al., 2009; Nakatsuji & Miller, 2001; Seyfired & Mukherjee, 2010; Sohn 
et al., 2006). The observed reduction of GM2 expression back to control levels following 
ET-1 alone at 21 d may imply that the brain has begun repair processes or the injury was 
less severe. GM2 expression levels within the combined Aβ/ET-1 rat brain remained 
elevated at 21 d which may indicate that the injury is persisting and thus more brain 
damage is occurring. This hypothesis supports previous pathological and behavioural 
findings using this combined animal model of Aβ/ET-1 in our lab (Amtul et al., 2014; 
Whitehead, Hachinski & Cechetto, 2005; Whitehead, Cheng, Hachinski, & Cechetto, 2005; 
Whitehead et al., 2007; Whitehead et al., 2011). It is possible that the observed 
accumulation of simple gangliosides is a result of the breakdown of the more complex a-
series gangliosides via enzymatic degradation; however, the expression patterns of both 
GM1 and GD1a observed in this study suggest that the degradation pathways may be more 
complex. A slight decrease in GM1 ganglioside occurred in the ET-1 alone group while an 
increase the simple species GM2 (at 3 d) and GM3 (at 21 d) was observed. This finding 
supports our initial A-series degradation hypothesis. Contrarily, in the combined Aβ/ET-1 
group, in which previous studies have shown that stroke induced damage was more severe 
(Whitehead et al., 2005; whitehead et al., 2007; Amtul et al. 2014), a significant increase in 
GM1 expression was observed despite there also being a significant increase in both GM2 
and GM3 at both 3 and 21 d. This finding does not rule out the A-series degradation 
hypothesis but suggests that the mechanism of simple ganglioside accumulation is more 
complex than degradation along the A-series pathway. Ganglioside synthesis from the 
common precursor GM3 can occur by adding sugar units to the oligosaccharide chain (i.e. 
along most of the A-series pathway) or by the addition of sialic acid residues (i.e. A to B-
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series pathway). It is possible that in the combined Aβ/ET-1 group, where an increase in 
both simple and complex a-series gangliosides was observed, the accumulation was due to 
the degradation of the sialic acid residues of B- or C-series gangliosides thus resulting in an 
increase in the A-series species. Further study into the enzymatic activities that regulate 
ganglioside metabolism during and post-brain injury is warranted to address this question. 
The accumulation of the simple ganglioside species GM3 is of particular interest 
due to evidence supporting its potential apoptotic properties (Chung et al., 2009; Nakatsuji 
& Miller, 2001; Seyfired & Mukherjee, 2010; Sohn et al., 2006). The immediate and 
significant increase along with the sustained expression of GM3 over time observed within 
in the combined Aβ/ET-1 rat brain may be reflective of the increased pathological response 
that was previously observed in this animal model (Amtul et al., 2014; Whitehead, 
Hachinski & Cechetto, 2005; Whitehead, Cheng, Hachinski, & Cechetto, 2005; Whitehead 
et al., 2007; Whitehead et al., 2011). Interestingly, GM3 did not show the same pattern of 
expression in the ET-1 alone brain, with a trend of increased expression only at 21 d post-
surgery, suggesting that the interaction between Aβ and the stroke injury was responsible 
for the observed accumulation of GM3 in the combined group and may have played a 
mechanistic role in the synergism of these two pathologies. Unexpectedly, results from the 
GM3 IHC and MALDI IMS images from the ET-1 alone group (Fig 2.2) were not fully 
congruent. This may be explained by the difference in the techniques themselves as IHC 
and MALDI IMS do not necessarily measure the same thing, especially with respect to 
detection of lipids. IHC measures the ability of the ganglioside antibody to bind to, and 
label GM3 on cellular membranes while MALDI IMS measures the signal intensity of ions 
of a particular mass-to-charge ratio corresponding to GM3 molecules. The lack of 
specificity for ganglioside antibodies to bind and label tissues in IHC is a significant 
challenge in the glycosphingolipid field and thus is the principle reason MALDI IMS was 
chosen as the main technique in this study. 
Previous work using a mouse model of stoke-reperfusion injury examined 
ganglioside expression in a number of key anatomical regions for ischemic risk, including 
the striatum, and found that there was an increase in complex ganglioside species GM1 and 
GD1a immediately after stroke which peaked at 3 d after injury then returned to basal 
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levels at later time points (Whitehead et al., 2011). This trend is similar to the results of the 
combined group in the current study. However, following stroke alone there was a decrease 
in GM1 and GD1a [K+] expression after injury. The differences in these results may be 
explained by the type and severity of injury the animals received. Whitehead et al. (2011) 
used a mouse model of middle cerebral artery occlusion (MCAO) that causes a severe, 
focal ischemic insult that damages a large region within the cerebral cortex, striatum, and 
hippocampus. This contrasts with the site specific striatal ET-1 ischemia model used in this 
study which was chosen as it best emulates the smaller, lacunar strokes seen in aging 
individuals who are at risk of developing dementia. The combination of Aβ-toxicity and 
stroke resulted in a more severe response than stroke alone, which may explain why the 
results of that surgical group better resemble the results of the severe MCAO stroke injury 
(Whitehead et al., 2011). 
Since the d18:1 and d20:1 species are hypothesized to have unique functions within 
the cell (Sekigawa et al., 2011), where possible, both species were quantified and analyzed. 
Although the main patterns of expression were similar, significant changes in expression 
were observed in the d20:1 species that did not reach statistical significance in the d18:1 
species. This leads to the possibility that a greater change in expression was occurring in 
the d20:1 species than its more prevalent d18:1 species within the site of ischemic injury; 
however, further investigations are needed to follow up on this finding. The significance of 
this finding lies in the potential for future therapeutics targeting gangliosides as the d20:1 
form may prove to be a more efficient therapeutic target than the d18:1 species. 
Although MALDI IMS has proven to be an invaluable and reliable tool for the 
investigation of ganglioside expression, this study is not without limitations. The most 
limiting factor to the use of MALDI IMS in clinically-relevant research is that it is 
generally considered to be only a semi-quantitative technique. According to Stoekli et al. 
(2007) and Lietz et al. (2013), MALDI IMS images differ from each other due to three 
main factors which vary from image to image: tissue heterogeneity, sample preparation, 
and ion suppression effects. These variations make it difficult to quantitatively compare 
between MALDI IMS images without producing a significant amount of error. However, 
this study was uniquely designed to circumvent all major sources of error that arise from 
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these factors. Firstly, MALDI IMS images from this study were not compared to each other 
but instead were compared to themselves. By comparing the stroke-injured hemisphere 
with the contralateral non-injured hemisphere, variability due to sample preparation and 
matrix application was negligible. Secondly, because the two quantified regions of interest 
were from the same tissue section on mirrored regions of each hemisphere of the brain, it 
can be assumed that any tissue heterogeneity would be equivalent in both regions and thus 
not a significant source of error. Finally, ionization suppression effects, which are mass 
spectrometry signals other than the signal of interest that suppress the overall signal 
obtained, can also be assumed to be equivalent based on this method of quantification. 
Quantification of MALDI IMS images remains a controversial and heavily researched area 
of study, and while our method of quantification does not eliminate all sources of error, 
variability, the largest source of error, was significantly minimized. 
This study was able to show, for the first time, that ganglioside expression was not 
only altered in stroke injury but is also differentially altered in a comorbid rat model of Aβ 
toxicity and stroke. Translating these animal findings to a potential clinical environment, 
changes in ganglioside expression may be indicative of a new mechanism of synergy and 
possible site of intervention for those at risk or currently suffering from AD and stroke 
comorbidities. 
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Chapter 3 : Age dependent and regional heterogeneity in the long-
chain base of A-series gangliosides observed in the rat brain using 
MALDI Imaging 
3  
In Chapter 2, both d18:1 and d20:1 species of a-series gangliosides were altered in response 
to the various neurodegenerative injuries. Interestingly, the d20:1 species often showed a 
more a severe perturbation of their homeostatic distribution in response to the injuries, 
suggesting that these species may be particularly susceptible to dysregulation. Little is 
known of the functional implications of gangliosides with varying carbon lengths, 
particularly for the less abundant simple ganglioside species, however, complex 
gangliosides with longer carbon chains have been reported to accumulate in an age-
dependent manner (Sugiura et al., 2008; Palestini et al., 1990; Sonnino et al., 2000). 
Limitations in the sensitivity and spatial resolution of MALDI IMS images of ganglioside 
observed in Chapter 2 meant that the d20:1 species of GM3 could not be detected. This led 
to establishment of refined sample preparation methodologies that, coupled with an 
upgraded instrument, led to dramatic improvements in ganglioside detection and spatial 
resolution (Appendix ii). Specifically, a modified sublimation protocol was developed 
which was tailored for the optimal detection of a-series gangliosides and published in the 
Journal of Visualized Experiments (Appendix iii). Therefore, armed with an improved 
MALDI IMS protocol, we sought to better understand the role of simple and complex 
ganglioside carbon chain length in the context of aging in Wt and Tg APP21 Fisher rats. 
 
3.1  Abstract 
Alterations in the long chain base of the sphingosine moiety of gangliosides have been 
shown to play a role in neurodevelopment and neurodegeneration. Indeed, the 
accumulation of d20:1 sphingosine has been referred to as a metabolic marker of aging in 
the brain, however, this remains to be shown in simple gangliosides GM2 and GM3. In this 
study, MALDI IMS was used to examine the neuroanatomical distribution of A-series 
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gangliosides with either 18 or 20 carbon sphingosine chains (d18:1 or d20:1) in Fisher 344 
rats across the lifespan. The ratio of d20:1/d18:1 species was determined across 11 regions 
of interest in the brain. Interestingly, a decrease in the d20:1/d18:1 ratio for GM2 and GM3 
was observed during early development with the exception of the peri-ventricular corpus 
callosum, where an age-dependent increase was observed for ganglioside GM3. An age-
dependent increase in d20:1 species was confirmed for complex gangliosides GM1 and 
GD1 with the most significant increase during early development and a high degree of 
anatomical heterogeneity during aging. The unique neuroanatomically-specific responses 
of d20:1 ganglioside abundance may lead to a better understanding of regional 
vulnerability to damage in the aging brain. 
 
3.2  Introduction 
Gangliosides are a class of glycosphingolipids that are found throughout all cells of the 
body, with certain species enriched in the central nervous system (CNS). They are part of a 
large family of lipid species that form an important structural and functional component of 
lipid rafts, a functional domain of the cell membrane enriched in phospholipids, 
cholesterol, and gangliosides in which protein-lipid interactions occur leading to signal 
transduction (Sonnino, Mauri, Ciampa, & Prinetti, 2013; Yu, Tsai, & Ariga, 2012). Within 
the CNS, each ganglioside appears to have unique effects on signal transduction. For 
example, ganglioside GM1 has been shown to enhance neuroprotection through modulation 
of neurotrophin release (Rabin, Bachis, & Mocchetti, 2002) and ion transport (Wu & 
Ledeen, 1994), while accumulation of ganglioside GM3 has been shown to lead to 
apoptotic cell death in astrocytes (Nakatsuji & Miller, 2001) and neurons (Sohn et al., 
2006). Moreover, perturbations in the homeostatic distribution of gangliosides has been 
observed in rodent models of brain injury such as middle cerebral arterial occlusion 
(MCAO) stroke (Whitehead et al., 2011), co-morbid stroke and amyloid beta toxicity 
(Caughlin et al., 2015), and traumatic brain injury (Woods et al., 2013), as well as in 
preclinical models and human patients with neurodegenerative diseases (Desplats et al., 
2007; Di Pardo, Amico, & Maglione, 2016; Kaya et al., 2017; Oikawa et al., 2009; 
Yamamoto, Nostrand, & Yanagisawa, 2006). Thus, there has been increasing interest in the 
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maintenance/enhancement of ganglioside homeostasis as a treatment for neurodegenerative 
conditions.  
Gangliosides are structurally composed of a hydrophilic domain, containing sialic acid 
residues attached to an oligosaccharide chain, along with a hydrophobic domain made up 
of a ceramide complex (Fig. 3.1 A). Ceramide is composed of a fatty acid attached to a 
sphingosine long-chain base (LCB). Gangliosides can be differentiated from each other 
based on the length of their oligosaccharide chain and the number of sialic acid residues in 
their hydrophilic domain, which determines the type of ganglioside as described by their 
designation (e.g. ganglio-monosialo 3 or GM3).  Gangliosides can also be differentiated by 
the type of fatty acid and number of carbons present within their ceramide domain. The 18 
carbon sphingosine, chemically denoted as d18:1, is the predominant species in brain 
gangliosides, with 20 carbon species (d20:1) being present in lower, but variable quantities 
(Rosenberg & Stern, 1966).  
Alterations in the LCB have been linked to neurodevelopment and also implicated as a 
potential mechanism in the development of neurodegeneration (Caughlin et al., 2015; 
Tamai et al., 1979). Structurally, the additional carbons present on the ceramide moiety 
lead to an increase in volume of the hydrophobic portion of the molecule. This alters the 
organization of the membrane and its fluid properties (Masserini, Palestini, & Freire, 
1989). Changes in the organization of the membrane has consequences for the ability of 
gangliosides in lipid-rich domains to interact with the external environment and carry out 
their function as modulators of cell signaling (Sonnino & Chigorno, 2000). Therefore, the 
presence of d18:1 or d20:1 species in the membrane may alter the effectiveness of signal 
transduction at the cell surface. The d20:1 species have also been referred to as a metabolic 
marker of aging (Palestini, Masserini, Sonnino, & Tettamanti, 1990) as these species have 
consistently been observed to increase with age in murine (Palestini et al., 1990; Palestini 
et al., 1993; Rosenberg & Stern, 1966; Sugiura et al., 2008; Valsecchi, Palestini, Chigorno, 
& Sonnino, 1996) and human brains (Mansson, Vanier, & Svennerholm, 1977). However, 
the literature on this topic has focused almost exclusively on major complex gangliosides 
GM1, GD1, GT1, and GQ1, with minimal neuroanatomically-specific information, and has 
not described how the LCB of minor, simple gangliosides shift during aging. This 
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information may be crucial as there is increasing evidence pointing to the potential role of 
simple ganglioside, such as GM3 and GM2, in the development and pathogenesis of 
neurodegenerative diseases and injuries (Caughlin et al., 2015; Whitehead et al., 2011; 
Woods et al., 2013), however, the role of the ceramide moiety remains unclear due to 
technical challenges in the detection of these low abundance species.  
Previous investigations have used MALDI IMS to visualize d18:1 and d20:1 species of 
ganglioside GM1 (Caughlin et al., 2015; Sugiura et al., 2008; Weishaupt, Caughlin, Yeung, 
& Whitehead, 2015; Whitehead et al., 2011). This technique has the advantage of 
simultaneously detecting multiple species of gangliosides (and other molecules) within the 
same sample based on their abundance and neuroanatomical location.  This tool is also a 
powerful technique to differentiate carbon numbers within ganglioside LCB, which cannot 
be done using antibody labelling.  A study describing the expression of d18:1 and d20:1 
species of all A-series gangliosides during the aging process has not yet been done.  
Therefore, the following study provides the first detailed examination of age-dependent 
changes in the LCB of both simple and complex A-series gangliosides across a large 
number brain regions in wildtype (Wt) and APP21 transgenic (Tg) Fisher 344 rats that 
contain the human mutations to the amyloid precursor protein (Agca et al., 2008; 
Weishaupt et al., 2015). We hypothesized that there would be significant regional 
differences in the ratio of d20:1 species relative to d18:1 across the brain throughout aging 
and that this would be enhanced in the Tg APP21 rat.  To achieve this, we used MALDI 
IMS (Fig. 3.1 B+C), for accurate neuroanatomically-localized detection of d18:1 and d20:1 
species across intact tissue sections. 
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Figure 3.1: Ganglioside structure and detection using MALDI IMS. Chemical structure 
and MALDI IMS of d18:1 and d20:1 gangliosides. (A) Gangliosides are composed of both 
a hydrophilic domain which extends into the extracellular space, and hydrophobic ceramide 
anchor (highlighted) which is embedded in the cell membrane. The hydrophillic portion 
contains an oligosaccharide chain and sialic acid residues which determine the type of 
ganglioside (i.e. GM1, GM2, GM3). The hydrophobic portion of the molecule is made up 
of a fatty acid and a sphingosine LCB tail with varying numbers of carbons. (B) 
Representative MALDI IMS molecular image depicting anatomical distribution of d18:1 
(blues), and d20:1 (yellow) GM3 species across a sagittal section of a P0 Fisher 344 rat 
head. (C) Representative mass spectrum using DAN matrix in negative reflection mode 
depicting the mass of a-series gangliosides (and corresponding m/z values) analyzed in the 
current study. From left to right: GM3 d18:1 (1179 Da), GM3 d20:1 (1207 Da), GM2 
d18:1 (1382 Da), GM2 d20:1 (1409 Da), GM1 d18:1 (1543 Da), GM1 d20:1 (1572 Da), 
GD1a[K+] d18:1 (1872 Da) and GD1a[K+] d20:1 (1901 Da). 
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3.3  Materials and Methods 
3.3.1 Animal model 
All procedures involving live animals were in accordance with the guidelines of the 
Canadian Council on Animal Care and approved by the University of Western Ontario 
Animal Use Committee (Protocol 2014–2016). Wt and Tg APP21 Fisher 344 rats were 
kindly provided by Dr. Yukel Agca (University of Missouri) and bred in-house. Tg APP21 
rats contained both human Swedish and Indiana mutations for the amyloid precursor 
protein gene. Because there were no significant transgene effects at each individual time 
point, the data for both Wt and Tg APP21 rats was pooled for all analysis for a final n value 
of 10 per group. Rats were aged to 4 different time points to be as representative as 
possible of the full lifespan, leading to a total of 40 rats included in the study. Rats were 
sacrificed via fresh-frozen extraction (described elsewhere) at either P0 (newborn), 3 
months (m, young rats), 12 m (middle aged), or 20 m (old). Brains were stored at −80°C 
until processed for MALDI IMS. 
3.3.2 MALDI IMS 
Brain tissue (or whole heads for P0 rats) were sectioned on a cryostat (Termo-Fisher 
Scientifc CryoStar NX50) at a thickness of 10 μm and thaw mounted onto electrically 
conductive Indium-Tin-Oxide (ITO) slides (Hudson Surface Technology Inc., Old Tappan, 
NY, USA). The slides were then coated in a thin layer of 1,5-Diaminonapthalene (DAN, 
Sigma-Aldrich, Oakville, ON, Canada) matrix via sublimation and incubated at −20 °C 
overnight. After a 10 min desiccation period, a 5 peptide calibration standard was applied 
(Sciex, Farmingham, MA. USA) and allowed to dry. An image of the plate was scanned for 
reference in the instrument and the instrument calibrated using the spotted standards to a 
mass tolerance of 50 ppm. Images were acquired using a Sciex MALDI 5800 TOF/TOF 
instrument in negative ion reflectron mode. MS images were acquired at a 70 μm raster 
with 20 shots/spectrum. This protocol has been previously described in detail (Caughlin et 
al., 2017). Representative MALDI IMS images of each ganglioside species quantified in 
the current study are shown in Fig 3.2.   
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Figure 3.2: Representative MALDI IMS images of each a-series ganglioside in all 4 
tissue sections. Representative images from the most anterior tissue section contained the 
ROIs for the cortical layers, striatum and aCC (A). The second tissue section contained the 
ROIs for the LSN and PVCC (B). The third section was at the level of the hippocampus 
and was used for all hippocampal ROIs (C). The most posterior section contained the ROI 
for the substantia nigra (D). Images are ordered from the earliest time point (P0 – left) to 
the latest time point (20 m – right) for each tissue section. 
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3.3.3 Data Analysis 
The regions of interest (ROIs) were confirmed using the rat brain atlas by Paxinos & 
Watson (1998). A total of 11 ROIs were quantified across the brain and were grouped into 
discrete anatomical/functional regions for quantitation. These clustered groups include: 
sub-cortical structures (striatum, lateral septal nucleus, and substantia nigra), the cortex 
(superficial, intermediate, and deep layers of the cortex), the hippocampus (CA1, dentate 
gyrus molecular layer, dentate gyrus granular layer), and white matter (anterior corpus 
callosum and peri-ventricular corpus callosum). MALDI IMS images were analyzed using 
TissueView sofware (Version 2, Sciex). A total of 4 tissue sections per brain were used to 
isolate discrete anatomical regions in order to quantify the 11 regions of interest, for a total 
of 160 MALDI MS images (40 rats×4 sections) and 440 total datasets (40 rats×11 ROIs). 
Peaks corresponding to major a-series gangliosides were isolated and identified, as 
confirmed by previous studies (Chan et al., 2009; Dufresne et al., 2017; Sugiura et al., 
2008; Woods et al., 2013) and the Lipidmaps database (www.lipidmaps.org). For 
quantification of MALDI-IMS data, the area under the curve (AUC) of the three largest 
isotopic peaks was determined and a ratio was obtained between the AUC of each species 
and total AUC. This corrected value was used to perform a ratio of the d20:1 species of 
each a-series ganglioside to the d18:1 species. This ratio value was used to make between 
group comparisons so as to reduce error produced by variability in sample preparation 
between images as previously published (Caughlin et al. 2015). For GD1, the more 
abundant K+ adduct peaks were used. Statistical analysis was performed using either a 
student’s t-test or a two-way ANOVA, followed by a Tukey’s post-hoc test. 
 
3.4  Results 
3.4.1 Genotype differences in LCB restricted to GM3 within the peri-ventricular 
corpus callosum. 
No significant differences in regional abundance across age were observed between Wt and 
Tg APP21 rats with the exception of ganglioside GM3 in the peri-ventricular corpus 
callosum where the fold increase of d20:1/d18:1 between P0 and 20 m was found to be 
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significantly higher in Tg APP21 rats than their Wt counterparts (Fig. 3.3). Given the lack 
of genotype specific differences in d20:1/d18:1 ratios at each individual time point, all 
future analysis used pooled data from both Wt and Tg APP21 rats. 
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Figure 3.3: Increased d20:1/d18:1 GM3 ratio in PVCC between birth and old age in 
TgAPP21 rats. Quantification of MALDI IMS data showing the fold change in 
d20:1/d18:1 signal between birth (P0) and old age (20 m) in the PVCC (A) and corpus 
callosum (B). Tg APP21 rats showed a significant increase in the d20:1/d18:1 LCB ratio 
between birth and old age compared to their Wt counterparts in the PVCC. A similar 
pattern was observed in the aCC, however, the fold change was not statistically different in 
this region. This transgene difference explains the high degree of variability observed at 
each individual time point in white matter regions. Data represented as group Means ± 
SEM,* indicates statistical significance, p < 0.05, via student’s T test, n=5 for each time 
point. 
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3.4.2 Significant anatomical heterogeneity throughout the rat life span within 
subcortical and basal ganglia structures for gangliosides GM1 and GM3 
Sub-cortical structures are susceptible to age related changes associated with Alzheimer’s 
disease (basal forebrain) Parkinson’s disease (substantia nigra) and Huntington’s disease 
(striatum). We measured the ratio between d20:1 and d18:1 species of gangliosides within 
the lateral septal nucleus (LSN) of the basal forebrain, substantia nigra (SN), and striatum 
of rats from P0 to 20 m of age (Fig. 3.4 A). There were no regional differences in GM1 
d20:1/d18:1 ratios in P0 rats. At 3 m, the d20:1/ d18:1 ratio was significantly lower in the 
SN (0.15) than the striatum (0.21), and remained the lowest of the three regions up to 20 m 
(Fig. 3.4 B). At 12 m, the ratio of GM1 d20:1/d18:1 species was significantly higher in the 
striatum (0.28) than the SN (0.20), with the LSN between the two (0.24), however, by 20 
m, the regional differences shifted back to a similar pattern as that of 3 m, with both the 
striatum (0.25) and LSN (0.23) demonstrating significantly higher GM1 d20:1/d18:1 ratios 
than the SN (0.17). When measuring differences in d18:1/d20:1 ratios for GD1, no regional 
differences were observed at any time point in the basal ganglia (Fig. 3.4 C). The GD1 
d20:1/d18:1 ratio increased from P0 to 12 m in all subcortical structures then dropped 
slightly by 20 m. 
With respect to simple ganglioside GM3 during aging, the d20:1/d18:1 ratio 
increased slightly from P0 (0.43, 0.34) to 12 m (0.49, 0.39) within the LSN and striatum 
respectively. The d20:1/d18:1 GM3 ratio within the SN decreased significantly from 0.6 in 
P0 rats to 0.32 at 3 m, which then continued to decrease slightly up to 20 m (0.27) (Fig. 3.4 
D). These divergent patterns for the GM3 LCB ratio during aging are indicative of 
significant regional differences within subcortical structures. Indeed, at P0, a regional 
difference was observed with significantly higher d20:1 content observed in the SN (0.6) 
over the striatum (0.35) and LSN (0.43). This pattern shifted at 12 m where the SN 
d20:1/d18:1 ratio decreased to 0.32 while the LSN ratio increased to 0.49, leading to a 
significant difference between these two brain regions. These regional differences 
disappeared at 20 m as the d20:1/ d18:1 ratio dropped in the LSN (0.38) (Fig. 3.4 D). There 
were no regional differences observed in the GM2 species (Fig. 3.4 E), however, all brain 
regions showed a significant decrease in the d20:1/d18:1 ratio between P0 and 3 m which 
then remained stable up to 20 m. 
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  Figure 3.4: Significant regional heterogeneity in ganglioside LCB ratio among sub-
cortical structures. Visualization of regional and age-dependent shifts in a-series 
gangliosides in sub-cortical rat brain structures. (A) Representative MALDI IMS overlay 
images showing the anatomical distribution of GM1 d18:1 (red) and d20:1 (green). (B–E) 
Quantification of the d20:1/d18:1 ratio at each time point for GM1 (B), GD1 (C), GM3 
(D), and GM2 (E). The d20:1/ d18:1 LCB ratio increased in an age-dependent manner for 
complex gangliosides GM1 and GD1 up to 12 m then plateaued up to 20 m (GM1) or 
decreased slightly (GD1). Significant anatomical heterogeneity in the LCB ratio was 
observed from simple ganglioside GM3 among sub-cortical structures, with a decrease 
during early development in the SN, and a stable ratio in the striatum and LSN throughout 
the lifespan. Data represented as group Means ± SEM, *indicates statistical significance, p 
< 0.05, via two-way ANOVA, Tukey multiple comparisons test, n = 10 for each time point. 
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3.4.3 Cortical layers show regional heterogeneity in ganglioside of LCB length 
Regional differences between the superficial, intermediate, and deep layers of the cerebral 
cortex have previously been reported (Weishaupt et al., 2015). The present study used 
similar cortical ROIs (Fig. 3.5 A) to evaluate alterations in the LCB length during aging in 
the rat. When measuring the LCB length of GM1, a similar d20:1/d18:1 ratio of 0.07–0.09 
was observed in all three layers of the cortex of P0 rats (Fig. 3.5 B). All three layers 
demonstrated variable but increased d20:1/d18:1 GM1 during aging with a plateau 
observed at 12 m. Interestingly, the intermediate layer demonstrated the highest ratio of 
d20:1/d18:1 expression for GM1 which became apparent at 3 m (intermediate – 0.30, 
superior – 0.25, deep – 0.20) and continued to be significantly higher than the deep layers 
up to 20 m. A similar pattern was observed for LCB length of GD1 whereby P0 rats had 
similar ratios of d20:1/d18:1 throughout all layers of the cortex followed by an increase in 
the ratio of d20:1/d18:1 at 3 m and a plateau at 12 m (Fig. 3.5 C). Like GM1, GD1 in the 
intermediate layer of the cortex also demonstrated the greatest increase in the LCB ratio 
which was most apparent at 12 m (intermediate – 0.61, superficial – 0.39, deep – 0.45) and 
continued to be significantly higher than the other cortical layers up to 20 m. The aging 
abundance profile of simple gangliosides GM3 and GM2 LCBs was the opposite of their 
complex ganglioside counterparts whereby the d20:1/d18:1 ratio was highest at P0, and 
then decreased during early development, plateauing at 3 m (Fig. 3.5 D,E). The deep layers 
of the cortex showed a significantly higher d20:1/d18:1 ratio at 3 m (0.43) than the 
superficial layers (0.32) (Fig. 3.5 D). GM2 demonstrated regional differences only at 20 m 
(Fig. 3.5 E), with the intermediate layers of the cortex showing a significantly higher 
d20:1/d18:1 LCB ratio (0.78) than the superficial layers (0.66). 
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  Figure 3.5: LCB ratio highest in superficial layers of the cortex and shows opposite 
pattern during early development among complex and simple gangliosides. 
Visualization of regional and age-dependent shifts in a-series gangliosides in the cerebral 
cortex of the rat. (A) Representative MALDI IMS overlay images showing the anatomical 
distribution of GM1 d18:1 (red) and d20:1 (green) across tissue along with the anatomical 
location of the ROIs in the superficial, intermediate, and deep layers of the cerebral cortex. 
(B–E) Quantification of the d20:1/d18:1 ratio at each time point for GM1 (B), GD1 (C), 
GM3 (D), and GM2 (E). The ratio of d20:1/d18:1 species increased in an age-dependent 
manner in complex gangliosides GM1 and GD1 up to 12 m of age, with the highest ratio 
observed in the intermediate layers of the cortex. The ratio then plateaued or decreased 
slightly at 20 m. The LCB ratio dropped between P0 and 3 m in simple gangliosides GM3 
and GM2. Data represented as group Means ± SEM, *indicates statistical significance, p < 
0.05, via two-way ANOVA, Tukey multiple comparisons test, n = 10 for each time point. 
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3.4.4 Hippocampus: Age-dependent accumulation in d20:1/d18:1 species in the 
dentate gyrus molecular layer observed in complex gangliosides only. 
Three regions of the hippocampus (Fig. 3.6 A) were selected for analysis based on previous 
reports of regional differences in the ratio of d20:1/d18:1 for GM1 (Sugiura et al., 2008; 
Weishaupt et al., 2015). The d20:1/d18:1 ratio of GM1 increased in an age-dependent 
manner within the CA1 and dentate gyrus (DG) molecular layer (mol) of the hippocampus, 
however, the ratio remained stable in the granular layer (gr) of the DG throughout the rat 
lifespan (Fig. 3.6 B). There were no regional differences within the hippocampus at P0, 
however, pronounced regional differences were observed between all three layers post-
natally. The ratio of d20:1/d18:1 GM1 was highest in the DG mol where it increased from 
0.14 at P0 to 0.44 at 3 m and continued to increase up to 20 m (0.51). A similar pattern was 
observed within the CA1 (P0–0.18, 3 m – 0.27, 20 m 0.33). The DG gr showed the lowest 
d20:1/d18:1 ratio of GM1 within the hippocampus remaining relatively unchanged from P0 
(0.18) to 20 m (0.17). As noted in the previous brain regions, the d20:1/d18:1 ratio of GD1 
was higher at P0 than for GM1. However, unlike GM1, not all layers of the hippocampus 
showed age-dependent increases in the ratio of d20:1/d18:1 species. This trend was only 
observed in the DG mol where the d20:1/d18:1 ratio increased from 0.26 at P0 to 0.4 at 3 
m, and continued to increase to 0.52 at 12 m, where it plateaued up to 20 m (Fig. 3.6 C). 
The DG gr demonstrated an unexpected decrease in the ratio of GD1 d20:1/d18:1 between 
P0 (0.37) and 3 m (0.25) which then increased at 12 m (0.34) only to drop back down at 20 
m (0.24). Equally interestingly, the CA1 region showed no change in the LCB ratio 
between P0 and 3 m, but increased between 3 m (0.26) and 12 m (0.37), then dropped 
slightly at 20 m (0.3). 
As was observed in the cortex, the ratio of d20:1/d18:1 for simple gangliosides 
GM2 and GM3 was highest at P0 followed by a large decrease at 3 m where it remained at 
this level or decreased slightly at 20 m (Fig. 3.6 D,E). There were no regional differences 
in the GM3 LCB ratio within the hippocampus, however, the d20:1/d18:1 ratio did 
decreased between P0 and 20 m (CA1 0.61–0.26, DG mol 0.55–0.22, DG gr 0.48–0.22), 
with the most significant drop occurring in early development. There were modest but 
statistically significant differences in the GM2 d20:1/d18:1 ratio at P0 (Fig. 3.6 D; CA1 – 
1.17, DG gr – 1.31) and 12 m (DG mol – 0.86, DG gr – 0.72) within the hippocampus. 
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Figure 3.6: Significant regional heterogeneity in d20:1/d18:1 ratio during aging 
among hippocampal layers. Visualization of regional and age-dependent shifts in A-series 
gangliosides in the hippocampus of the rat. (A) Representative MALDI IMS overlay 
images showing the anatomical distribution of GM1 d18:1 (red) and d20:1 (green). (B–E) 
Quantification of the d20:1/d18:1 ratio at each time point showing the significant regional 
differences across the lifespan for each A-series ganglioside, GM1 (B), GD1 (C), GM3 (D), 
and GM2 (E). Significant anatomical heterogeneity in the age-dependent accumulation of 
d20:1 species was observed in the various sub-regions of the hippocampus for complex 
gangliosides GM1 and GD1 while the LCB ratio dropped during early development in 
simple gangliosides GM3 and GM2. Data represented as group Means ± SEM,* indicates 
statistical significance, p < 0.05, via two-way ANOVA, Tukey multiple comparisons test, n 
= 10 for each time point. 
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3.4.5 Age-dependent increase in LCB ratio observed in the white matter for both 
complex gangliosides and simple ganglioside GM3. 
Changes in white matter have been linked to several aging related neurodegenerative 
diseases. We investigated two distinct regions within the corpus callosum that clinically 
demonstrate differing vulnerability to structural changes in AD patients (Gao et al., 2014) 
(Fig. 3.7 A). The two regions used in our analysis were the anterior corpus callosum (aCC) 
adjacent to the striatum, and a more caudal sampling from the white matter adjacent to the 
ventricles, peri-ventricular corpus callosum (PVCC). Interestingly, the PVCC expressed 
higher ratios of d20:1/d18:1 ganglioside species than the more rostral aCC. Both GM1 and 
GD1 gangliosides showed an increase in d20:1 species up to 12 m which then plateaued to 
20 m (Fig. 3.7 B,C). For GM1 (Fig. 3.7 B), the d20:1/d18:1 ratio increased significantly 
from P0 (aCC–0.07, PVCC – 0.08) to 3 m (aCC – 0.13, PVCC – 0.14), and continued to 
increase at 12 m (aCC – 0.18, PVCC – 0.21). A more pronounced age-dependent increase 
in d20:1 species was observed for ganglioside GD1 in the PVCC. The d20:1/d18:1 ratio 
increased between each time point (Fig. 3.7 C; P0 – 0.22, 3 m – 0.48, 12 m – 0.7, 20 m – 
0.75). For the aCC, a similar pattern was observed to that of the PVCC, however, the 
d20:1/d18:1 ratio dropped between 12 m (0.5) and 20 m (0.4). Interestingly, regional 
differences were observed between the two white matter regions for the GD1 LCB ratio 
which became apparent at 3 m (PVCC – 0.48, aCC – 0.3) and continued at 12 m (PVCC – 
0.7, aCC – 0.5) and 20 m (PVCC – 0.75, aCC – 0.4). 
The aging shifts of LCBs were completely different between simple gangliosides 
GM2 and GM3 (Fig. 3.7 D,E). The ratio of d20:1/d18:1 for GM3 increased steadily in the 
PVCC throughout aging, similar to what was observed for GM1 and GD1 (Fig. 3.7 D; P0 – 
0.58, 3 m – 0.67, 12 m – 0.82, 20 m – 0.96) whereas the aCC remained relatively constant 
(P0 – 0.5, 3 m – 0.54, 12 m – 0.59, 20 m – 0.55) resulting in significant differences 
between the aCC and PVCC ratios at 12 and 20 m of age. This was the only brain region to 
show an increase in the GM3 d20:1/d18:1 ratio during aging. Simple ganglioside GM2 
(Fig. 3.7 E) showed a similar pattern to that of the other brain regions, with a significant 
decrease in the d20:1/d18:1 ratio from P0 (aCC–1.06, PVCC–1.14) to 3 m (aCC–0.74, 
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PVCC – 0.74) where the ratio remained unchanged up to 20 m in the PVCC (0.75) and 
dropped slightly in the aCC (0.65). 
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Figure 3.7: Unique pattern of d20:1 LCB accumulation in the white matter for simple 
ganglioside GM3 as well as significant differences among white matter regions during 
aging. Visualization of regional and age-dependent shifts in a-series gangliosides in the 
white matter of the rat. (A) Representative MALDI IMS overlay images showing the 
anatomical distribution of GM1 d18:1 (red) and d20:1 (green) (B–E) Quantification of the 
d20:1/d18:1 ratio at each time point showing the significant regional differences across the 
lifespan for each a-series ganglioside, GM1 (B), GD1 (C), GM3 (D), and GM2 (E). An 
age-dependent increase in the d20:1/d18:1 ratio was observed in the PVCC for gangliosides 
GM1, GD1, and also simple ganglioside GM3. Data represented as group Means ± 
SEM,*indicates statistical significance, p < 0.05, via two-way ANOVA, Tukey multiple 
comparisons test, n = 10 for each time point. 
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3.4.6 Overall age effects 
In order to make global anatomical and age-dependent comparisons between all 11 regions 
of interest in d20:1/d18:1 content, the fold change was calculated between P0 and 3 m old 
rats (Fig. 3.8 A–D). This time period corresponds to the early post-natal stages of 
neurodevelopment and also served as the time period of the greatest observed changes in 
LCB length in the current study. We also calculated the fold change between 3 m and 20 m, 
a time period corresponding adolescence and old age in Fisher rats (Fig. 3.8 E–H). 
There was a 1.5–4 fold increase in the ratio of d20:1/d18:1 species between P0 and 
3 m for ganglioside GM1 in most brain regions examined, with the exception of the DG gr 
layer of the hippocampus, which remained unchanged. The largest fold increases occurred 
in the cerebral cortex, striatum, and the DG mol (Fig. 3.8 A). There was a 1.5–3 fold 
increase in the d20:1/d18:1 ratio for ganglioside GD1 between birth and 3 m, with the 
exception of the CA1 and DG gr of the hippocampus, in which the former remained 
unchanged, and the latter decreased 1.5 fold (Fig. 3.8 B). The largest fold increase in GD1 
d20:1/d18:1 content during early development occurred in the cerebral cortex and white 
matter regions. GM3 d20:1/d18:1 content decreased 1.5 to 3 fold across the brain with the 
exception of the two white matter regions, the LSN, and the striatum which remained 
unchanged (Fig. 3.8 C). GM2 d20:1/d18:1 content decreased roughly 2 fold across all brain 
regions examined, with the largest drop occurring in the superficial layer of the cortex and 
DG gr of the hippocampus (Fig. 3.8 D). 
During adulthood, the PVCC showed the largest fold increase for gangliosides 
GM1, GD1, and GM3 (Fig. 3.8 E–G). The PVCC was the only brain region which the 
d20:1/d18:1 ratio was significantly altered between 3 and 20 m of age. For ganglioside 
GD1, the PVCC along with the intermediate layers of the cerebral cortex and DG mol layer 
of the hippocampus had significantly elevated d20:1/d18:1 ratios, all other regions 
remained either unchanged or increased less than 50% during adulthood (Fig. 3.8 F). The 
PVCC was the only region where the LCB of GM3 was significantly increased between 3 
and 20 m, however, the DG gr layer of the hippocampus showed a significant decrease 
within the same period, while all other brain regions remained statistically unchanged (Fig. 
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3.8 G). There were no significant alterations in the d20:1/d18:1 ratio of GM2 between 3 m 
and 20 m of age (Fig. 3.8 H). 
  
113 
 
 
Figure 3.8: Differential alterations in LCB during early brain development and 
adulthood in Fisher rats. Overall age effects of d20:1/d18:1 ratio during post-natal rat 
brain development and adulthood. Quantification of the fold-change in the d20:1/d18:1 
ratio between P0 - 3 m (A–D) and 3 m–20 m (E–H). Ganglioside GM1 shows a significant 
fold increase between P0 and 3 m (A) which only continued to increase in the PVCC 
during adulthood (E). Ganglioside GD1 increased in all brain regions except the CA1 and 
DG gr layers of the hippocampus in early development (B) with a few regions continuing 
to increase into old age (F). Ganglioside GM3 showed either a decreased or stable LCB 
ratio in early development (C) which remained unchanged throughout adulthood except for 
the PVCC, which increased, and the DG gr, which decreased (G). Ganglioside GM2 LCB 
ratio decreased significantly in early development across the brain (D) and remained stable 
throughout adulthood (H). In order to calculate the global changes in early development 
and adulthood, an average value for the d20:1/d18:1 ratio was calculated (either P0 or 3 m) 
and used for comparison to each animal in the later time point (3 m or 20 m). Data 
represented as group Means ± SEM, *indicates statistical significance, p < 0.05, via two-
way ANOVA, Tukey multiple comparisons test, n = 10 for each time point. 
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3.5  Discussion 
Work in this study describes the age-dependent changes in the d20:1/d18:1 ratio of 
gangliosides across multiple cortical, subcortical, and white matter regions of the brain 
using MALDI IMS. It is the first to examine age-related alterations in the LCB of minor 
ganglioside components GM2 and GM3 which are currently gaining interest as potential 
mediators of neurodegeneration in a number of neurodegenerative diseases and injuries 
(Caughlin et al., 2015; Dufresne et al., 2017; Kaya et al., 2017; Whitehead et al., 2011; 
Woods et al., 2013). This work builds upon previous studies by Weishaupt et al. 2015, 
which described regional differences in the d18:1/d20:1 ratio of ganglioside GM1 in 3 m 
old Fisher rats, as well as the work of Sugiura et al. 2008, which was the first to use 
MALDI IMS to described age-dependent changes within hippocampus of mice. The 
current study confirmed many of the findings from the aforementioned studies pertaining to 
complex gangliosides GM1 and GD1. For example, Weishaupt et al. 2015 used similar 
regions of interest in the cortex and found, like the current study, that the lowest 
d20:1/d18:1 ratio occurred in the deep layers of the cortex, with significantly higher ratios 
in the intermediate and superficial layers. Anatomically, the intermediate and superficial 
layers of the cortex have a particularly high density of neurons which receive inputs from 
cholinergic neurons in the basal forebrain (Garofalo, Ribeiro-da-Silva, & Cuello, 1993) 
while the deep layers of the cortex have high connectivity to thalamic nuclei (Zarrinpar & 
Callaway, 2006).  A heterogeneous expression of A-series gangliosides have also been 
reported in various layers of brain cortices of normal and injured mice.  Specifically, Kwak 
et al. 2005 found that ganglioside GM3 was upregulated in deep layers of the cortex (layers 
4-6) after an MCAO stroke injury while GM1 was upregulated in more superficial layers 
(2-3) as well as the deep layers. The regional differences in the d20:1/d18:1 ratio observed 
in the current study may also reflect important functional differences in connectivity within 
the cortex that play a role in normal brain aging as well as the brain’s response to injury, 
however, this connection remains unclear and would be an interesting avenue of further 
investigation.  
We also observed significant regional differences within the various layers of the rat 
hippocampus from 3 m of age through to 20 m. The DG mol showed the highest ratio of 
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d20:1/d18:1 gangliosides followed by the CA1 and DG gr. Sugiura et al. 2008 reported an 
age-dependent accumulation of d20:1 species of ganglioside GD1 compared to d18:1 
species in the DG molecular layer of the mouse hippocampus. While this age-dependent 
accumulation was also observed in the current study, the CA1 region was only observed to 
increase between P0 and 12 m of age, while the DG gr showed a decrease in d20:1/d18:1 
between P0 and 20 m. This data suggests that not all layers of the hippocampus show an 
increase in GD1 d20:1/d18:1 ratio between birth and old age, which may be related to the 
various functions of different anatomical domains within the hippocampus. For example, 
the DG mol is known to be a critical area of connectivity in the perforant pathway, which 
receives input from the entorhinal cortex and sends connections to the CA3 (Witter & 
Amaral, 1991). It has been previously suggested that the high proportion of d20:1 species 
observed in the DG mol could be linked to the particular vulnerability of this perforant 
pathway to neurodegeneration during the development of Alzheimer’s disease (Hirano-
Sakamaki et al., 2015). Similarly, the sub-cortical structures examined in the current study 
are particularly vulnerable to the development of neurodegenerative diseases and 
perturbations in ganglioside homeostasis, as previously mentioned. Treatments focused on 
restoring depleted complex ganglioside GM1 have been therapeutically promising both in 
pre-clinical models of neurodegenerative diseases and clinically (Kreutz et al., 2011; 
Maglione et al., 2010; Schneider et al., 2013), pointing to the importance of understanding 
these ganglioside perturbations during aging. Interestingly, very different patterns of 
d20:1/d18:1 LCB ratios were observed for simple ganglioside GM3 among these sub-
cortical structures throughout the lifespan of the Fisher rats. The LCB ratio dropped during 
early development only in the SN (similar to the hippocampus and cortex) while levels 
remained unchanged in the striatum and LSN. This regional and age-dependent 
heterogeneity in GM3 LCB suggests that the d20:1 species of GM3 is differentially 
regulated within these subcortical structures and may be an indicator of regional 
vulnerability to damage and/or disease during aging. 
 While information on general alterations in the LCB length of simple gangliosides is 
scarce, our findings do not match with what has been hypothesized to occur based on 
previous studies conducted on complex gangliosides. Specifically, the age dependent 
accumulation of d20:1 species in the brain has been suggested to be a hallmark of the aging 
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process (Palestini et al., 1993), however this assertion was based on the analysis of 
complex gangliosides only. The results of the current study demonstrated that, relative to 
the d18:1 species, d20:1 content generally decreased between P0 and 3 m of age for 
gangliosides GM2 and GM3 and this ratio remains fairly constant throughout adult life. 
One potential reason for the observed decrease in the d20:1/d18:1 ratio in the early life of 
the rat may be related to the role of these gangliosides during neurodevelopment. It is 
possible that the observed decrease in d20:1 content in simple gangliosides may be due to 
an increase in d18:1 content during the first 3 months, however, this remains unclear in the 
current study and is thus an important caveat. Future studies which examine and compare 
alterations in individual ganglioside species may address this pitfall.   
Overall, data from this study showed that the greatest changes in LCB composition 
occurred between P0 and 3 m of age in the rat. This finding is in accordance with previous 
literature, using alternative techniques, focused on the very early stages of development 
(Palestini et al., 1990; Valsecchi et al., 1996). We demonstrated that the alterations in LCB 
length between P0 and 3 m of age was highly variable depending not only on the 
ganglioside species, whether it be simple or complex, but more importantly on the brain 
region as well.  In addition to examining the changes in LCB length in the early stages of 
rat brain development, we included a detailed report of the LCB length changes in the 
mature brain in order to determine if there are distinct regions and/or gangliosides that are 
particularly connected to the process of aging in the rat brain. Interestingly, the PVCC 
showed the largest fold increase in the d20:1/d18:1 ratio during adulthood for complex 
gangliosides GM1 and GD1, as well as the pro-apoptotic simple ganglioside GM3. This 
accumulation of d20:1 species in the PVCC suggests that this region of the brain may be 
particularly susceptible to the effects of aging and neurodegeneration in rats. Indeed, 
alterations in gangliosides abundance has been shown to produce abnormalities in white 
matter (Sheikh et al., 1999) and more recently, Di Pardo, Amico, and Maglione 2016 found 
decreased levels of complex gangliosides in the corpus callosum of a mouse model of 
Huntington’s disease. Moreover, the PVCC was the only region that showed an age-
dependent increase in the proportion of simple ganglioside GM3 d20:1. This finding in 
particular supports the notion of susceptibility to neurodegeneration due to the toxic nature 
of GM3 accumulation reported in the literature (Chung et al., 2009; Nakatsuji & Miller, 
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2001; Prokazova, Samovilova, Gracheva, & Golovanova, 2009; Sohn et al., 2006), the 
reported accumulation of GM3 in senescence-accelerated mice (Ohsawa & Shumiya, 
1991), as well as increased simple ganglioside content in the brains of both animal models 
and clinical patients with AD (Kaya et al., 2017; Oikawa et al., 2009; Yamamoto et al., 
2006). Regional differences between the two sub-regions of white matter observed in the 
current study may also have clinical relevance. In a study using magnetic resonance 
imaging to evaluate white matter hyperintensities in human patients with cerebrovascular 
diseases, the authors found that PVWM hyperintensities, but not deep white matter 
hyperintensities, were associated with aging and the incidence of dementia (Gao et al., 
2014).  Future studies should focus on evaluating the mechanism for ganglioside LCB 
alterations during aging in order to determine whether there are links to white matter-
specific pathological changes associated with brain aging and disease. 
Although the mechanisms involved in the age-dependent accumulation of d20:1 
gangliosides are not fully understood, there are several theories as to what may contribute 
to this finding. Firstly, it has been suggested that different types of enzymes, or enzyme 
modulators capable of distinguishing between LCB, may be present and are differentially 
active throughout neurodevelopment and aging (Palestini et al., 1990; Sonnino & 
Chigorno, 2000). Alternatively, Palestini et al. 1990 suggested that d20:1 intermediates 
may be preferentially used during biosynthesis and recycling of ganglioside degradation 
products with aging. Rosenberg and Stern 1966 were one of the first to report an age-
dependent increase in d20:1 sphingosine in the murine brain. In that study, using whole 
brain extracts, they also found that there was an age-dependent decrease of stearic acid 
content in ganglioside fractions. Overall, these studies along with the current study suggest 
that understanding the role of LCB length in mediating in neurodevelopment and brain 
aging are worthy pursuits for continued investigation.  
MALDI IMS is currently the only technique capable of simultaneously providing 
accurate detection, ionic abundance, and anatomical distribution data of gangliosides based 
on both their oligosaccharide and ceramide moieties, making it a powerful analytical tool 
for the study of gangliosides in the brain. The evolution of MALDI instrumentation along 
with refined sample preparation protocols allows for very high resolution imaging for the 
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visualization and analysis of discrete anatomical structures within intact tissue sections. 
This technique, however, is not without drawbacks. It is considered a semi-quantitative 
technique due to variability in sample preparation and instrumentation between runs. 
Additionally, detection of multisialylated ganglioside species such as GD1 are susceptible 
to in-source fragmentation and ionize attached to salt adducts [Na+] and [K+] (Richards et 
al., 2012). These factors dampen the signal obtained for this species and complicate the 
interpretation of GM1 data as well. However, because the current study quantified the ratio 
of one species to another within the same spectrum (d20:1/d18:1), direct comparisons 
between images and individual species abundance was avoided, thus reducing the effects of 
dampened signal and error produced by between-scan variability. In the end, the numerous 
benefits of MALDI IMS outweigh the pitfalls and it continues to be the most valuable tool 
for the investigation of membrane lipids in the brain. 
Overall, data from our study, for the first time, provide insight into the changing 
composition of simple ganglioside LCB throughout the brain during aging and provide a 
more in depth examination of LCB alterations in complex gangliosides. This study contains 
the most detailed examination of the anatomical distribution of d18:1 and d20:1 
ganglioside species to date in order to better understand the role of these membrane lipids 
during aging. Detailed analyses of ganglioside anatomical distribution patterns and 
abundance during healthy and pathological aging may provide valuable insight for the 
creation of effective lipid-derived therapeutics for neurodegenerative diseases and injuries.  
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Chapter 4 : Membrane lipid homeostasis in a prodromal rat model of 
AD: Characteristic profiles in ganglioside distributions during aging 
detected using MALDI imaging mass spectrometry 
 
In the previous chapter, accumulation of d20:1 ganglioside species in the aging brain was 
found to be more complex than previously thought. Firstly, simple gangliosides GM3 and 
GM2 generally showed a stable or decreased ratio of d20:1/d18:1 species during aging, 
countering the hypothesis that the accumulation of d20:1 species is a hallmark of the aging 
process (Palestini et al., 1990). Secondly, the pattern of the d20:1/d18:1 ratio during aging 
was highly heterogeneous across the brain, particularly for simple ganglioside GM3. To 
build upon the findings of the previous chapter, we next examined the abundance of each 
ganglioside species separately for a more detailed examination and comparison of simple 
and complex ganglioside patterns during aging in wild-type (Wt) and transgenic (Tg) 
APP21 Fisher rats. Additionally, a MALDI tandem MS (MS/MS) experiment was 
performed in order to identify some of the major ganglioside species examined in this 
work. The results has been provided as an appendix (Appendix iv). 
4.1  Abstract 
Accumulation of simple gangliosides GM2 and GM3 and gangliosides with longer long-
chain bases (d20:1) have been linked to toxicity in the brain and the pathogenesis of 
Alzheimer’s disease (AD).  Conversely, complex gangliosides, such as GM1, have been 
shown to be neuroprotective. Recent evidence using matrix-assisted laser desorption 
ionization (MALDI) imaging mass spectrometry (IMS) has demonstrated that a-series 
gangliosides are differentially altered during normal aging, yet it remains unclear how 
simple species are shifting relative to complex gangliosides in the prodromal stages of AD. 
Ganglioside profiles in Wt and Tg APP21 Fischer rats were detected and quantified using 
MALDI-IMS at P0 (birth), 3, 12, and 20 months (m) of age and each species quantified to 
allow for individual species comparisons. Tg APP21 rats were found to have a decreased 
level of complex gangliosides in a number of brain regions as compared to Wt rats and 
showed higher levels of ganglioside GM3. A unique pattern of expression was observed in 
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the white matter as compared to gray matter regions, with an age-dependent decrease in 
GD1 d18:1 species that was more pronounced in Tg APP21 rats coupled with significantly 
elevated levels of GM3 only in Tg APP21 rats. These results are indicative of a 
pathological shift in ganglioside homeostasis during aging that is worsened in Tg APP21 
rats. 
 
4.2  Introduction 
Mounting evidence points to the complex interaction of risk factors that can lead to the 
development of neurodegenerative diseases in the aging brain. As such, there is increased 
interest in identifying early indicators of brain vulnerability. These early changes could 
hold the key to a better understanding of disease progression and help identify mechanisms 
for preventative intervention. The cell membrane is the first line of defense against changes 
in the external environment. It can dictate how cells respond to adverse stimuli and 
ultimately determine the fate of the cell. Gangliosides are sialic acid-containing 
glycosphingolipids (GSLs) enriched within brain which form an important component of 
lipids rafts in cell membranes Lipid rafts are a major site of cell signal transduction and 
serve as a platform for protein-protein and protein-lipid interactions (Sonnino et al., 2013; 
Yu et al., 2012). The healthy brain maintains a homeostatic distribution of gangliosides in 
order to regulate signal transduction, however, perturbations in this distribution have been 
observed in both pre-clinical models and clinical cases of neurodegenerative diseases such 
as Alzheimer’s disease (AD) (Oikawa et al., 2009), Huntington’s disease (Maglione et al., 
2010), Parkinson’s disease (Schneider et al., 2013), as well as prion diseases (Ohtani et al., 
1996; Tamai et al., 1979). Ganglioside distribution has also been found to be perturbed in 
response to neurodegenerative injuries such as stroke (Caughlin et al., 2015; Whitehead et 
al., 2011) and traumatic brain injury (Woods et al., 2013). 
Glycosphingolipids are made up of two main domains, an oligosaccharide moiety 
exposed to the extracellular environment, and a ceramide moiety embedded within the lipid 
bilayer. The oligosaccharide moiety acts as a coding unit which can dictate the types of 
interactions that take place within a specific microdomain (Ledeen & Wu, 2015). The 
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ceramide moiety contains a sphingosine tail with varying numbers of carbons which can 
alter the fluidic properties of the membrane and has regulatory effects on the 
oligosaccharide moiety (Masserini et al., 1989).  A-series gangliosides contain structurally 
simpler precursor species GM3 and GM2 and complex species GM1 and GD1. Complex 
gangliosides are the predominant form of gangliosides expressed within the healthy adult 
brain while simple gangliosides are only expressed in small quantities.  
The quantity of simple and complex gangliosides shifts during early development 
and is dictated by the expression and activity of metabolic enzymes such as sialyl-
transferases and glycosyltransferases. After birth, synthesis of complex gangliosides is 
upregulated while synthesis of simple gangliosides is downregulated (Rosenberg & Stern, 
1966). This shift in expression during early development is related to the function of each 
ganglioside. For example, simple ganglioside GM3 has been shown to upregulate apoptotic 
and inhibit angiogenic vascular endothelial growth factor (VEGF) signalling pathways in 
vitro (Chung et al., 2009; Nakatsuji & Miller, 2001; Sohn et al., 2006), an important 
function in early brain development to regulate plasticity, but potentially problematic if 
upregulated in the adult brain. Moreover, accumulations of simple gangliosides in the brain 
have been linked in a number of neurodegenerative diseases (Dufresne et al., 2017) and 
injuries (Caughlin et al., 2015; Whitehead et al., 2011; Woods et al., 2013).  
Ganglioside GM1 is highly expressed throughout the mammalian brain but is 
particularly abundant in cerebral white matter (Ledeen & Wu, 2015; Rubovitch et al., 
2017). In rats, increases in GM1 during development are thought to be linked to myelin 
thickening (Aydin et al., 2000). GD1 is highly expressed in the dendrites and synapses of 
rat brains and is thought to play an important role in cell differentiation as well as cell 
contact and interaction during development (Aydin et al., 2000; Palestini et al., 1990). 
Total ganglioside content has been observed to increase 8 fold in adult mouse brains 
compared to embryonic mouse brains. In humans, complex gangliosides GM1 and GD1 
increase 12 – 15 fold between gestation and infancy (Yu et al., 2009). This increase in 
complex gangliosides is thought to be vital to the proper maintenance of brain networks 
during adulthood.  
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Altered ganglioside homeostasis has been observed in the brains of patients with 
AD such that there is a depletion of protective complex gangliosides GD1 and GM1 along 
with an increase in simple gangliosides GM2 and GM3. In early onset AD, complex 
gangliosides have been observed to decrease 58-70% in gray matter regions and 81% in 
frontal white matter (Svennerholm & Gottfries, 1994). An accumulation of simple 
ganglioside GM3 has been observed both clinically in patients with AD and in transgenic 
mouse models of AD, which show regional accumulations of GM3 in the entorhinal cortex, 
forebrain, and surrounding cerebral blood vessels (Chan et al., 2012; Knight et al., 2014; 
Yamamoto et al., 2006).  Previous evidence has shown that there are significant regional 
differences in the vulnerability to altered lipid metabolism in the human AD brain (Cutler 
et al., 2004; Hirano-Sakamaki et al., 2015).  The balance between complex and simple 
gangliosides may play an important role in the development and progression of AD. 
Indeed, Oikawa et al. showed that transgenic mice overexpressing mutant amyloid 
precursor protein (APP) coupled with a defective GM2 synthase gene demonstrated 
increased GM3, decreased GM1 and a concomitant deposition of beta-amyloid within their 
brain (Oikawa et al., 2009).  Additionally, alterations in the ceramide moiety of 
gangliosides may also play an important role in the development of neurodegenerative 
diseases. The accumulation of long chain ceramides during normal aging has been 
observed in the mouse brain (Cutler et al., 2004; Sugiura et al., 2008).   Moreover, post-
mortem brains of patients with AD have shown that the accumulation of long chain 
ceramides was exacerbated in regions which were susceptible to neurodegeneration and 
was correlated with disease severity (Cutler et al., 2004). Oikawa et al. 2009, found an 
increased ratio of d20:1 to d18:1 species of GD1b in the cerebral cortex of brains of 
patients with AD compared to controls and suggested that this increased ratio may be a 
major cause of enhance Aβ assembly in the brain. An altered d20:1/d18:1 species ratio was 
also observed in the molecular layer of the hippocampus in human AD brains suggesting a 
role for variable sphingosine base length in mediating neurodegeneration along the 
perforant pathway (Hirano-Sakamaki et al., 2015). These studies highlight the importance 
of examining both the ceramide and oligosaccharide domains of gangliosides within the 
context of patients with AD. 
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To date, there is very little understanding from a neuroanatomical perspective on how 
gangliosides change their composition profile during aging, partly due to a lack of 
technology capable of performing such analysis. MALDI IMS can overcome this challenge 
by performing mass spectrometry directly on intact brain tissue to provide neuroanatomical 
spatial information with respect to the gangliosides. The following study uses MALDI IMS 
to detect and quantify gangliosides in multiple brain regions during aging in the rat. We can 
further test the hypothesis of ganglioside perturbation as an early indicator of AD using a 
Tg rat (APP21). These Tg rats were created on a Fischer 344 background and express the 
human amyloid precursor protein (APP) gene with both the Swedish and Indiana mutations 
(Agca et al., 2008). As reported previously, these rats do not develop histological hallmarks 
of AD spontaneously when aged up to 30 months (Rosen et al., 2012). They do, however, 
develop histopathological signs of AD when challenged with brain extract from AD 
patients injected intracerebrally (Rosen et al., 2012), or when experimental hydrocephalus 
is induced (Silverberg et al., 2015). More importantly, these rats show age related cognitive 
impairment related to white matter damage, making them a strong pre-clinical model to 
investigate the prodromal phase of AD (Levit et al., 2017). 
4.3  Materials and Methods 
4.3.1 Animal Model 
All procedures involving live animals were in accordance with the guidelines of the 
Canadian Council on Animal Care and approved by the University of Western Ontario 
Animal Use Committee (Protocol 2014–2016). Wild-type (WT) Fischer  and transgenic 
(Tg) APP21 rats (Agca et al., 2008) were kindly provided by Dr. Yuksel Agca (University 
of Missouri) and bred in-house. Tg APP21 rats are homozygous for both human Swedish 
and Indiana mutations for the APP gene. Rats were euthanized at either P0 (newborn), 3 
months (m, young rats), 12 m (middle aged), or 20 m (old), with an N of 5 rats (either Wt 
or Tg APP21) per group. Intact fresh frozen brains were stored at -80° C until processed for 
MALDI IMS. 
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4.3.2 MALDI IMS 
Brain tissues (or whole heads for P0 rats) were sectioned on a cryostat (Thermo-Fisher 
Scientific CryoStar NX50, Toronto, Canada) at a thickness of 10 μm and thaw mounted 
onto electrically conductive Indium-Tin-Oxide (ITO) slides (Hudson Surface Technology 
Inc., Old Tappan, NY, USA). Slides were then coated with a thin layer of 1,5-
Diaminonapthalene (DAN, Sigma-Aldrich, Oakville, ON, Canada) matrix via sublimation 
and incubated at -20° C overnight. After a 10 min desiccation period, calibration standards 
were applied (Sciex, Farmingham, MA. USA) and allowed to dry before an image of the 
plate was scanned for reference in the instrument. Images were acquired using a Sciex 
MALDI 5800 TOF/TOF instrument in negative ion reflectron mode. The instrument is 
equipped with a 349 nm Nd:YLF “OptiBeam On-Axis” laser. The laser pulse rate used was 
1000 Hz. Data acquisition and processing of profiling data were respectively done using a 
TOF-TOF Series Explorer and Data Explorer (SCIEX). ITO-coated glass slides with tissue 
sample sections were mounted onto a MALDI plate adapter and loaded into the mass 
spectrometer.  Mass calibration was conducted at a 50 ppm mass tolerance and MS images 
were acquired at a 70 μm raster with 20 shots/spectrum. This protocol has been previously 
described in detail elsewhere (Caughlin et al., 2017). 
4.3.3 Data Analysis 
The regions of interest (ROIs) were confirmed using the rat brain atlas by Paxinos & 
Watson (1998). A total of 11 ROIs (Fig. 4.1) were quantified across the brain and were 
grouped into discrete anatomical/functional regions for quantitation. These clustered 
groups include: sub-cortical structures (striatum, lateral septal nucleus - LSN, and 
substantia nigra - SN), cortical layers (superficial, intermediate, and deep), the 
hippocampus (CA1, dentate gyrus - DG molecular layer, DG granular layer), and white 
matter (anterior corpus callosum – aCC, and peri-ventricular corpus callosum - PVCC). 
MALDI IMS was analyzed using TissueView software (Version 2, Sciex). A total of 4 
tissue sections per brain were used to isolate discrete anatomical regions in order to 
quantify the 11 regions of interest in the current study. Peaks corresponding to major a-
series gangliosides were isolated, as confirmed through the Lipidmaps database 
(www.lipidmaps.org).  In order to quantify changes in individual ganglioside species, the 
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total signal for each ROI in each image was summed by calculating the area under the 
curve (AUC) of the mass spectrum (between m/z 1100-1930) using Graphpad Prism 
(Version 7). The AUC of the 3 largest isotopic peaks for each individual ganglioside was 
summed and a ratio of the AUC of the individual ganglioside species relative to the total 
spectrum AUC of the ROI was determined. For GD1, both Na+ and K+ adduct peaks were 
detected and showed similar patterns, therefore, the more abundant K+ adduct was used to 
represent GD1 data.  For data analysis pertaining to Figure 2,  the AUC of simple 
gangliosides (GM3 and GM2 d18:1 and d20:1) were summed and compared to the total 
AUC of all A-series gangliosides at each time point for both Wt and Tg APP21 rats.  
Statistical analysis was performed using a two-way ANOVA, followed by a Sidak’s post-
hoc test +/- SEM.   
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Figure 4.1: MALDI IMS Detection and visualization of A-series gangliosides across 
rat brain tissue. A-series gangliosides contain species GM3, GM2, GM1, and GD1 and 
can be detected using DAN matrix in negative ion mode as d18:1 species (the predominant 
form) or d20:1 species via MALDI IMS. (A) Representative MALDI IMS overlaid images 
of four tissue sections containing the 11 regions of interest examined in the current study. 
Each region of interest is circled in yellow and labelled for reference.  (B) Representative 
H&E histology sections indicating the coordinates of each section according to the rat brain 
atlas by Paxinos & Watson (C) MALDI IMS data plot showing peaks corresponding to 
d18:1 and d20:1 a-series gangliosides along a 1100 – 1950 mass range. 
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4.4  Results 
4.4.1 Increased proportion of simple gangliosides at 12 m in Tg APP21 rats 
across the brain 
An accumulation of simple gangliosides has been observed clinically in AD brains, 
however it remains unclear whether this accumulation occurs in the prodromal stages of 
AD and whether alterations in levels of simple gangliosides can be observed in normal 
aging. We predicted that Tg APP21 rats would show a higher proportion of simple 
gangliosides than Wt rats and that this difference due to the effect of transgene would 
appear at the latest time point (20 m).  Although Tg APP21 rats did show a higher 
proportion of simple gangliosides, this transgene effect was not observed in 20 m rats. It 
was instead observed at 12 m (Fig. 4.2 C) which then disappeared at 20 m (Fig. 4.2 D). 
The transgene effect was statistically significant in several brain regions including white 
matter regions (PVCC and aCC), intermediate and deep cortical layers, DG gr layer of the 
hippocampus, and the striatum (Fig. 4.2 C). 
 As expected, the highest percentage of simple gangliosides was observed at P0 
(Fig. 4.2 A), which then dropped by 3 m and remained relatively stable up to 20 m (Fig. 
4.2 B,D). This finding fits with the reported downregulation of simple ganglioside synthetic 
enzymes and upregulation of complex ganglioside synthesis during early development in 
rats (Rosenberg & Stern, 1966). Although no significant transgene differences were 
observed at P0, regional differences were apparent. The DG gr layer of the hippocampus 
showed the highest percentage of simple gangliosides along with the DG mol and CA1 
hippocampal layers and the LSN (Fig. 4.2 A), while the deep layers of the cortex and the 
aCC showed the lowest percentage of simple gangliosides. Interestingly, regional 
differences in the quantity of simple gangliosides were less pronounced after birth and 
shifted at 3 m such that the PVCC showed the highest proportion of simple gangliosides in 
the brain, along with the DG gr layer of the hippocampus and SN (Fig. 4.2 B). At 12 m, 
regional differences became more pronounced as the proportion of simple gangliosides 
increased in certain brain regions, particularly in Tg APP21 rats, such as the white matter, 
DG gr layer of the hippocampus, as well as intermediate and deep cortical layers (Fig. 4.2 
C). The regional distribution of simple gangliosides at 20 m was similar to that of 3 m, but 
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the highest proportion of simple gangliosides was observed in the DG gr layer of the 
hippocampus (Fig. 4.2 D). These results suggest that the quantity and regional distribution 
of simple gangliosides in the aging brain varies and that a potentially detrimental shift in 
ganglioside homeostasis occurs as early as 12 m in Tg APP21 rats. 
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Figure 4.2: The percentage distribution of simple gangliosides in various brain 
regions of Tg APP21 rats. MALDI IMS area under curve (AUC) data was pooled for each 
A-series gangliosides to show the percentage of simple gangliosides at each time point as 
compared to total A-series ganglioside AUC for both Wt and Tg APP21 rats. (A) Highest 
percentage of simple gangliosides observed in P0 rats. (B) Simple ganglioside content 
decreased at 3 m and showed an alteration in regional abundance, with fewer regional 
differences. (C) Transgene differences were observed at 12 m (as indicated by blue *) with 
the increase in simple gangliosides being more pronounced in Tg APP21 rats. (D) Simple 
ganglioside content dropped again at 20 m and regional differences decreased. Significant 
regional differences are indicated with letters a-d. Brain regions with different letters were 
found to be statistically different from each other (Wt and Tg APP21 data pooled for 
regional analysis) while regions with no letters indicate no significant difference from any 
other brain region.  *indicates statistical significance, p<0.05 via multiple T-tests; letter 
indicates statistical significance, p<0.05 via two-way ANOVA, Tukey multiple 
comparisons post-hoc test. 
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4.4.2 GD1 d18:1 species decreased in the gray matter of Tg APP21 rats with 
maintenance or increases in d20:1 species 
A-series gangliosides were analyzed individually (Fig 4.3) relative to P0 in order to better 
understand age-dependent shifts in complex and simple gangliosides, and to determine the 
source of the increased proportion of simple gangliosides in Tg APP21 rats observed at 12 
m in Figure 4.2. The d18:1 and d20:1 species of each a-series ganglioside were analyzed 
and presented separately, as the ratio between the d20:1/d18:1 species of complex 
gangliosides has been reported to increase in an age-dependent manner during normal 
aging in mice (Sugiura et al., 2008) and has shown unique alterations in the hippocampus 
of AD patients compared to controls (Hirano-Sakamaki et al., 2015).  However, it remains 
unclear if the altered ratio is caused by an increase in d20:1 species or a decrease in the 
d18:1 species. In general, GD1 d18:1 levels dropped at 12 m in both Wt and Tg APP21 rats 
but either dropped more significantly or continued to drop up to 20 m in Tg APP21 rats 
whereas levels generally increased at 20 in Wt rats. In the cortex, the abundance of GD1 
d18:1 species increased between P0 and 3m in both Wt and Tg APP21 rats, with the 
exception of the deep layers of the cortex where levels remained statistically unchanged in 
Tg APP21 rats. Levels then dropped between 3 and 12 m and remained stable until 20 m in 
the Int and Deep layers. In the Superficial layers, GD1 d18:1 species remained stable 
between 3 and 20 m in Wt rats while levels dropped at 12 m in Tg APP21 rats such that 
they were no longer significantly different from P0 levels. However, levels then increased 
again at 20 m in Tg APP21 rats (Fig. 4.3 B).  
Similar to the cortex, GD1 d18:1 levels increased between P0 and 3 m throughout 
the hippocampus. Levels then steadily dropped between 3 m and 20 m in Tg APP21 rats 
but increased at 20 m in Wt rats. This lead to the Wt, but not Tg APP21 rats showing 
significantly elevated levels of GD1 d18:1 species compared to P0 at 20 m in the CA1 and 
DG mol layers of the hippocampus (Fig. 4.3 C). Among the subcortical structures, GD1 
d18:1 species increased between P0 and 3 m in the striatum and LSN, but only increased 
significantly in Wt rats in the SN (Fig. 4.3 D). Levels remained statistically elevated from 
P0 in both Wt and Tg APP21 rats up to 20 m in the striatum despite a slight drop at 12 m 
(Fig 4.3 D – left panel). Wt and Tg APP21 rats showed opposite patterns at 20 m within the 
LSN and SN regions with GD1d18:1 increasing significantly from P0 levels only in Tg 
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APP21 rats in the LSN (Fig 4.3 D – center panel) and only in Wt rats in the SN (Fig 4.3 D 
– right panel). 
Age-dependent increases in the ratio of d20:1/d18:1 species of GD1 have been 
reported in the mouse hippocampus during normal aging (Sugiura et al., 2008) While GD1 
d18:1 showed between a 2 – 5 fold increase from P0 throughout the brain, d20:1 species of 
GD1 increased between 3 – 8 fold, with the largest increase observed in the DG mol layer 
of the hippocampus and striatum. This supports the hypothesis that d20:1 species are 
indeed increasing in the brain compared to d18:1 species. However, the increase in d20:1 
species was not observed to be age-dependent in most brain regions. In the SN, striatum, 
hippocampus, DG mol, intermediate and deep layers of the cortex, GD1 d20:1 species 
increased between P0 and 3 m then remained significantly elevated but stable up to 20 m in 
both Wt and Tg APP21 rats (Fig 4.3 E-G). A similar pattern occurred in the superficial 
layers of the cortex but was only significantly elevated from P0 in Wt rats (Fig 4.3 E – left 
panel). In the hippocampus, Wt and Tg APP21 rats showed divergent patterns at 20 m with 
GD1 d20:1 species decreasing in Tg APP21 rats and increasing in Wt rats, leading to 
statistical differences relative to P0 levels (Fig 4.3 F). The only transgene difference 
observed for GD1 d20:1 species was in the LSN where levels dropped in Wt rats at 20 m 
and increased in Tg APP21 rats, contrary to what was observed in the hippocampus, 
leading to a statistical difference between the two groups (Fig. 4.3 G – center panel). 
Overall, results of MALDI IMS analysis of GD1 suggests that the increased ratio of 
d20:1/d18:1 species previously reported is due to both an increase/stable abundance of 
d20:1 species and a decreased in d18:1 species during aging. 
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Figure 4.3: Distribution of the GD1 d18:1 and d20:1 species during aging. (A) 
Representative MALDI IMS overlaid images showing the anatomical distribution of the 
d18:1 (magenta) and d20:1 species (cyan) of GD1. (B-G) Quantification of MALDI IMS 
data showing the percent of GD1 d18:1 (B-D) and d20:1 (E-G) species compared to the 
total signal at each time point. GD1 d18:1 dropped at 12m in both Wt and Tg APP21 rats 
which either continued to drop at 20 m or increased slightly. Statistical differences were 
observed in relative to P0 throughout aging (B-D). GD1 d20:1 species increased 
significantly between P0 and 3 m which then remained stable or increased slightly at 20 m 
(E-G). A transgene difference was observed at 20 m in the LSN in which Tg APP21 rats 
showed elevated levels of d20:1 species of GD1 whereas levels dropped in Wt rats (G – 
center panel). * indicates statistical significance, p<0.05 via two-way ANOVA, Tukey 
post-hoc test. 
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4.4.3 Significant increase in GM1 observed during aging with characteristic drop 
in d18:1 species at 12 m 
The largest increase in complex gangliosides GD1 and GM1 occurred between P0 and 3 m 
due to alterations in synthetic enzyme regulation during early post-natal development (Yu 
et al., 2009) and was more pronounced for d20:1 species than d18:1 species. The increase 
between P0 and 3 m was greater for GM1 d20:1 species (5 – 17 fold) than for GD1 d20:1 
species (3 – 4 fold), with a greater degree of anatomical heterogeneity. Unlike GD1, GM1 
reached its highest abundance at 20 m in all brain regions, suggesting an age-dependent 
accumulation. However, this accumulation was not linear and after the initial increase after 
birth, remained either stable or decreased slightly between 3 m and 12 m. GM1 levels then 
increased between 12 m and 20 m for both the d18:1 and d20:1 species (Fig. 4.4). 
 GM1d18:1 species increased from around 5% of the total signal at P0 to 20% at 3 
m. The LSN and SN showed the lowest levels of GM1 d18:1 of all gray matter brain 
regions at 3 m. The pattern of GM1 d18:1 species abundance was very similar between Wt 
and Tg APP21 rats throughout aging, with no transgene differences observed; however, 
statistical differences were observed relative to P0 throughout aging which varied 
depending on transgene (Fig. 4.4 B-D). Wt rats showed slightly higher levels of GM1 
d18:1 in the LSN and SN at 12 and 20 m respectively (Fig 4.4 D – center and right panels), 
while Tg APP21 rats showed higher levels of GM1 d18:1 species in the intermediate layers 
of the cortex at 3 m (Fig 4.4 B – center panel). Additionally, GM1 d18:1 species decreased 
at 12 m in Tg APP21 rats across the brain while levels remained stable in a number of brain 
regions examined in Wt rats. 
GM1 d20:1 species increased from below 1% of the total signal at P0 to around 4% 
at 3 m in cortical and sub cortical brain regions as well as the DG gr layer of the 
hippocampus (Fig 4.4 E-F). The CA1 and DG mol layers showed the most significant 
increase in GM1 d20:1 species, increasing to 6 and 8% of the total signal by 3 m and 
continued to increase to 10% by 20 m in the DG mol. (Fig. 4.4 F – left and center panels). 
Overall, GM1 showed an age-dependent increase with only minor variations between Wt 
and Tg APP21 rats. 
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Figure 4.4: Increased levels of GM1 during aging with characteristic drop at 12 m in 
Fischer rats. (A) Representative MALDI IMS overlaid images showing the anatomical 
distribution of GM1 d18:1 (magenta) and d20:1 (cyan) species across intact tissue sections 
containing all regions of interest.  (B-G) Quantification of MALDI IMS data showing the 
percent signal of GM1 d18:1 (B-D) and d20:1 (E-G) species relative to total signal.  
GM1d18:1 increased between P0 and 3 m which then decreased at 12 m in both Wt and Tg 
APP21 rats and increased again by 20 m (B-D). GM1 d20:1 species increased in an age-
dependent manner throughout the brain with the highest levels observed in the CA1 and 
DG mol layers of the hippocampus (E-F). * indicates statistical significance, p<0.05 via 
two-way ANOVA, Tukey post-hoc test. 
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4.4.4 Decreased GM2 d20:1 species in early life with elevated levels of GM2 
d18:1 species in Tg APP21 rats. 
Little is known on how simple gangliosides are altered during normal aging. However, 
based on their reported upregulation in a number of neurodegenerative injuries and 
diseases, including AD, as well as the observed increase in the proportion of simple 
gangliosides at 12 m in the current study, we analyzed the anatomical distribution and 
abundance of the d18:1 and d20:1 species of simple ganglioside GM3 and GM2 in order to 
compare their alterations in abundance to complex gangliosides in Wt and Tg APP21 rats. 
GM2 d18:1 species remained statistically unchanged throughout the lifespan of 
both Wt and Tg APP21 rats, however, Tg APP21 rats showed a strong trend of increased 
abundance over Wt rats (Fig. 4.5 B-D). This was particularly evident at 12 m as Wt rats 
showed either stable of decreased levels of GM2d18:1 relative to 3 m whereas levels 
increased in Tg APP21 rats. This divergence in d18:1 species patterns led to a statistical 
transgene difference in the striatum, with significantly more GM2 d18:1 species observed 
in Tg APP21 rats. One exception to this trend was observed in the DG mol layer of the 
hippocampus where GM2 d18:1 levels dropped significantly from P0 levels at 20 m. 
Interestingly, GM2 d20:1 species showed more robust changes with aging. GM2 d20:1 
species dropped significantly in all gray matter regions between P0 and 3 m in both Wt and 
Tg APP21 rats and remained stable up to 20 m (Fig. 4.5 E,F). Tg APP21 rats showed a 
slight increase in GM2 d20:1 species at 12 m while levels in Wt rats remained stable, with 
the exception of the LSN and SN. These results demonstrate that the d20:1 species of GM2, 
and not the d18:1 species, were decreased during early development and remained stable 
during adulthood and that Tg APP21 rats have slightly elevated levels of GM2 over their 
Wt counterparts. 
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Figure 4.5: Tg APP21 rats have elevated levels of GM2 with a significant drop in 
GM2 d20:1 species in early life for both groups. (A) Representative MALDI IMS 
overlaid images showing the anatomical distribution of GM2 d18:1 (magenta) and d20:1 
(cyan) species across intact tissue sections containing all regions of interest. (B-G) AUC 
Quantification of MALDI IMS data showing the signal corresponding to d18:1 (B-D) and 
d20:1 (E-G) species of GM2 as a percentage of total signal. (B-D) GM2 d18:1 species 
often showed diverging patterns of abundance between Wt and Tg APP21 rats throughout 
the lifespan, with a trend of increased GM2 d18:1 species in Tg APP21 rats, however, this 
was not statistically significant. (E-G) GM2 d20:1 species dropped significantly from P0 
levels at 3 m in all brain regions and remained stable up to 20 m with a trend of increased 
GM2 d20:1 species at 12 m in Tg APP21 rats. * indicates statistical significance, p<0.05 
via two-way ANOVA, Tukey post-hoc test. 
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4.4.5 Early increases in GM3 in Tg APP21 rats with transgene differences at 12 
m. 
Simple ganglioside GM3 has been widely studied in the field of oncology due to its ability 
to induce apoptosis, decrease angiogenesis, and prevent cell proliferation when 
accumulated in vitro (Chung et al., 2009; Nakatsuji & Miller, 2001; Prokazova et al., 2009; 
Sohn et al., 2006). In the brain, GM3 has been associated with the propagation of 
neurodegeneration after stroke (Caughlin et al., 2015; Whitehead et al., 2011) and the 
seeding of toxic Aβ fibrils in mouse models of AD (Kreutz et al., 2011; Oikawa et al., 
2009). GM3 d18:1 was observed to be anatomically located in medial structures of the 
brain and lining ventricular regions (Fig. 4.6 A).   
Unlike GM2, no consistent trend in the overall GM3 d18:1 species abundance was 
observed during aging, rather, Tg APP21 rats and levels varied based on anatomical brain 
region. For instance, Tg APP21 rats were born with significantly higher levels of GM3 
d18:1 species in the striatum, LSN, and DG gr layer of the hippocampus, with a similar 
trend in the DG mol layer (Fig. 4.6 B-D). A significant transgene difference was observed 
at 3 m in the CA1 and DG mol layers of the hippocampus, with elevated levels of GM3 in 
Tg APP21 rats over Wt rats (Fig. 4.6 C). Finally, a similar transgene difference in GM3 
d18:1 species was observed at 12 m in the intermediate layers of the cortex (Fig. 4.6 B). Wt 
rats showed a consistent pattern of decreased or stable GM3 d18:1 species at 12 m whereas 
this species generally increased in Tg APP21 rats at the same point. GM3 d18:1 species 
were most abundant in the striatum, LSN, and DG gr layer of the hippocampus at birth 
whereas the cortical layers and SN showed the lowest abundance. Because GM3 d18:1 
species showed a trend of accumulating in an age-dependent manner in the DG gr of Tg 
APP21 rats, it consistently showed the highest levels throughout aging, reaching 1.6% of 
the total signal by 20 m of age (Fig 4.6 C – right panel). Tg APP21 rats also displayed a 
more severe fluctuation of GM3 d18:1 species relative to P0 than Wt rats, generally 
showing elevated levels from birth, with the exception of the striatum, LSN, and CA1, 
which decreased or remained stable after P0. Overall, Tg APP21 rats at some point during 
aging had increased levels of GM3 d18:1 species over Wt rats in all brain regions 
examined. 
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More consistent trends were observed for GM3 d20:1 species across the brain with 
similar patterns observed among discrete brain regions. As was observed with simple 
ganglioside GM2, a divergence in ganglioside patterns occurred at 12 m between Wt and 
Tg APP21 rats. While GM3 d20:1 species either remained stable or decreased between 3 
and 12 m in Wt rats, Tg APP21 rats showed elevated levels at this time point. This led to 
significant transgene differences in the intermediate and deep layers of the cortex, with a 
similar trend in all other selected brain regions, with the exception of the SN. GM3 d20:1 
species remained statistically unchanged between P0 and 20 m among all layers of the 
cortex (Fig. 4.6 E). Hippocampal layers showed a different pattern, with a drop in GM3 
d20:1 species observed between P0 and 3 m which then remained stable up to 20 m (Fig. 
4.6 F). This drop was most significant in the CA1 layer with statistical differences from P0 
levels observed for both Wt and Tg APP21 rats. The striatum showed a similar pattern to 
that of the hippocampal layers with a drop in GM3 d20:1 species between P0 and 3 m. 
Levels then continued to drop and became statistically lower than P0 at 12 m only in Wt 
rats, whereas levels increased slightly in Tg APP21 rats (Fig. 4.6 G – left panel). The LSN 
showed a similar pattern to that of the cortical layers, remaining statistically unchanged 
between P0 and 20 m (Fig. 4.6 G – center panel). While GM3 d20:1 species also remained 
statistically unchanged during aging in the SN, Wt and Tg APP21 rats showed opposite 
patterns during early life, with a slight drop observed in Wt rats between P0 and 3 m which 
then gradually increased up to 20 m and a slight increase between P0 and 3 m in Tg APP21 
rats which then gradually dropped until 20 m (Fig. 4.6 G – right panel). Overall, these 
results indicate that there is an increased abundance of GM3 gangliosides in Tg APP21 rats 
in early and mid-life and unique patterns of abundance during aging among Wt and Tg 
APP21 rats. 
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Figure 4.6: Increased GM3 in Tg APP21 rats. (A) Representative MALDI IMS overlaid 
images showing the anatomical distribution of GM3 d18:1 (magenta) and d20:1 (cyan) 
species across intact tissue sections containing all regions of interest. (B-G) Quantification 
of MALDI IMS data showing the signal corresponding to d18:1 (B-D) and d20:1 species 
(E-G) of GM3 relative to total signal. (B-D) Significant transgene differences were 
observed at P0, 3 m and 12 m across the various brain regions, with Tg APP21 rats 
displaying elevated levels of GM3 d18:1 species over their Wt counterparts. GM3 d20:1 
species remained statistically unchanged from P0 in the cortical layers, however, Tg 
APP21 rats showed significantly elevated levels over Wt rats at 12 m in the Int and Deep 
layers (E). GM3 species dropped between P0 and 3 m in the hippocampus, particularly in 
the CA1 region, then remained stable up to 20 m (F). Each sub-cortical layer had a slightly 
different GM3 d20:1 species pattern during aging, with the striatum showing a similar 
pattern to that of hippocampal regions, the LSN having a similar pattern to that of the 
cortical layers, and the SN showing opposite patterns between Wt and Tg APP21 rats (G). 
* indicates statistical significance, p<0.05 via two-way ANOVA, Tukey post-hoc test. 
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4.4.6 Age-dependent decrease in GD1 d18:1 species in white matter regions with 
increases in simple gangliosides only in Tg APP21 rats. 
A unique ganglioside pattern was observed in the white matter as compared to gray matter 
regions during aging, thus these regions are presented separately. Interestingly, an age-
dependent decrease in GD1 d18:1 species in the PVCC was observed, with a similar drop 
occurring between 3 and 12 m in the aCC (Fig 4.7 A). This pattern is unlike the gray matter 
regions, which all showed either a stable or increased abundance of GD1 d18:1 species 
during early development. GD1 d20:1 species increased significantly between P0 and 12 m 
only in the Wt rats where it then dropped significantly by 20 m. In Tg APP21 rats, GD1 
d20:1 species showed a trend of increasing in an age-dependent manner up to 20 (Fig 4.7 B 
- left). In the aCC, GD1 d20:1 species increased significantly between P0 and 3 m in both 
Wt and Tg APP21 rats where it then gradually decreased up to 20 m (Fig. 4.7 B – right). 
Overall, GD1 levels appear to decrease in the white matter during the later stages of the rat 
lifespan. 
Complex ganglioside GM1 showed similar patterns of abundance in white matter to 
what was observed in gray matter regions, with an increase in GM1 d18:1 species between 
P0 and 20 m, along with a drop at 12 m (Fig 4.7 C – left panel). However, this drop only 
occurred in Tg APP21 rats in the aCC while it remained stable in the Wt rats (Fig 4.7 C – 
right panel), suggesting that GM1 levels may be more severely depleted in Tg APP21 rats 
at this time point. GM1 d20:1 species increased significantly between P0 and 3 m, and 
again between 12 m and 20 m while remaining stable between 3 m and 12 m in the PVCC. 
Overall, GM1 species accumulate during both early development and during the later 
stages of aging in the rat. 
Simple gangliosides GM2 and GM3 also showed unique alterations in abundance in 
the white matter as compared to gray matter regions with a number of transgene 
differences. For example, GM2 d18:1 species increased between P0 and 3 m in both the 
PVCC and aCC where it decreased slightly but remained stable up to 20 m in the Wt rats. 
However, GM2 d18:1 species continued to increase or remained stable up to 12 m in Tg 
APP21 rats, becoming significantly elevated from P0 levels in the PVCC and remaining 
elevated up to 20 m (Fig 4.7 E). The d20:1 species of GM2 decreased slightly between P0 
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and 3 m in the white matter where it remained stable in the PVCC of Wt rats and continued 
to drop up to 12 m in the aCC, decreasing significantly from P0 levels. Tg APP21 rats 
instead showed a slight increase in GM2 d20:1 species at 12 m which then decreased by 20 
m (Fig 4.7 F). Overall, Tg APP21 rats showed higher levels of GM2 at 12 m over their Wt 
counterparts. 
 Similar to what was observed in the striatum, LSN, and DG gr regions for GM3 
d18:1 species, Tg APP21 rats showed elevated levels of GM3 d18:1 species at birth over 
their Wt counterparts, however, this difference was not statistically significant. GM3 d18:1 
species remained fairly stable between birth and old age in Wt rats, whereas levels 
remained elevated in Tg APP21 rats such that there was a significant transgene difference 
observed at 12 m in both the PVCC and aCC before levels dropped at 20 m (Fig 4.7 G). An 
age-dependent increase in GM3 d20:1 species was observed only in Tg APP21 rats up to 
12 m of age where it became significantly increased from P0 levels in the PVCC and 
remained significantly elevated at 20 m. This increase in GM3 d20:1 species up to 12 m led 
to a statistical difference between Wt and Tg APP21 rats at 12 m in the aCC (Fig 4.7 H). 
Taken together, these results suggest a more severe pathological shift in white matter 
ganglioside content during aging that is enhanced in Tg APP21 rats. 
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Figure 4.7: Unique ganglioside alterations in white matter regions of the brain during 
aging. AUC Quantification of MALDI IMS data in the white matter showing the signal 
corresponding to each a-series ganglioside as a percentage of the total signal, with the 
d18:1 species on the left and d20:1 species on the right. (A) GD1 d18:1 species decreased 
in an age-dependent manner up to 20 m in the PVCC (left). A similar trend was observed in 
the aCC, however, the Wt rats only showed a significant decrease after 3 m. (B) GD1 d20:1 
species increased in and age-dependent manner in the PVCC up to 12 m in Wt rats and 20 
m in Tg APP21 rats, whereas a significant increase in GD1 d20:1 species was only 
observed between P0 and 3 m in the aCC before dropping until 20 m. (C+D) GM1 d18:1 
species increased between P0 and 20 m, however, the characteristic drop in GM1 content 
observed at 12 m was more pronounced in Tg APP21 rats in the aCC. (E) GM2 d18:1 
species increased significantly between P0 and 12 m only in Tg APP21 rats and remained 
elevated at 20 m in the PVCC. (F) GM2 d20:1 species dropped significantly from P0 levels 
at 12 m in the aCC of Wt rats but did not drop until 20 m in Tg APP21 rats. GM3 d18:1 
species showed a trend of increased abundance at 12 m in the aCC of Tg APP21 rats (G+H) 
Tg APP21 rats showed significantly elevated levels of GM3 at 12 m over their Wt 
counterparts as well as a significant increase in GM3 d20:1 species from P0 levels at 12 
and 20 m in the PVCC. * indicates statistical significance from P0, # indicates statistical 
significance between Wt and Tg APP 21 rats, p<0.05 via two-way ANOVA, Tukey post-
hoc test. 
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4.5  Discussion 
This is the first study to examine age and neuroanatomic-specific alterations in the 
expression profile of a-series gangliosides in both Wt and Tg APP21 rats using MALDI 
IMS. Gangliosides have been observed to shift in a characteristic manner during AD such 
that there is a depletion of complex gangliosides, such as GM1, and an accumulation of 
simple ganglioside GM3 (Chan et al., 2012; Knight et al., 2014; Svennerholm & Gottfries, 
1994; Yamamoto et al., 2006). The reason for this shift in ganglioside homeostasis is 
poorly understood but has been suggested to play an important mechanistic role in the 
development of AD (Oikawa et al., 2009). MALDI IMS is the only technique capable of 
accurately detecting gangliosides based on both their oligosaccharide and ceramide 
moieties while simultaneously providing high resolution imaging of the ionic distribution 
across intact tissue sections, making it the ideal tool for the study of membrane lipids in the 
aging brain. However, it is important to note that this technique is not without limitations. 
For example, due to run-to-run variation in sample preparation and instrument variables, 
MALDI IMS data is considered to be semi-quantitative. While there is currently no single 
approach to quantifying MALDI-IMS data, the goal remains to reduce run-to-run 
variability as much as possible in order to obtain the most accurate and meaningful results. 
In the current study, we compared the area under the curve corresponding to each 
individual ganglioside species to the total signal of the spectrum within a mass range of 
1100-1950 in order to minimize sources of variability. While gangliosides account for the 
largest peaks in this mass range, as can be seen in Figure 4.1 C, smaller, unidentified peaks 
are also present which may fluctuate during aging, thus affecting total signal. Therefore, 
while MALDI IMS remains an incredibly powerful tool for the analysis of gangliosides, 
limitations surrounding the semi-quantitative nature of the technique should be considered 
when interpreting the data. 
An examination of the percentage of simple gangliosides GM3 and GM2 compared 
to total a-series gangliosides at each time point revealed a high degree of anatomical 
heterogeneity in the proportion of simple gangliosides throughout the brain at P0 which 
may be related to the function of these brain regions during development and adulthood. 
For example, The DG gr layer of the hippocampus showed the highest percentage of simple 
149 
 
gangliosides at P0 of all the 11 regions of interest across the brain. This layer is composed 
largely of the cell bodies of granule cells which project dendrites and processes into the DG 
mol layers of the hippocampus. This is a region where neurogenesis is thought to occur, not 
only during development, but throughout adulthood as well (Amaral, Scharfman, & 
Lavenex, 2007). Neurogenesis in the DG gr layer is said to be in a steady-state as opposed 
to an accretion over time, this implies tight regulation of neurogenesis in this region 
(Amaral et al., 2007). It is possible that the increased abundance of simple gangliosides in 
this region may thus be related to the regulation of neurogenesis in the DG gr layer of the 
hippocampus. Indeed, the DG gr layer had one of the highest proportions of simple 
gangliosides at every time point, further supporting this hypothesis.  
The percentage of simple gangliosides dropped at 3 m, again, matching what has 
been reported to occur with ganglioside synthetic enzymes during this period (Rosenberg & 
Stern, 1966). Indeed, the most significant increase in complex gangliosides occurred 
between P0 and 3 m, which would account for the decreased relative abundance of simple 
gangliosides at this time point. One of the most intriguing findings, however, was the 
increased percentage of simple gangliosides at 12 m in many brain regions which was 
enhanced in Tg APP21 rats such that a number of transgene differences were observed 
across the brain. This increase in simple gangliosides was accompanied by a concurrent 
drop in complex gangliosides at 12 m, which would account for the significant increase in 
the proportion of simple gangliosides at this time point. These findings suggests that a 
pathological shift in the homeostasis of gangliosides may be occurring as early as 12 m of 
age and is enhanced in Tg APP21. This evidence supports the hypothesis that lipid 
alterations may occur in the prodromal stages of AD. 
Age-dependent changes in complex gangliosides have been previously examined 
using liquid chromatography-based techniques. In a study published in 2000, Aydin et al. 
found that ganglioside GM1 increased slightly between 3 and 24 months of age, while GD1 
increased up to 12 m then dropped by 20 % by 24 m. A similar pattern was observed in the 
current study. Aydin et al. also found an age-dependent increase in GM1 fractions 
compared to other complex gangliosides, however, the authors ascribed this finding to a 
decrease in GD1 and GT1 components rather than an increase in GM1, which was found to 
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remain relatively stable at later time points (Aydin et al., 2000).  GM1 d20:1 species in 
particular showed a higher fold increase in abundance from P0 than GM1 d18:1 species 
and increased up to 20 m in most brain regions. This finding confirms the presence of an 
age-dependent accumulation of long chain ceramide species in the brain, as has been 
previously reported (Hirano-Sakamaki et al., 2015; Palestini et al., 1993; Sugiura et al., 
2008).  
While GM1 was found to be consistently increased during adulthood in both Wt 
and Tg APP21 rats, a less pronounced effect was observed for ganglioside GD1. The d20:1 
species showed, in most cases, an age-dependent increase up to 12 m which then plateaued 
or decreased at 20 m. Wt rats also showed higher levels of GD1 than Tg APP21 rats in a 
number of brain regions, particularly at 20 m in the hippocampus. Although the 
senescence-related drop in GD1 and GT1 described by Aydin et al., 2000 is not fully 
understood, the authors suggest that it may be related to degenerative processes in dendrites 
and synapses in which these species are highly expressed. Alternatively, the breakdown of 
GD1 may be related to maintenance of GM1 (Aydin et al., 2000). In a study which 
measured GM1, GD1, and GT1 levels in the CSF of “probable AD” patients versus age-
matched controls, an increase in GM1 levels was observed, particularly in younger 
“probable AD” patients while GD1 and GT1 levels were decreased, suggesting that this 
breakdown may be further enhanced in during AD development and progression (Blennow 
et al., 1992). The neuroprotective properties of GM1 have been well documented and are 
ascribed to its ability to modulate neurotrophin release and regulate ion transport (Ledeen 
& Wu, 2015; Wu & Ledeen, 1994). In fact, of all the a-series gangliosides, GM1 has been 
found to have a high degree of functional importance in the maintenance of cells. This is 
further supported by the finding of GM1’s resistance to breakdown by sialidase as 
compared to other complex gangliosides (Palestini et al., 1993). Multi-sialylated species, 
such as GD1 and GT1, are highly susceptible to sialidase (Palestini et al., 1993), leading 
some to suggest that it may serve as a reserve pool for the maintenance of GM1 levels in 
the brain (Ledeen & Wu, 2015). The transgene difference observed in the current study 
with respect to the drop in GD1 levels may therefore be the result of an increased need to 
breakdown GD1 in order to maintain GM1 levels in Tg APP21 rats.  Future studies should 
address the changes in both ganglioside synthetic and catabolic enzymes during aging.  
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A previous study in our lab reported a decrease the d20:1/d18:1 species ratio of 
GM2 between P0 and 3 m which remained stable up to 20 m (Caughlin et al., 2017b). The 
current study confirms that this decreased ratio was due to a significant drop in d20:1 
species of GM2 and not an increase in d18:1 species, which remained statistically 
unchanged throughout the rat lifespan. Tg APP21 rats also showed a trend of increased 
GM2 at 12 m across a number of brain regions and led to a significant transgene difference 
in striatum. Interestingly, the accumulation of GM2 has been reported in human brains of 
patients with AD and frontotemporal dementia (Pernber et al., 2012), thus, the increased 
abundance of GM2 in our Tg APP21 rats may be indicative of a pathological shift in 
ganglioside homeostasis. 
GM3 has been shown to upregulate pro-apoptotic signaling pathways as well inhibit 
VEGF receptor activity leading to toxicity when accumulated in neural cells (Chung et al., 
2009; Nakatsuji & Miller, 2001) and is thought to play an important mechanistic role in the 
development of AD (Oikawa et al., 2009). Several transgene differences were observed in 
which Tg APP21 rats had significantly elevated levels of GM3 over Wt rats. Interestingly, 
Tg APP21 rats were born with higher levels of GM3 d18:1 species than Wt rats which 
remained elevated throughout aging. The observed increase in GM3 coupled with elevated 
levels of GM2 in Tg APP21 rats suggests that the brains of these rats may be entering a 
state of vulnerability earlier than previous thought and supports the hypothesis of a 
pathological shift in ganglioside homeostasis in Tg APP21 rats.  
Ganglioside-based alterations in the white matter of the aging brain have been 
observed to be different than those of the gray matter (Caughlin et al., 2017b). Ganglioside 
GD1 d18:1 showed a very unique age-dependent decrease in abundance in white matter 
that has not been previously reported. This drop in d18:1 species was accompanied by the 
maintenance or increase in d20:1 species. Previous work in our lab examining the ratio of 
d20:1 species relative to d18:1 found a significant age-dependent increase in the GD1 
d20:1/d18:1 ratio in the PVCC, with a similar trend occurring in the aCC (Caughlin et al., 
accepted). It was assumed that this increased ratio was caused by the age-dependent 
accumulation of d20:1 species, as had been reported in gray matter regions. However, the 
current study demonstrates that the increased ratio was instead due to a significant drop in 
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the d18:1 species, highlighting the importance of analyzing gangliosides individually. 
Another unique alteration in white matter was observed for ganglioside GM3 in that levels 
of d20:1 species were significantly elevated only in Tg APP21 rats. The white matter of the 
brain has demonstrated a particular vulnerability during aging (Gao et al., 2014). While 
GD1 was not observed to be a major component of white matter in the current study, it has 
been identified as an important binding site for myelin-associated protein (MAG), which 
plays a major role in the formation and maintenance of myelin in the central nervous 
system (Al-bashir, Mellado, & Filbin, 2016). The age-dependent depletion of GD1 along 
with the increased abundance of simple ganglioside GM3 in Tg APP21 rats may be 
indicative of a mechanism of neurodegeneration in this region during AD. 
The brains of aging Tg APP21 rats are thought to be in a vulnerable state due to the 
accumulation of APP. It is possible that the vulnerable state of the Tg APP21 rat brain may 
have deleterious effects on the proper functioning of cell membranes and that, in an attempt 
to restore/maintain homeostatic GM1 levels, GD1 is degraded to GM1. An examination of 
the activities of sialidase and sialyl-transferase enzymes is a future goal and would provide 
valuable insight into this hypothesis. A greater understanding of the role of altered lipid 
profiles in the aging and injured brain could lead to the development of lipid-based 
biomarkers for individuals at risk of developing neurodegenerative diseases as well as more 
effective lipid-targeted therapeutics for the early stages of AD. 
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Chapter 5 : Restoring ganglioside homeostasis after stroke using 
chloroquine is associated with pathological and functional 
improvements in Wistar rats 
 
In Chapter 4, a pattern of ganglioside dysregulation was observed in the Tg APP21 rats 
whereby the d20:1 species of both GM3 and GD1 were increased in a number of brain 
regions susceptible to injury in the aging brain such as the white matter and the DG mol 
layer of the hippocampus. Tg APP21 rats also displayed a lower abundance of both d18:1 
and d20:1 species of GM1 at the later time points over Wt rats, indicating that the overall 
levels of GM1 were lower in the Tg APP21 rats. GM1 is known to exert a number of 
neuroprotective functions in the brain and may thus be a mechanism that leaves the brain 
vulnerable to injury in the Tg APP21 rats. In the current chapter, we explore the potential 
therapeutic benefits of preventing the catabolism of GM1 and the subsequent accumulation 
of toxic simple gangliosides after stroke using the lysosomotropic agent Chloroquine. 
5.1  Abstract 
Perturbations of ganglioside homeostasis have been observed following stroke whereby 
simple gangliosides GM2 and GM3 accumulate while protective complex species GM1 and 
GD1 are reduced, leading to the hypothesis that complex species are being degraded to 
simple species. Thus, there is a need for therapeutic interventions which can prevent 
ganglioside dysregulation after stroke. A pharmacological intervention using chloroquine 
(CQ) was selected for its transient lysosomotropic properties which disrupt the activity of 
catabolic ganglioside enzymes. CQ was administered both in vitro, to primary cortical 
neurons exposed to GM3 toxicity, and in vivo, to 3 month old male Wistar rats that 
underwent a severe stroke, induced through the co-administration of a striatal endothelin-1 
(ET-1) injection and intracerebral-ventricular injections of Aβ(25-35). CQ was 
administered (45mg/kg i.p.) for 7 consecutive days beginning 3 days prior to surgery and 
gangliosides were examined using MALDI imaging mass spectrometry at 3 and 21 days 
after the injury. The ladder motor task was used to examine the functional effects of CQ 
treatment on day 20. CQ treatment prevented ganglioside dysregulation 3 d post-stroke and 
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partially prevented complex ganglioside depletion 21 d post-stroke. Exogenous GM3 was 
found to be toxic to primary cortical neurons which was protected by CQ treatment. Motor 
deficits were prevented in the forelimbs of rats with CQ treatment and were associated with 
decreased inflammation, neurodegeneration, and an increase in cell survival at the site of 
injury. CQ prevents ganglioside dysregulation acutely, protects against GM3 toxicity in 
neurons, and is associated with long-term functional and pathological improvements after 
stroke in the rat. 
 
5.2  Introduction 
Strokes are the most frequent cause of permanent disability in individuals aged 60 years 
and older with the global burden of stroke care expected to increase in line with the aging 
population (Chamorro, Dirnagl, Urra, & Planas, 2016; Feigin et al., 2014). However, there 
is currently no clinically effective approach to prevent the damage caused by stroke with 
the exception of tissue plasminogen activator, which has a very narrow therapeutic window 
of effectiveness (Zhang et al., 2015). Therefore, the development of new preventative 
approaches and therapeutic interventions which can improve recovery after stroke injuries 
is imperative. Membrane lipid dysregulation is observed after neurodegenerative injuries in 
the brain and is thought to play a key mechanistic role in the propagation of 
neurodegeneration (Caughlin et al., 2015), thus, preventing this dysregulation may provide 
a novel avenue of intervention for stroke injuries. 
Gangliosides are a major component of lipid rafts and play an important role in 
protein-lipid interactions on the cell surface leading various signal transduction events. 
Structurally, simple minor gangliosides GM2 and GM3, while crucial during 
neurodevelopment, have been linked to neurodegeneration in the adult brain. GM3 in 
particular has been shown to upregulate pro-apoptotic signaling pathways (Nakatsuji & 
Miller, 2001), inhibit angiogenesis (Chung et al., 2009; Seyfried & Mukherjee, 2010) as 
well as cell proliferation (Choi et al., 2006), leading to toxicity when accumulated in neural 
cells (Prokazova et al., 2009; Sohn et al., 2006). Perturbations in ganglioside homeostasis 
resulting in the depletion of the more abundant protective complex species, GM1 and GD1, 
158 
 
along with the accumulation of toxic simple species have been observed in response to 
neurodegenerative insults such as stroke and traumatic brain injuries (TBI) (Caughlin et al., 
2015; Whitehead et al., 2011; Woods et al., 2013). Additionally, previous work from our 
lab has demonstrated that the degree of ganglioside dysregulation is correlated with the 
severity of the neurodegenerative insult, with more severe stroke insults resulting in an 
earlier and prolonged accumulation of toxic simple ganglioside species (Caughlin et al., 
2015). Altogether, this suggests that ganglioside dysregulation may be playing an important 
role in the propagation of neurodegeneration following stroke.  
Therapies targeting the restoration of depleted GM1 in the brain through exogenous 
administration have demonstrated a strong protective effect in preclinical models of stroke  
(Carolei et al., 1991; Karpiak, Li, & Mahadik, 1987; Kharlamov et al., 1994; Li, Tian, 
Long, Chen, & Lu, 2016; Zhang et al., 2015) and was found to prevent behavioural deficits 
in mice following TBI (Rubovitch et al., 2017). GM1 is thought to exert its protective 
effects through modulation of neurotrophin release and the maintenance of ion balance 
(Ledeen & Wu, 2015; Lim, Esfahani, Avdoshina, & Mocchetti, 2011; Rabin et al., 2002; 
Zhang et al., 2015). However, clinically, GM1 administration alone has produced mixed 
results and has often failed to confer adequate protection following stroke (Argentino et al., 
1989; Candelise, 2002; Hoffbrand et al., 1988). One potential explanation for this finding 
may be that the restoration of complex gangliosides alone does not prevent those species 
from being enzymatically degraded to simple gangliosides during the ischemic cascade, 
thus the resulting toxicity is not prevented. Therefore, there is a need for targeted therapies 
which can prevent the catabolism of complex gangliosides as well as the resulting 
accumulation of toxic simple species in order to better protect cells from the damage 
associated with ganglioside dysregulation after a neurodegenerative injury. 
Chloroquine is best known as an anti-malarial drug but has also used been used as 
an anti-rheumatic agent due to its anti-inflammatory properties (Lehmeyer, 1978). It has 
been shown to reduce the accumulation of reactive oxygen species after glutamate-induced 
toxicity in hippocampal HT22 cells (Hirata et al., 2011) and block the activity of Toll-like 
receptor 3-mediated inflammatory pathway following stroke in rats (Cui et al., 2013). In 
addition to its widely acknowledged role in the inhibition of autophagy, low doses of CQ 
159 
 
have also been shown to have beneficial effects on the vascular system through vessel 
normalization (Maes et al., 2014) and protection of the blood brain barrier (Hirata et al., 
2011). CQ freely diffuses across lipid bilayers as it is uncharged at neutral pH, but is a 
weak base and becomes protonated upon entering acidic compartments such as lysosomes, 
causing it to accumulate in acidic organelles and raise their pH above their acidic optimum 
(Ohkuma & Poole, 1978). This disrupts the normal function of acidic lysosomal enzymes 
such as β-galactosidase and β-hexosaminidase, the enzymes responsible for the catabolism 
of complex ganglioside GM1 to simple species GM2 and GM3 (Riboni et al., 1991). CQ 
has been used to inhibit the catabolism of gangliosides in vitro (Riboni et al., 1995; Riboni 
et al., 1991; Shacka, Klocke, & Roth, 2006), making it a promising candidate for the 
prevention ganglioside dysregulation after stroke. 
In the current study, we used several experimental approaches to examine the 
effects of CQ treatment in the brain stroke in the rat. Our previous work in this area 
demonstrated that co-administration of endothelin-1 (ET-1) into the striatum to produce 
focal ischemia, alongside with  bilateral intracerebral-ventricular injections of toxic Aβ 
(25-35) in Wistar rats, produces a more severe neurodegenerative response as well as 
increased ganglioside dysregulation than either ET-1 stroke or Aβ toxicity alone (Caughlin 
et al., 2015; Whitehead et al., 2005). Therefore, this particular model was chosen for the 
present study as it is the ideal platform to assess the effects of CQ treatment on ganglioside 
homeostasis as well as pathological and functional recovery after a severe stroke. In order 
to visualize and quantify the abundance of gangliosides in the rat brain, MALDI IMS was 
performed at 3 and 21 days post-stroke. For the first time, we further demonstrate the 
toxicity of GM3 accumulation on primary cortical neurons and show the neuroprotective 
effect of CQ treatment in neurons. Finally, we show the restoration of behavioural deficits 
following CQ treatment in rats post-stroke (Fig. 5.1).  
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Figure 5.1: Chloroquine and ganglioside catabolism. (A) Schematic diagram of the 
Chloroquine-mediated disruption of gangliosides catabolism. Chloroquine accumulates in 
acidic compartments such as lysosomes which raises the pH above its acidic optimum and 
disrupts the activity of ganglioside catabolic enzymes β-galactosidase, which cleaves a 
galactose (Gal) subunit from the GM1 oligosaccharide chain to form GM2, and β-
hexosaminidase, which cleaves an N-acetylgalactosamine (GalNAc) sugar subunit to form 
GM3. With the catabolic enzymes disrupted, CQ can transiently block the degradation of 
complex gangliosides in response to a stroke. (B) Experimental paradigm. Rats in the 
treatment group were administered a daily intraperitoneal injection of CQ (45 mg/kg) 
beginning 3 days prior to stroke surgery and ending 3 days post-stroke. MALDI and IHC 
took place 3 d post stroke (day 7) and 21 d post-stroke. On day 20 post-stroke, rats 
underwent behavioural testing. 
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5.3  Materials and Methods 
5.3.1 Stroke Model 
All animal handling and surgical procedures were in accordance with guidelines of the 
Canadian Council on Animal Care and approved by the University of Western Ontario 
Animal Use Subcommittee. Three month-old male Wistar rats weighing 300–400 g 
(Charles River Laboratories, Quebec, Canada) were housed in pairs under standard 
conditions (12:12 light/dark cycle) and provided food and water ad libitum. Rats were 
randomly assigned to experimental groups and were housed individually following surgery. 
To induce the severe stroke injury, rats received both a bilateral intra-cerebral ventricular 
injection of the toxic amyloid beta (Aβ) fragment (25-35) followed by a unilateral striatal 
injection of ET-1, a potent vasoconstrictor as previously described (Caughlin et al., 2015). 
This enhanced stroke model has previously been shown to exacerbate the pathological 
response (inflammation, neurodegeneration and infarct size) (Whitehead et al., 2007, 2005) 
and more severely perturb ganglioside homeostasis than either injury alone (Caughlin et al., 
2015), providing the ideal platform to test a therapeutic agent aimed at restoring 
ganglioside homeostasis. Control surgery rats underwent identical surgical procedures with 
injections being replaced with saline. A total of 80 rats were used for the current study with 
5 rats per group used for MALDI IMS analysis at 3 and 21 d, 6 rats per group for IHC, and 
8 rats per group used for behavioural analysis. 
5.3.2 Chloroquine Administration 
Chloroquine (CQ, Sigma-Aldrich, St. Louis, USA) was prepared daily at a concentration of 
45 mg/mL in 0.9 % saline. Animals were weighed immediately prior to injection and were 
administered 45 mg/kg of CQ by intraperitoneal (i.p.) injection for seven consecutive days 
beginning 3 days prior surgery and ending 3 days after surgery (Fig 5.1 B).  
5.3.3 Immunohistochemistry and Fluoro Jade B 
Immunohistochemistry, standard histochemistry, and Fluoro Jade B staining were 
performed as previously described (Caughlin et al., 2015). 
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5.3.4 Primary cortical neuron cultures 
Primary cortical neurons were extracted from Wistar rat embryos and plated on coverslips 
in 24-well plates as previously described (Park et al., 2016). Half of the media was 
exchanged with fresh neurobasal media (NBM) every 2 days until 14 days in vitro (DIV). 
Each coverslip represented a single biological replicate with 8 biological replicates in each 
experimental group. Experiments were repeated on 3 separate cultures.  On DIV 13, each 
well in the 24-well plates were assigned as either control cells, CQ control cells (0.1 µM of 
chloroquine dissolved in NBM), 1 µM of GM3, 100 µM of GM3, 1 µM GM3 with CQ, or 
100 µM GM3 with CQ. Cells were then fixed with 4 % paraformaldehyde for 15 min then 
washed 3x with 10 mM PBS either 1, 6, 24, or 48 h after administration of CQ and/or 
GM3. Propidium Iodide (PI) was administered (1 mg/mL) 45 min before cell fixation in 
order to assess cell viability via fluoresce microscopy. Cells were also fluorescently stained 
with TUNEL using a cell death apoptosis kit (Sigma, St. Louis, MO, U.S.A.) after fixation 
to assess apoptotic cell death and mounted onto microscope glass slides with Fluoroshield 
(Sigma, Toronto, Canada) containing DAPI (Sigma, Toronto, Canada). 
5.3.5 Fluorescence Microscopy 
Neurons were imaged with DAPI (blue), TUNEL (green), and PI (red) and quantified using 
a Nikon Eclipse Ni (Nikon Instruments Inc., Melville, NY, U.S.A.) microscope and Nikon 
Analysis software. Microscope settings for each fluorescent filter were kept consistent for 
all analysis. Nikon analysis software allows for cell counting based on staining intensity 
and cell shape. This feature was used to perform all quantification of DAPI, TUNEL, and 
PI positive cell staining. Positive TUNEL and PI staining was presented as a ratio to total 
DAPI positive cells. 
5.3.6 MALDI IMS 
Rats from each experimental group (n = 5) were sacrificed at either 3 or 21 d post-surgery 
for MALDI IMS analysis. Rat brains were removed via fresh frozen extraction and 
prepared for MALDI IMS following the protocol published in Caughlin et al., 2017 
(Caughlin et al., 2017). Briefly, frozen rat brains were sectioned coronally at a thickness of 
10 μm. Sections were obtained from the site of stroke injury (bregma +1.92 mm) then 
163 
 
mounted onto indium-tin-oxide (ITO) slides. 1,5-Diaminonapthalene (DAN) matrix was 
then applied via sublimation followed by overnight incubation at - 20° C. Images were 
acquired in negative mode with a 70 uM laser step size. Data was exported to Tissue View 
(Sciex, Toronto, Canada) to visualize ganglioside distribution. Representative MALDI 
Images were exported from Tissue View to be pseudo-coloured and overlaid in Image J 
(Wayne Rasband, National Institutes of Health, Bethesda, MD, U.S.A.). MALDI data was 
acquired in Tissue View by isolating a region of interest (ROI) of equal size at the site of 
stroke within the striatum and in the corresponding contralateral uninjured striatum 
(comparable ROIs were used in control animals when no stroke was present). The 
numerical data from each A-series ganglioside species was then imported into Prism 
statistical software to determine the area under the curve (AUC) corresponding to the 3 
largest isotopic peaks of each species. This AUC measurement was then divided by the 
total signal as a means of normalizing the data for between scan comparisons. The AUC of 
the individual species relative to total signal was then compared between the ipsilateral 
hemisphere and contralateral hemisphere to the stroke. 
5.3.7 Ladder task – Motor assessment. 
The ladder test was used to assess motor function and determine if CQ treatment could 
rescue any motor impairments induced by the stroke. The ladder task consists of two long 
pieces of plexi-glass 20 cm apart with metal pegs placed at irregular intervals along the 
bottom. The ladder is raised 30 cm above the ground and connects an empty cage to the 
rat’s home cage. The rat is placed at one end of the ladder (with the empty cage) and must 
cross the ladder to reach its home cage on the opposite side. The home cage and empty 
cage are switched sides after 3 successful runs of the ladder in one direction. A total of 6 
runs (3 from each direction) were used to calculate the average number of correct paw 
placements, errors in paw placement, and peg misses with each limb. Metz et al., described 
correct paw placement and total misses along with 5 different types of errors in paw 
placement that can occur in the ladder test (Metz & Whishaw, 2002). For the purpose of the 
current study, the four variations of errors described by Metz et al., were grouped together 
and simply referred to as “errors”. 
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5.3.8 Novel Object Recognition – Short Term Memory Task 
The novel object recognition task (NOR) can be used to assess both short and long term 
memory depending of the experimental paradigm (Antunes et al., 2012). In the current 
study, rats were first habituated to an empty box for 10 min at which time they were 
returned to their home cage for a delay period of 45 min before being placed back into the 
box. The box contained two identical objects, either two robot toys or two dinosaur toys. A 
video camera was placed above the box to record the movements of the rats while they 
familiarized themselves with the objects for 4 min. The rats were then removed from the 
box and placed back in their home cage for a 1 hr delay period. After the 1 hr delay, rats 
were placed back in the box for a third time but with one of the objects having been 
replaced with a novel objects (one robot, one dinosaur). The rats were then allowed to 
explore both objects again for 4 min before being placed back in their home cage. The 
objects were rotated for each trial and carefully wiped down with 70% ethanol and allowed 
to dry between each session, along with the inside of the box to avoid familiarity based on 
scent. The location of the novel object was also rotated to be either on the right of the left 
side of the box for each trial. Sham surgery control rats showed no preference for either the 
robot or dinosaur objects, despite the variability in colour and shape, and were thus judged 
to be suitable objects for this task. The video recording and a stopwatch were used to add 
up the total amount of time rats spent interacting with each object during the familiarization 
and novel object trials. ”Interaction” was defined as sniffing, touching, standing, or rearing 
on the objects There was no statistical difference between the amount of time rats spent 
with the two identical objects during the familiarization trial (data not shown). Data is 
represented for the NOR trial as the percent of time rats spent with either the familiar or 
novel objects out of the total amount of time spent exploring both objects. A two-way 
ANOVA and tukey multiple comparisons test was performed to establish statistical 
differences between groups (p < 0.05). 
5.3.9 Data Analysis 
Data are represented as mean +/- the standard error of the mean.  Statistical analysis was 
performed using a two-way ANOVA with a Tukey’s post-hoc test. N values are described 
in each figure legend. 
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5.4 Results 
5.4.1 Pathological shift in ganglioside homeostasis prevented with CQ treatment 
at 3 d 
Ganglioside homeostasis has been shown to be severely perturbed in the early stages of 
recovery after a stroke such that an accumulation of simple ganglioside species and a 
depletion of complex species is observed at the site of injury and is correlated to the 
severity of the neurodegenerative insult (Caughlin et al., 2015). This finding would suggest 
that complex gangliosides, which are protective to cells, may be undergoing degradation in 
response to the injury, leading to the accumulation of toxic simple species, further 
perpetuating neurodegenerative damage. Using MALDI IMS, we examined the ability of 
CQ (45 mg/kg i.p.) to prevent the dysregulation of ganglioside homeostasis after a severe 
stroke injury. Sham surgery rats were used as controls and displayed no significant 
differences in ganglioside abundance between the ipsilateral and contralateral sides of the 
brain in response to the surgical procedures (Fig 5.2 A+B). Confirming previous findings 
from our lab, the stroke-injured rats showed a significant increase in simple gangliosides 3 
day after injury. The d18:1 and d20:1 species of GM2 showed the most significant increase 
in abundance in response to the injury, while only the d20:1 species of GM3 was 
significantly increased at the site of injury (Fig 5.2 A). CQ treatment resulted in a 
significant reduction in the abundance of simple ganglioside species at the site of injury 
compared to the untreated stroke group, showing no significant differences from sham-
surgery controls (Fig 5.2 A). Therefore, CQ treatment successfully prevented the 
accumulation of simple ganglioside species 3 days after a severe stroke insult. 
In addition to examining the ability of CQ to prevent the accumulation of simple 
gangliosides, we examined the abundance of protective complex gangliosides GM1 and 
GD1 to determine if CQ treatment can prevent their depletion at the site of the stroke. 
Ganglioside GD1 attaches to salt adducts [K+] and [Na+] when analyzed via MALDI IMS. 
These two adducts of GD1 have previous been observed to have unique responses 
following stroke (Caughlin et al., 2015), therefore we included both adducts in all of the 
following analyses. As predicted, both the d18:1 and d20:1 species of ganglioside GM1 
were significantly lower at the site of injury compared to controls 3 days post-surgery (Fig 
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5.2 B). Similar to what was previously reported for the [K+] and [Na+] adducts of GD1, 
they indeed showed unique responses following stroke such that the [K+] adduct of GD1 
was significantly depleted at the site of injury, while the [Na+] adduct remained unchanged. 
Treatment with CQ prevented the depletion of both the d18:1 and d20:1 species of 
ganglioside GM1 and the [K+] adduct of GD1 while significantly increasing the abundance 
of d18:1 GD1 [Na+] at the site of injury compared to untreated injured rats. Overall, these 
results suggest that CQ treatment is effective at restoring ganglioside homeostasis 3 days 
after a severe stroke injury. 
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Figure 5.2: Ganglioside homeostasis restored at 3 d in comorbid injured rats treated 
with CQ. (A) MALDI IMS overlaid images (left) and data (right) showing the AUC ratio 
of simple gangliosides GM3 and GM2 in the ipsilateral versus contralateral hemisphere to 
the site of injury in sham surgery, stroke, and CQ treated stroke rats 3 d after surgery. 
Gangliosides GM3 d20:1, GM2 d18:1, and GM2 d20:1 were all significantly elevated in 
response to the stroke injury which was prevented with CQ treatment. (B) MALDI IMS 
overlaid images (left) and quantified data (right) showing the ratio of abundance of 
complex gangliosides GM1, GD1[K+], and GD1[Na+] in the ipsilateral versus contralateral 
hemisphere to the site of injury at 3 d. Both GM1 and GD1[K+] were significantly depleted 
in response to the stroke insult whereas GD1[Na+] remained unchanged. CQ treatment 
prevented the depletion of GM1 and GD1[K+] while increasing the abundance of 
GD1[Na+] at the site of injury. Data presented as the ratio between the ipsilateral and 
contralateral hemispheres to the stroke injury +/- SEM, n = 5 per group. Scale bar is equal 
to 4 mm. * Indicates significant difference from control group, # indicates significant 
difference between stroke and CQ-treated groups, p < 0.05 via two-way ANOVA, Tukey 
post-hoc test. 
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5.4.2 Ganglioside homeostasis partially restored by CQ 21 d after comorbid 
stroke injury 
Previous work from our lab has demonstrated that the comorbid stroke injury used in the 
current study results in increased inflammation, larger stroke size, and poorer cognitive 
outcomes at the later stages of recovery than when just stroke or Aβ toxicity are present 
alone (Whitehead et al., 2007, 2005). This increased neurodegenerative response at later 
time points was also associated with an increased abundance of simple ganglioside species 
within the site of injury (Caughlin et al., 2015), further supporting the proposed role of 
simple ganglioside accumulation in the perpetuation of neurodegeneration after stroke. We 
examined the distribution of A-series gangliosides 21 days after stroke, as previously 
described, in order to examine the effect of CQ treatment on ganglioside homeostasis 
during the later stages of recovery.  
Simple ganglioside GM3 showed a significant increase in abundance for both the 
d18:1 and d20:1 species 21 days following stroke (Fig 5.3 A). While GM2 levels decreased 
from their initial upregulation in the early stages of recovery, d18:1 species of GM2 
remained significantly higher than controls even at 21 d (Fig 5.3 A). This response to the 
stroke is consistent with what has been previously reported by our group (Caughlin et al., 
2015). CQ treatment was not able to significantly reduce the increased abundance of either 
GM3 or GM2 at the site of injury 21 d post-stroke, although d20:1 species of GM3 and 
both GM2 species were not significantly different from controls either. This suggests that 
the accumulation of certain simple ganglioside species were, at least, partially reduced 
during the later stages of recovery with CQ treatment. 
 Complex gangliosides, on the other hand, were still subject to the protective action 
of CQ 21 d post-stroke. Injured rats continued to show a significant depletion of complex 
gangliosides GM1 and GD1 at the site of injury, indicating that these species may have 
continued to undergo degradation 21 d after the stroke. CQ treatment prevented this 
significant drop in GM1 and significantly increased the abundance of GD1 species at the 
site of injury, although GD1 [K+] levels in the CQ treated injured rats were still 
significantly lower than controls (Fig 5.3 B). While the degree of protection conferred by 
CQ in the maintenance of ganglioside homeostasis following stroke was reduced at the 
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later stages of recovery, CQ effectively reduced the degree of ganglioside perturbation, 
particularly for complex ganglioside species.  
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Figure 5.3: Partial restoration of complex ganglioside homeostasis observed at 21 d 
via MALDI IMS. (A) MALDI IMS overlaid images (left) and data (right) showing the 
AUC ratio of simple gangliosides GM3 and GM2 in the ipsilateral versus contralateral 
hemisphere to the site of injury in sham surgery, stroke, and CQ treated stroke rats 21 d 
after surgery. GM3 d18:1, GM3 d20:1, and GM2 d18:1 were all significantly elevated over 
controls at the site of injury at 21 d after surgery. This increase in simple gangliosides was 
not significantly reduced through CQ treatment, however, GM3 d20:1 and GM2 d18:1 
were not significantly elevated over controls either. (B) MALDI IMS overlaid images (left) 
and quantified data (right) showing the ratio of abundance of complex gangliosides GM1, 
GD1[K+], and GD1[Na+] in the ipsilateral versus contralateral hemisphere to the site of 
injury at 21 d post-surgery. All complex gangliosides examined, with the exception of 
GD1[Na+] d20:1 were significantly reduced at the site of injury 21 d after surgery. GM1 
and GD1[Na+] levels were not significantly different from controls in CQ treated rats and 
GD1[K+] abundance was significantly increased compared to untreated injured rats. Data 
presented as the ratio between the ipsilateral and contralateral hemispheres to the stroke 
injury +/- SEM, n = 5 per group. Scale bar is equal to 4 mm. * Indicates significant 
difference from controls, # indicates significant difference between stroke and CQ-treated 
groups, p < 0.05 via two-way ANOVA, Tukey post-hoc test. 
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5.4.3 Exogenous GM3 results in toxicity in primary cortical neurons which is 
protected by CQ treatment 
Toxicity associated with the accumulation of GM3 has been established in a number of 
neural (Nakatsuji & Miller, 2001; Sohn et al., 2006) and non-neural cell lines (Choi et al., 
2006; Chung et al., 2009; Seyfried & Mukherjee, 2010) but has yet to be demonstrated in a 
rat primary neuron cell line. Given our previously published and current findings that GM3 
is increased post stroke, and that CQ can acutely reduce this increase in GM3, we sought to 
determine if GM3 could directly cause neurodegeneration. GM3 was administered to 
primary cortical neurons cultured from embryonic Wistar rats after 14 days in vitro (d.i.v.) 
at either a low dose (1 μM) or a high dose (100 μM) and cell viability was assessed through 
TUNEL and Propidium Iodide (PI) staining 1, 6, 24, and 48 hrs after administration.  
The exogenous administration of gangliosides has been shown to lead to their 
incorporation into the plasma membrane of mammalian cells (Choi et al., 2006; Riboni et 
al., 1991; Nakatsuji & Miller, 2001). A separate experimental group was co-administered a 
low dose of CQ (1 μM) along with either the low or high dose of GM3 in order to 
determine if CQ can prevent changes in cell viability induced by the exogenous 
administration of GM3. CQ administration alone did not significantly alter TUNEL or PI 
positive staining from control levels (data not shown). A low dose of GM3 (1 μM) was 
found to significantly increase TUNEL and PI positive staining 48 hrs after administration 
compared to controls (Fig 5.4 A). While CQ treatment prevented the increase in PI positive 
staining at this time point, it did not significantly reduced TUNEL positive staining. In the 
high dose (100 μM) GM3 groups, an increase in TUNEL and PI positive staining was 
observed at 24 and 48 hrs after administration relative to controls which was significantly 
reduced through treatment with CQ (Fig 5.4 B). Overall, our results show that exogenous 
administration of both low and high doses of GM3 resulted in a significant increase in 
apoptosis and a decrease in cell viability which can be prevented by co-administration with 
CQ. 
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Figure 5.4: CQ increases cell viability and decreases apoptosis in response to toxic low 
and high dose GM3 administration. (A) Quantification of TUNEL and PI positive 
staining relative to control primary cortical neurons administered a low dose (1 μM) GM3 
or co-administered CQ (1 μM) with low dose GM3. Low dose GM3 significantly increase 
TUNEL and PI positive staining relative to controls at 48 hrs after GM3 administration. PI 
positive staining, but not TUNEL positive staining was significantly reduced by co-
administration of low dose GM3 with CQ. (B) Quantification of TUNEL and PI positive 
staining relative to control primary cortical neurons administered a high dose (100 μM) 
GM3 or co-administered CQ (1 μM) with high dose GM3. High dose GM3 resulted in a 
significant increase in both TUNEL and PI positive staining at 24 and 48 hrs. CQ treatment 
significantly reduced TUNEL and PI positive staining at 24 and 48 hrs compared to high 
dose GM3 alone. However, a significant increase in TUNEL positive staining was 
observed at 48 hrs in the CQ treated cells. Data presented as a fold change relative to 
control cells +/- SEM, n = 6 per group *p < 0.05 via two-way ANOVA, Tukey post-hoc 
test. 
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5.4.4 Stroke-induced motor and cognitive impairments prevented by CQ 
treatment. 
Impairments in motor function and gait are a common complication of sub-cortical stroke 
in the rat, generally affecting both fore- and hind-limbs on the contralateral side of the body 
to a greater extent than the ipsilateral side.  In order to assess motor function in our rats, we 
used the ladder task which examines the rat’s ability to cross a horizontal ladder with 
unevenly spaced metal pegs. This task requires the rat to correctly place their paws on each 
rung of the ladder in order to reach the other side. We assessed the total number of limb 
placement errors (described by Metz et al., 2002) in both the fore-limbs and hind-limbs of 
the rat in each of the experimental groups to determine if CQ treatment can protect against 
stroke-induced impairments of motor function. As expected, stroke-injured rats displayed 
significantly more errors in limb placement during the ladder task than the sham surgery 
control group for all four limbs (Fig 5.5 A). Interestingly, the fore-limbs of the injured rats 
showed a higher number of limb placement errors than the hind-limbs. As expected, the 
contralateral fore-limb, displayed the highest number of limb placement errors. CQ-treated 
rats showed a significant reduction in fore-limb placement errors compared to the untreated 
stroke group, with no significant differences in performance from the control group (Fig 
5.5 A). However, this protective effect of CQ treatment was not observed in the hind-limbs 
of the CQ treated rats, which showed a significant increase in limb placement errors 
compared to controls, similar to the stroke group. Overall, CQ treatment was effective at 
preventing fore-limb, but not hind-limb motor impairments after stroke injury. 
CQ has previous been shown to prevent stroke-induced deficits of short-term 
memory in Sprague-Dawley rats using an electroshock Y-maze task (Cui et al., 2013). We 
therefore assessed the short-term memory of sham surgery, stroke-injured, and CQ-treated 
stroke rats 20 days after surgery using a Novel Object Recognition task (NOR). In this task, 
rats are first introduced to two identical objects and are given 4 minutes to explore and 
interact with the objects. After 1 hr, rats are returned to the box with one of the objects 
having been replaced with a novel object and are allowed to again explore and interact with 
the objects for an additional 4 min. As expected, Sham-surgery rats spent significantly 
more time interacting with the novel object than the familiar object (Fig 5.5 B). This occurs 
due to the rat’s preference for interacting with novel objects. Stroke-injured rats, on the 
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other hand, spent the same amount of time exploring both the novel and familiar objects 
(Fig 5.5 B). The lack of preference for the novel object is indicative of an impairment in 
short-term memory in the stroke injured rats (Antunes & Biala, 2012). Interestingly, CQ-
treated stroke injured rats spent significantly more time with the novel object than the 
familiar object. Although the degree of preference for the novel object was not identical to 
that of the sham-surgery control group, these results suggest that short-term memory 
deficits induced by the stroke injury can be prevented with CQ treatment. 
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Figure 5.5: Reduced forelimb Motor and cognitive impairments in stroke injured rats 
treated with CQ. (A) Quantification of limb placement errors on the Ladder motor 
assessment task (top) with representative image of ladder task (right). Stroke injured rats 
showed a significant increase in limb placement errors compared to controls in all four 
limbs. The number of limb placement errors was significantly reduced in the forelimbs of 
rats treated with CQ. CQ treatment did not significantly reduced the number of limb 
placement errors in the hind-limbs of stroke injured rats. (B) Quantification of time spent 
with novel and familiar objects on Novel Object Recognition task (NOR – bottom) with 
representative image of NOR task. Sham surgery control rats spent significantly more time 
with the novel object than familiar object while stroke injured rats spent the same amount 
of time with both objects, indicating a deficit of short-term memory, CQ treated rats, like 
control rats, spent significantly more time with the novel object than the familiar object, 
suggesting that memory deficits were prevented by CQ treatment. * Indicates sig difference 
from control group, # indicates sig difference between stroke and CQ-treated group, p < 
0.05 via two-way ANOVA, Tukey post-hoc test. 
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5.4.5 Reduced brain pathology at 21 d in CQ-treated stroke injured rats 
The stroke model used in the current study has previously been shown to produce an 
increase in infarct size as well as an exacerbated inflammatory response (Whitehead et al., 
2007, 2005). We used immunohistochemistry to examine cell survival, neurodegeneration, 
and inflammation at the site of injury within each experimental group at 3 and 21 d post-
stroke in order to assess the effects of CQ treatment on pathology at the site of injury. 
NeuN, a neuronal nuclear antigen, was used to assess cell survival. Stroke injured rats 
treated with CQ had significantly more NeuN positive staining at the site of injury 
compared to untreated stroke injured rats at both 3 and 21 d post-stroke (Fig 5.6 A). Fluoro 
Jade B was used as a marker of neurodegeneration and was significantly reduced in CQ 
treated rats at 21 d compared untreated stroke injured rats (Fig 5.6 B). Inflammation was 
assessed using the microglia marker OX-6. Stroke injury led to a significant increase in 
OX-6 positive staining at the site of injury at 21 d (Fig 5.6 C). CQ treatment in stroke 
injured rats prevented the significant increase in OX-6 positive staining observed in 
untreated stroke rats at 21 d post-stroke, indicating that inflammation was significantly 
reduced in CQ-treated rats. Overall, the results demonstrate a neuroprotective effect 
(increase in NeuN, decrease in FJB) with a concomitant decrease in neuroinflammation 
post-stroke with CQ administration. 
  
177 
 
 
Figure 5.6: CQ treatment reduces brain pathology after stroke. IHC Quantification of 
NeuN (A), Fluoro jade B (B), and OX-6 (C) staining at the site of injury at 3 and 21 d post 
stroke. CQ treatment significantly increased positive NeuN staining at the site of injury at 
both 3 and 21 days post stroke compared to the untreated stroke group (A). FJB staining 
was significantly reduced at the site of stroke injury at 21 d in CQ treated rats (B). CQ 
treatment prevented the significant increase in OX-6 staining observed in the stroke group 
at 21 d (C). * Indicates sig difference from stroke 3 d group, # indicates sig difference 
between stroke and CQ-treated groups, p < 0.05 via two-way ANOVA, tukey multiple 
comparisons. 
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5.5  Discussion 
In the current study, we used MALDI IMS, IHC, primary cortical neurons, and a 
behavioural task to examine the effect of CQ treatment on neurodegeneration. The 
combination of these techniques allows for the most in-depth examination of ganglioside 
dysregulation after stroke to date and provides novel insight into the benefits of 
pharmacological interventions targeting ganglioside metabolism for neurodegeneration. 
CQ treatment successfully prevented ganglioside dysregulation of both complex 
and simple species 3 d post-stroke. These findings support our hypothesis that CQ can be 
used to prevent the degradation of complex gangliosides and accumulation of simple 
gangliosides acutely after stroke. Ganglioside dysregulation was partially prevented 21 d 
post-stroke by CQ treatment and was more effective at preventing complex ganglioside 
degradation than simple ganglioside accumulation. Several additional species of GM3 with 
a varied number of carbons in their ceramide moieties were also detected and showed a 
similar pattern in response to stroke injury and CQ treatment as the d18:1 and d20:1 species 
at both time points (appendix v). Treatment at this time point was also associated with a 
significant decrease in inflammation, neurodegeneration, and cell death at the site of injury, 
and significantly reduced motor impairments in the forelimbs of stroke-injured rats. It is 
possible that preventing ganglioside dysregulation in the early stages of recovery was 
sufficient to confer long-term protection during recovery from stroke. Indeed, in the case of 
ischemic reperfusion injuries, neuroprotection strategies in the acute stage are crucial in 
mediating damage to penumbral regions and ultimately the severity of long term 
impairments (Chamorro et al., 2016; Ginsberg, 2016). Alternatively, it is possible that the 
pre-treatment phase of the CQ paradigm was able to confer protection to neurons prior to 
the stroke, leading to increased membrane lipid integrity and a less severe acute injury 
response. In this way, the results of the current study point to a potential preventative 
intervention that may be neuroprotective to individuals at high risk of developing stroke 
injuries or recurring strokes. The timing of CQ administration may also be an important 
factor when considering its therapeutic window (Maes et al., 2014), thus it is possible that 
altering the timing of the treatments would provide a more effective long term therapeutic 
response. 
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Additionally, we showed, for the first time, that the exogenous administration of 
GM3 to primary cortical neurons at both a low and high doses was toxic to primary cortical 
neurons, supporting the hypothesis that the accumulation of this simple ganglioside at the 
site of injury after a stroke may be playing a mechanistic role in the propagation of 
neurodegeneration. CQ administration effectively reduced apoptosis and increased cell 
viability in primary cortical neurons exposed to exogenous GM3. Although the 
mechanisms in which CQ was able to protect primary cortical neurons from GM3 toxicity 
remain unclear, it is possible that CQ was able to block GM3 from binding and/or 
incorporating into cells to effect cell signaling and alter membrane composition. Further 
investigation into the interaction of CQ with GM3 in neural cells are needed to address this 
question. Regardless, this finding points to the possibility that CQ may not only be 
preventing the breakdown of complex gangliosides in response to the stroke through its 
lysosomotropic properties, but may also confer protection against external sources of GM3 
present in the extracellular environment during the ischemic cascade. 
Rubovitch et al., suggest that the restoration of GM1 shortly after the injury may be 
preventing the cascade of events that lead to neurodegeneration after stroke (Rubovitch et 
al., 2017). Mechanisms such as excitatory amino acids (EEAs), nitric oxide, inflammatory 
mediators, reactive oxygen species, immune modulation, withdrawal of trophic factors, and 
apoptosis are all thought to be involved in the development of the ischemic cascade (Zhang 
et al., 2015). Interestingly, GM1, like CQ, has been found to inhibit autophagy after a 
stroke injury (Li et al., 2016) and can upregulate brain-derived neurotrophic factor (Lim et 
al., 2011), promoting cell survival. GM1 has also been associated with the attenuation of 
secondary neuronal damage when administered in the acute stages of stroke by blocking of 
EEAs-related neurotoxicity (Lipartiti et al., 1990). One of the protective effects of CQ 
administration observed in the current study was the restoration of depleted GM1 at the site 
of injury. It is, therefore, possible that the decreased pathological response and motor 
impairments observed in the treated rats at the later time point were associated with both 
the attenuation of simple ganglioside accumulation in the acute stages of recovery along 
with the maintenance of GM1 levels throughout. 
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Overall, chloroquine treatment can be used to restore ganglioside homeostasis after 
a severe ischemic stroke injury and is associated with long-term pathological and 
functional improvements in rats. Interventions targeting membrane lipid dysregulation may 
be a crucial component of effective multifactorial approaches to stroke prevention and 
treatment and are worthy of further investigation.  
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Chapter 6 : Discussion 
6.1  Summary 
The purpose of the studies presented in this work was to better understand the role of 
ganglioside dysregulation in neurodegeneration and aging. To accomplish this, we first 
used animal models of stroke and Aβ toxicity to examine the interaction between simple 
ganglioside accumulation and the severity of neurodegenerative injury. We then considered 
the role of simple and complex gangliosides with either 18 or 20 carbons present in their 
ceramide moiety in Wt and Tg APP21 Fischer rats to determine if the LCB ratio shifted in 
a characteristic manner among all a-series gangliosides. Next, we further examined the 
abundance of each individual ganglioside species in the aging brain of Wt and Tg APP21 
Fischer rats to better understand the unique patterns of alterations that occur in simple and 
complex gangliosides during aging. Finally, a pharmacological agent (CQ) was used to 
assess protection from ganglioside dysregulation after a severe stroke in Wistar rats. 
6.2  Gangliosides and pathological inflammation  
The brain’s major immune/inflammatory cells, astrocytes and microglia, are thought to 
play an important role in the accumulation of simple ganglioside species in response to 
injury and disease. GM3 has been reported to be an important component of astrocytes. 
Indeed, it has been reported to be the major ganglioside in rat and chick primary cultured 
astrocytes according to HPTLC and IHC analysis, along with simple species GD3, while 
complex species GM1 was not detected (Asou, Hirano, & Uyemura, 1989; Murakami et al., 
1999; Sbaschnig-Agler, Dreyfus, & Norton, 1988). The composition of gangliosides in 
astrocytes is thought to be fluid, changing depending on their activation state (Raff et al., 
1983). Kawai et al., found that GD3 was elevated in reactive astrocytes but not normal 
astrocytes which the authors hypothesized may be related to astrocyte’s role in lesion repair 
as GD3 was increased in glial scars (Kawai et al., 1994). These studies support the 
hypothesis that GM3 accumulation is linked to the neuroinflammatory process and 
provides an interesting rationale for further investigations of the role of GM3 and GD3 in 
astrocytes. 
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While little is known of the ganglioside composition of microglia, a similar increase 
in simple gangliosides has been reported in microglia in response to environmental 
stressors. A study by Simon et al., showed that microglia release simple ganglioside GD3 
in response to inflammatory cytokines and lipopolysaccharide (LPS) and that an increase in 
GD3 is toxic to oligodendrocytes, leading to apoptosis (Simon et al., 2002). 
Oligodendrocytes are particularly vulnerable to inflammatory cytokines, with TNF-α and 
interferon-γ thought to play a major role in their degeneration (D’souza, Alinauskas, & 
Antel, 1996; Vartanian, Li, Zhao, & Stefansson, 1995). The authors confirmed the toxicity 
of elevated GD3 on oligodendrocytes by exogenous administration of several gangliosides 
to in vitro cultures of oligodendrocytes and saw that only exogenous GD3 lead to an 
increase in cell death markers and condensation/fragmentation of the nucleus of 
oligodendrocytes (Simon et al., 2002). Indeed, unpublished work from our lab has shown 
that cultured microglia also release GM3 in response to LPS, further supporting the 
hypothesis that brain inflammatory cells may be contributing to the accumulation of simple 
gangliosides under toxic/stressful conditions. 
6.3  Ganglioside dysregulation 
This work provides detailed evidence of the degree and location of ganglioside 
dysregulation during neurodegeneration and aging in the brain of rats, however, much 
remains to be explored. To better understand the accumulation of simple gangliosides, 
there is a need for a thorough examination of the enzymes that govern their metabolism. 
Chapter 5 provided compelling evidence that the depletion of complex gangliosides is tied 
to the accumulation of simple species as the disruption of catabolic enzymes by CQ 
restored the homeostatic distribution of all a-series gangliosides acutely after a stroke 
injury. A detailed examination of mRNA and protein expression of all catabolic enzymes 
using polymerase chain reaction (PCR) and western blotting could reveal if certain 
enzymes are more affected than others in response to neurodegeneration, thus providing a 
more specific target for ganglioside dysregulation treatments. 
Additionally, while the work presented here focuses exclusively on the distribution of 
a-series gangliosides, b-series gangliosides have also been implicated in the pathogenesis 
of neurodegenerative diseases such as HD (Di Pardo, Amico, & Maglione, 2016), with 
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simple ganglioside GD3 being linked to toxicity, similar to GM3 (Desplats et al., 2007; 
Scorrano, Petronilli, Lisa, & Bernardi, 1999). An interesting avenue of further study would 
be to examine how the ratio of a to b series gangliosides are altered during aging and if the 
Tg APP21 rats or rats who have undergone stroke would show a different distribution of 
these species. Additionally, although gangliosides have important regulatory functions in 
the cell and are thus of particular interest in the context of injury and disease, their 
behaviour only scratches the surface of the total burden of lipid dysregulation in the brain. 
Other membrane associated lipids such as phospholipids and cholesterol are also altered in 
response to changes in the external environment. Techniques such as MALDI IMS can, and 
are, being used to better understand the global impact of lipid dysregulation in the brain. 
6.4  Role of the ceramide moiety in aging and neurodegeneration 
Prior to this work, the accumulation of d20:1 species in the brain was thought to be a 
metabolic marker of aging in the brain (Palestini, Masserini, Sonnino, & Tettamanti, 1990; 
Sugiura et al., 2008). Chapters 3 and 4 demonstrated that the accumulation of d20:1 species 
in the brain is far more complex than previously hypothesized, with a high degree of 
anatomical heterogeneity. We showed, for the first time, that the d20:1 species of simple 
gangliosides do not increase in an age-dependent manner, with the exception of GM3 in the 
white matter. We also showed that an increase in the proportion of d20:1 species relative to 
d18:1 does not necessarily mean that that the d20:1 species are accumulating, but rather 
could be indicative of a depletion of d18:1 species, as was observed for complex 
ganglioside GD1 in the white matter. 
While the functional consequences of alterations in the ceramide moiety are thought 
to be related to membrane fluidity and cell signaling properties on the membrane, much 
remains unknown (Masserini, Palestini, & Freire, 1989; Sonnino & Chigorno, 2000). 
However, this work provides new, detailed information regarding their anatomical 
distribution during aging, which may help elucidate the role of the ceramide moiety. For 
example, Hirano-Sakamaki et al., found that 18 carbon species of GM1 and GD1 are highly 
expressed in the hillium and inner molecular layers of the hippocampus. These regions 
contain mossy fiber axons and dendrites from granule cells and play a critical role in 
memory and learning, which suggests that the 18 carbon species of complex gangliosides 
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may be critical to these processes. The increased abundance of complex d20:1 species in 
the molecular layer suggest that these species are highly localized on axons and perforant 
pathway fibers from entorhinal cortex neurons, a pathway highly susceptible to 
neurodegeneration in AD (Hirano-Sakamaki et al., 2015). This study suggests the regional 
distribution of ganglioside species with various carbon chain length may be crucial to the 
functions of that brain region.  
Furthermore, Cutler et al., described a correlation between the location of long 
chain ceramide accumulation and brain regions which were susceptible to pathology in AD 
patients (Cutler et al., 2004). Therefore, it is possible that the brain regions which showed 
the highest ratio of d20:1 to d18:1 species in Chapter 3 are most vulnerable to the 
development of pathology in our rats. The regions with the highest overall d20:1/d18:1 
ratios included the DG Mol layer of the hippocampus, intermediate layer of the cortex, and 
the white matter PVCC for complex gangliosides, and the PVCC, and to a lesser extent the 
aCC, striatum, and LSN for simple ganglioside GM3 (GM2 showed a fairly stable ratio in 
all brain regions). Indeed, Chapter 4 revealed several differences with regards to the 
ceramide moiety in Tg APP21 and Wt rats which support this hypothesis. Firstly, Tg 
APP21 rats had elevated d20:1 species of GD1 at 20 m in the PVCC over Wt rats, while the 
aCC showed a more severe depletion of d18:1 species at 20 m. Secondly, Tg APP21 rats 
accumulated d20:1 species of GD1 earlier than their Wt counterparts in the DG Mol layer 
of the hippocampus and did not show an increase in d18:1 species at 20 m that was 
observed in Wt rats. Thirdly, the intermediate layer of the cortex showed the largest 
discrepancy between d18:1 and d20:1 species of GM1 and GD1 for both Wt and Tg APP21 
rats, with relatively stable levels of d18:1 during aging accompanied by a significant 
increase in d20:1 species. However, Wt rats had significantly more d18:1 species of GD1 at 
12 m, with a similar pattern observed for GM1. Altogether, Tg APP21 rats had either 
higher levels of d20:1 species or lower levels of d18:1 species in all three of the 
aforementioned brain regions. In terms of simple ganglioside GM3, Tg APP21 rats showed 
significantly more d20:1 species in all cortical, subcortical, and white matter brain regions 
at 12 m than Wt rats. However, this significant increase only persisted at 20 m in the 
PVCC. Thus, while the d20:1 species of GM3 did not necessarily accumulate in an age 
dependent manner across the brain, Tg APP21 rats still showed higher levels of these 
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species than their Wt counterparts, suggesting that an increase in d20:1 species may be a 
mechanism which makes the brain more susceptible to damage in Tg APP21 rats.  
6.5  CQ and ganglioside metabolism – limitations/benefits 
In chapter 5, CQ treatment prevented the dysregulation of gangliosides 3 d after a severe 
stroke injury. However, the effect of this treatment was not as pronounced at 21 d and a 
toxic pattern of ganglioside distribution began to emerge. It has been suggested that CQ 
may be more effective in treating damage caused by ischemic reperfusion injuries in the 
early stages of recovery than later stages (Fang, Liu, Dahmen, & Dirsch, 2013). Further 
studies examining the effects of CQ on ganglioside metabolism after stroke are needed to 
establish the optimal timing for effective treatment. 
The inhibition of ganglioside catabolic enzymes by CQ leads to the accumulation of 
GM1 through a number of different mechanisms. Other than preventing direct GM1 
catabolism, CQ can increase GM1 indirectly through GD1a. Riboni et al., demonstrated 
that GD1a and b can be broken down by sialidase at the level of the plasma membrane, 
independent of the lysosome, while the degradation of GM1 to GM2 and GM3 were 
lysosome-dependent (Riboni, Prinetti, Bassi, & Tettamanti, 1991). This suggests that CQ’s 
ability to increase GM1 likely stems not only from the disruption of catabolic enzymes 
which degrade GM1, but also from the normal degradation of GD1 to GM1 by membrane-
bound sialidase which then accumulates as GM1. For this reason, targeting the catabolic 
enzymes βGal and βHex may be a particularly effective approach for both preventing the 
accumulation of simple gangliosides and increasing/maintaining GM1 levels. 
One limitation of using CQ to modulate the catabolism of gangliosides in vivo is 
that this compound has a number of biological effects both within and outside of the 
lysosome, therefore, the beneficial effects of CQ treatment after stroke demonstrated in 
chapter 5 cannot be strictly ascribed to the restoration of ganglioside homeostasis. CQ is a 
known inhibitor of autophagy and has been used in pre-clinical models and clinically as an 
anti-inflammatory agent (Ferraz et al., 1994; Popert, Meijers, Sharp, & Bier, 1961; Suarez‐
Almazor et al., 2000; Yang et al., 2013), both functions which have also been shown to be 
beneficial in treating stroke injuries (Cui et al., 2013; Hirata et al., 2011; Li et al., 2016; 
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Zheng et al., 2014). Therefore, it is possible that these mechanisms may also be playing a 
role in reducing stroke pathology and preventing behavioural deficits in the rats. However, 
chapter 5 also demonstrates, for the first time, that CQ is able to reduce toxicity caused by 
the exogenous administration of GM3 in primary cortical neurons. These results directly 
link the therapeutic effects of CQ with a ganglioside-derived mechanism of toxicity. 
Importantly, these results were recapitulated in the in vivo rat model 3 d post-stroke, in 
which the increase in toxic simple gangliosides was prevented by CQ treatment. While the 
findings of chapter 2 demonstrated that ganglioside dysregulation was tied to the severity 
of neurodegeneration, chapter 5 showed that the restoration of ganglioside homeostasis by 
CQ was tied to pathological and functional recovery from a severe neurodegenerative 
stroke. 
In the end, Chapter 5 serves as a valuable proof of principle that ganglioside 
dysregulation can be treated using the anti-malarial drug CQ and that the restoration of 
ganglioside homeostasis is associated with pathological and functional recovery. While CQ 
itself is known to produce a variety of symptoms in humans, such as severe stomach pains, 
psychosis, delirium, vomiting, and blurred vision, synthetic analogues of CQ have been 
created which have the same properties but produce milder symptoms. In a clinical setting, 
a pharmacological agent, such as CQ, could be administered alone or in conjunction with 
other therapies as part of a multi-factorial approach to treatment in patients who have either 
suffered a stroke or are at high risk of suffering from recurring strokes. However, further 
studies are needed to demonstrate the specific role of βGal and βHex inhibition in 
neurodegeneration. 
6.6  Alternative approaches for modulation of ganglioside metabolism 
In order to better understand the specific effects associated with the restoration of 
ganglioside homeostasis during neurodegeneration, catabolic enzymes βGal and βHex 
would have to be selectively targeted and transiently blocked. Although there is currently 
no pharmacological agent which can accomplish this, genetic approaches may hold the key 
to answering this question.  
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KO animal models have been developed which lack the synthetic enzymes 
necessary for the formation of certain types of gangliosides, leading to a depletion of 
downstream gangliosides. These models have been useful in understanding the role of the 
depleted species during development and in the adult brain (Chiavegatto, Sun, Nelson, & 
Schnaar, 2000; Harlalka et al., 2013; Takamiya et al., 1996). KO models targeting the 
catabolic enzymes have also been developed that lead to an accumulation of the upstream 
species. For example, the βGal KO mouse model leads to an accumulation of GM1. These 
models are generally used to simulate gangliosidoses (Hauser, Kasperzyk, D’Azzo, & 
Seyfried, 2004; Tessitore et al., 2004). A permanent KO of any gene associated with 
ganglioside metabolism or catabolism would disrupt the normal homeostatic balance 
needed at various stages of development. Thus, while KO models can be quite specific in 
their genetic target, they do not offer the required transient properties to be a useful 
therapeutic approach to treating ganglioside dysregulation and would not be transferable to 
a clinical setting. Rather a genetic knock-down approach would be more suitable.  
Small interfering ribonucleic acid, or siRNA, is a technique used for sequence 
specific knock down of a desired gene, for example, βGal. The sequence is synthetically 
created then injected into the cell (in vitro) or desired region (in vivo). The effects are 
transient as the siRNA eventually gets degraded or diluted below a therapeutic threshold 
(Whitehead, Langer, & Anderson, 2009). siRNA has been shown to last between 3-7 d in 
rapidly dividing cells, and several weeks in non-dividing cells (Bartlett & Davis, 2006). 
Future studies using siRNA to target βGal and βHex both in in vitro models of toxicity and 
in vivo models of stroke may reveal specific neuroprotective mechanisms involved in 
preventing ganglioside dysregulation. 
6.7  Gangliosides and white matter 
One of the most interesting findings from chapter 3 and 4 was the unique changes in 
ganglioside composition that occurred in the white matter of both Wt and Tg APP21 rats 
during aging. The age-dependent increase in the d20:1/d18:1 LCB ratio of GD1 in the 
white matter observed in chapter 3 was revealed to be the result of an age-dependent 
depletion of d18:1 species with only a minor increase in the d20:1 species, an effect that 
was exacerbated in the Tg APP21 rats. This GD1 pattern was unique to the white matter, 
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with an increased or stable abundance of d18:1 species during aging throughout the rest of 
the brain. As previously mentioned, GD1 is a major receptor for MAG binding and plays 
an important role in the long term stability of axons. Thus, a depletion of these species in 
the white matter of the aging brain may represent a mechanism of vulnerability to axonal 
damage in the corpus callosum. Indeed, depletion of GD1 and GM1 has been observed in 
the corpus callosum of a pre-clinincal model of HD and may, according to the authors, 
represent a critical molecular change influencing the pathogenesis of neurodegenerative 
diseases (Di Pardo et al., 2016). 
Chapter 3 also showed that GM3 had a unique pattern of abundance in the white 
matter during aging, with an age-dependent increase in the d20:1/d18:1 LCB ratio. This 
ratio either decreased or remained unchanged between birth and old age in every other 
brain region. Chapter 4 expanded upon these findings and revealed that both the d18:1 and 
d20:1 species of GM3 were significantly higher at 12 m in Tg APP21 rats in brain regions 
such as the substantia nigra and cortex, an effect that was masked in chapter 3 due to the 
focus on the d20:1/d18:1 ratio. These results suggest that GM3 accumulation during aging 
may play a much larger role than anticipated in the brains of Tg APP21 rats. Importantly, 
the increased GM3 LCB ratio observed in the PVCC in chapter 3 was found to be the result 
of an increase in d20:1 species in Tg APP21 rats at both 12 and 20 m, and not a decrease in 
the d18:1 species. The accumulation of GM3 in the white matter of Tg APP21 rats is of 
particular interest due to its hypothesized role in the development of vascular dementia. 
GM3 was reported to be a major component of vascular smooth vessel walls in the brain 
and is thought to be critical driver of Aβ aggregation in blood vessel walls of Tg APP mice 
with the Dutch mutation (Yamamoto, Hirabayashi, Amari, & Yamaguchi, 2005). Indeed, 
our Fischer Tg APP21 rats are vulnerable to the development of micro-infarcts in the 
corpus callosum as they age, a pathology reminiscent of leukaoriosis in human patients 
with vascular dementia. Thus, the data presented in this work supports the hypothesis of 
GM3 accumulation as a driver of early pathology in AD and an important target for 
preventative interventions. 
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6.8  MALDI IMS – limitations and future directions 
Advancements in the MALDI IMS technique have increased exponentially in the last 
decade, not only in terms of technology, but also in sample preparation methodology. The 
deposition of dry matrix by sublimation has enabled increased sensitivity and spatial 
resolution of lipid imaging that has made the findings reported in this work possible. 
However, there remain a number of limitations to the technique that we, and others in the 
MALDI IMS field, are working on improving moving forwards. 
One of the largest pitfalls of MALDI IMS is the semi-quantitative nature of the data 
it produces. Finding new statistical approaches to analyzing the data and reducing error 
produced by between scan variability is one the biggest challenges currently facing the 
field. In chapter 2, the average peak height corresponding to the three largest isotopic peaks 
was used to perform a ratio between the stroke-injured, ipsilateral hemisphere in the rat 
brain compared to the undamaged tissue of the contralateral hemisphere. The three largest 
isotopic peaks of each species were used to ensure the data was as representative as 
possible of abundance of each ion. Although it is often the case, the first isotopic peak is 
not always the largest, and thus, measuring only one isotopic peak can be misleading. By 
comparing the ratio of each species within two regions of interest of the same image, error 
produced by between scan variability was greatly reduced. In chapters 3, 4, and 5, the peak 
height analysis was replaced by an area under the curve (AUC) measurement, which has 
become a common method of quantifying MALDI IMS data in similar published studies 
(Sugiura et al., 2008; Weishaupt, Caughlin, Yeung, & Whitehead, 2015). In chapter 3, this 
AUC measurement was used to calculate the ratio between the d20:1 and d18:1 species of 
each ganglioside, which, similar to chapter 2, prevented the need for direct image 
comparisons. Data from chapters 4 and 5 were further normalized by a total ion current 
ratio, comparing the AUC of each species to the total AUC of the mass spectrum, allowing 
for between species comparisons. Chapter 5 combined the analytical approaches of 
chapters 2 and 4 by both normalizing the data to the total ion current and comparing the 
injured ipsilateral hemisphere with the undamaged contralateral hemisphere. Although the 
approach to data analysis had evolved throughout this work, the field of IMS is always 
pushing for newer, more quantitative approaches to analyzing MALDI IMS data. 
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 Standards of specific ions of interest can be used for tandem MS (MS/MS) to 
identify ions that have a low abundance in tissue samples (Chan et al., 2009; Dufresne et 
al., 2017). However, pure standards of each ganglioside species do not currently exist, 
limiting the applications of this method for large scale ganglioside identification and 
analysis. Using mathematical algorithms to cluster trends in MALDI MS data peak 
distribution, called principle component analysis (PCA), has been used to describe 
differences between experimental groups or identify patterns in MALDI IMS data (Hong et 
al., 2016). These alternative approaches to quantifying and analyzing MALDI IMS data 
may increase the robustness of findings. 
Advancements in technology are also a key factor in addressing some of the 
limitations of MALDI IMS. For example, with the Sciex 5800 MALDI instrument used in 
chapters 3 through 5, acquisition of a full rat brain coronal section took upwards of 2 hrs 
and 30 min at a spatial resolution of 70 μM. This long acquisition time makes running an 
experiment with a large sample size very costly and time consuming. Additionally, certain 
dry matrices begin sublimating while under the vacuum of the instrument, further limiting 
the types of matrices that can be used to acquire these full images. New MALDI MS 
instruments have been developed to address these issues including the recent launch of the 
Bruker Rapiflex MALDI MS, which can acquire images several times faster than any 
previous model (Prentice & Caprioli, 2016). This opens the door to a new realm of 
application opportunities and greatly increases the number of dry matrices that can be used 
to acquire large images (Potocnik et al., 2015). Increasing acquisition time makes the 
application of full body imaging more practical, which would allow for a more detailed 
examination of lipid distribution across the entire body of healthy and diseased/injured 
mice or rats, or tracking a peripherally administered drug to its target location. Full body 
imaging and Rapiflex technology would offer an interesting expansion to the work 
presented here. 
6.9  Significance of the research 
Our brains are largely composed of lipids, yet their role in aging and disease remains 
poorly understood. This work provides a unique interdisciplinary approach to examining 
the role of gangliosides during aging and neurodegeneration. Novel insight into the age-
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dependent accumulation of long chain gangliosides was provided, showing, for the first 
time, that it is not a hallmark of the aging process but rather is largely dependent on 
ganglioside structure and anatomical location. The white matter was identified as a region 
that is particularly susceptible to ganglioside dysregulation in Tg APP21 rats and showed 
unique age-dependent alterations in ganglioside composition compared to grey matter 
regions. Further, a link between the severity of neurodegeneration and the degree of 
ganglioside dysregulation was shown and identified the depletion of complex species GM1 
and GD1, along with the accumulation of GM3 and GM2 as major pathological events at 
the site of stroke injury. It also demonstrates that ganglioside dysregulation can be 
prevented with CQ and provides a foundation upon which refined, specific inhibitors of 
ganglioside catabolism can be examined as potential preventative/therapeutic approaches to 
ganglioside dysregulation. Overall, ganglioside dysregulation was highlighted as a crucial 
component of a highly complex set of pathological events which can play a mechanistic 
role in the propagation of neurodegeneration after stroke and increase susceptibility to the 
development of neurodegenerative diseases, making it a worthy target of future 
investigation. However, in the end, this work underlines the vast gap in knowledge that 
exists with regards to the role of membrane lipids in the brain and the need for innovative 
interdisciplinary approaches to better understand their role in health, disease, and injury. 
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Appendices 
Appendix i: Incubation time and spatial resolution 
A number of troubleshooting experiments were performed in order to establish a working 
protocol that enhanced both the detection of gangliosides as well as spatial resolution. One 
experiment which demonstrated superior imaging resolution was the addition of an 
incubation period between sublimation and image acquisition. This effect was enhanced 
when the tissue was stored at -20° C as opposed to room temperature. This is thought to 
occur due to increased interaction time between the matrix and the tissue, as well as a 
rehydration effect when the tissue is removed from the freezer and place in the desiccator.  
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Appendix i: Effect of incubation time and freezing on spatial resolution of ganglioside 
GM1 in MALDI imaging of mouse brain tissue. All tissue samples were sectioned and 
sublimated at the same time to avoid day-to-day variation in sample prep parameters. The 
left panel shows the spatial resolution of GM1 on a mouse brain tissue section when the 
image was acquired as soon as sublimation was completed. The image appears to have an 
uneven signal intensity across the tissue and has a “grainy” appearance as compared to the 
other images. The middle panel shows a separate tissue imaged after a 24 hr incubation 
period at room temperature. The image appears to be much more even and less pixelated. 
The final panel on the right show the spatial resolution of a third tissue section after a 24 hr 
incubation period in a -20° C freezer. Signal intensity of GM1 appears to have been 
increased evenly across the tissue as compared to the other panels and spatial resolution 
also increased, making it possible to observe discrete anatomical features of the tissue. 
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Appendix ii: Evolution of MALDI IMS sample prep protocols 
The development of an optimized sample prep protocol is imperative for the detection and 
visualization of gangliosides across brain tissue sections. Significant improvements in 
sample prep and instrumentation between chapters 2 and 5 of this work occurred which 
allowed for improvements in accurate detection and visualization of A-series gangliosides 
across the rat brain. 
 
Appendix ii: The evolution of the MALDI IMS protocol and improvements in signal 
intensity and spatial resolution over time. The first panel shows a representative image 
from one of the first MALDI IMS experiments at the begging of this work performed using 
a Sciex 4700 MALDI instrument and CMBT matrix dissolved in a solvent and sprayed 
using a pneumatic sprayer. Refinements in the CMBT protocol led to improved spatial 
resolution and increased the signal to noise (S/N) ratio (shown in panel 2). With the 
purchase of an updated Sciex 5800 MALDI instrument and the use of a sublimation 
protocol with DAN matrix, sensitivity and spatial resolution exponentially increased (panel 
3). Finally, further refinements in sample prep methodologies and image processing using 
Image J software to pseudocolour and overlay species allowed for the simultaneous 
visualization of different species (panel 4). 
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Appendix iii: Sublimation protocol 
 
A specialized MALDI IMS sample prep protocol was developed upon completion of 
chapter 2 in order to improve MS signal and imaging resolution of gangliosides. This 
protocol was created to address limitations in sensitivity observed in chapter 2. For 
example, the d20:1 species of GM3 fell below the threshold of detection, thus, valuable 
information on the abundance of a toxic ganglioside species in the context of 
neurodegeneration was missing. This protocol, in conjunction with an updated MALDI MS 
instrument allowed for a more detailed analysis of ganglioside dysregulation in the rat brain 
and was published in the Journal of Visualized Experiments in February 2017. This 
manuscript was accompanied by a visual demonstration of the protocol to allow other 
researchers to replicate the technique used in this work. 
 
Sublimation of DAN Matrix for the Detection and Visualization of 
Gangliosides in Rat Brain Tissue for MALDI Imaging Mass Spectrometry 
Abstract 
Sample preparation is key for optimal detection and visualization of analytes in MALDI 
IMS experiments. Determining the appropriate protocol to follow throughout the sample 
preparation process can be difficult as each step must be optimized to comply with the 
unique characteristics of the analytes of interest. This process involves not only finding a 
compatible matrix that can desorb and ionize the molecules of interest efficiently, but also 
selecting the appropriate matrix deposition technique. For example, a wet matrix deposition 
technique, which entails dissolving a matrix in solvent, is superior for desorption of most 
proteins and peptides, whereas dry matrix deposition techniques are particularly effective 
for ionization of lipids. Sublimation has been reported as a highly efficient method of dry 
matrix deposition for the detection of lipids in tissue by MALDI IMS due to the 
homogeneity of matrix crystal deposition and minimal analyte delocalization as compared 
to many wet deposition methods (Hankin, Barkley & Murphy, 2007; Thomas, 
Charbonneau, Fournaise & Chaurand, 2012). Broadly, it involves placing a sample and 
powdered matrix in a vacuum-sealed chamber with the samples pressed against a cold 
surface. The apparatus is then lowered into a heated bath (sand or oil), resulting in 
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sublimation of the powdered matrix onto the cooled tissue sample surface. Here we 
describe a sublimation protocol using 1,5-diaminonaphthalene (DAN) matrix for the 
detection and visualization of gangliosides in the rat brain using MALDI IMS. 
Introduction 
Matrix-assisted Laser Desorption/Ionization (MALDI) Imaging Mass Spectrometry (IMS) 
is becoming a highly sought after technique for visualization of the spatial distribution of 
lipids, peptides and proteins across intact sample surfaces. MALDI IMS was previously 
known as an analytical technique for pre-purified analytes, but in recent years, it has been 
drawing attention in many other disciplines because of the ability to combine the accuracy 
of mass spectrometry with high resolution visual/anatomical reference points without the 
need for any external labelling. 
As the scientific pool of researchers utilizing this technique continues to grow, there 
is increased need for standardized, easy-to-follow protocols to assist in the development 
and optimization of IMS experiments. Gangliosides, a group of membrane lipids highly 
abundant in the central nervous system, are ideal for MALDI IMS experiments as their 
location, embedded within the membrane, makes certain species impossible to detect using 
conventional Immuno-labelling. Additionally, we have shown, using MALDI IMS, that 
these lipids, which function as modulators of cell signaling, among other things, have 
unique anatomical distribution patterns in the healthy rodent brain that are altered after 
brain injury (Caughlin et al., 2015; Weishaupt, Caughlin, Yeung & Whitehead, 2015; 
Whitehead et al., 2011). Gangliosides are located at a higher mass range compared to most 
lipid species, and are thus most suited to the MALDI imaging platform. 
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Figure 1. Workflow of MALDI IMS Experiment. 
Diagram of the general workflow of a MALDI IMS experiment using sublimation. Tissue 
frozen at -80 °C is sectioned in a cryostat and 10 μm sections are thaw mounted onto 
conductive ITO slides. The slide is then placed in a desiccator until sublimation. Slides are 
inserted into the sublimation apparatus and an even layer of matrix is applied to the tissue 
sample surface. Samples are frozen overnight in a -20 °C freezer then placed in a desiccator 
for 10 min. Once standards have been applied, the samples are inserted into the MALDI 
instrument where a laser is directed across the tissue causing desorbed molecules in the 
matrix to ionize. The ions travel down a flight tube and separate based on their mass (time-
of-flight/TOF) until they reach the detector. The information on the ionic abundance of 
analytes within a predetermined mass-to-charge (m/z) range is displayed as both a 
molecular image and mass spectrum. This data can be used to both visualize and quantify 
the ionic abundance of the analyte of interest within the imaged tissue. 
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Sample preparation for MALDI IMS is highly variable as each step of the process 
must be customized to the analytes of interest. The defining feature of MALDI-based 
experiments is the use of a matrix coating deposited onto the sample surface prior to 
analysis. In addition to the role of absorbing and transferring radiation energy from the 
laser during the ablation process, the matrix also serves to isolate various analytes from the 
sample, thereby facilitating the analysis of compounds of interest (Fuchs et al., 2010; 
Barcelo-Coblijn & Fernandez, 2015). Homogenous application of the matrix to the sample 
surface is the most crucial step in the sample preparation process. Improper matrix 
deposition can lead to large heterogeneous matrix crystal formations and the development 
of artifacts, low ion-signal, and poor reproducibility (Barcelo-Coblijn & Fernandez, 
2015)(Figure 1). 
Due to the affinity of certain matrices to isolate specific analytes, the type of matrix 
selected for an experiment can significantly alter the outcome. The matrices used for 
imaging of proteins and peptides often differ from those used for imaging lipids and the 
process is further complicated by the need for additional procedures such as washing and 
rehydration steps in order to successfully detect signals from tissue. Although washing 
steps exist for the enhancement of lipid signals (Angel, Spraggins, Baldwin & Caprioli, 
2012), they are not a prerequisite for the detection of most lipid species. When selecting a 
matrix for a lipid imaging experiment, it is important to consider the polarity of the lipid of 
interest as this will narrow the range of suitable matrices. For example, gangliosides 
contain sialic acid residues which give them an overall negative polarity. There are a 
number of matrices that can effectively desorb and ionize gangliosides from tissue; 
however, factors such as matrix-derived peaks in the spectrum and stability of the matrix 
under vacuum must be taken under consideration. 1,5-diaminonapthalene (DAN) matrix is 
sufficiently stable under instrument vacuum conditions for the majority of imaging 
applications and has demonstrated a high degree of sensitivity for lipid desorption and can 
be used for the analysis of lipids in both positive and negative ion modes (Thomas, 
Charbonneau, Fournaise & Chaurand, 2012). DAN matrix, when compared to other 
negative lipid affinity matrices such as dihydroxybenzoic acid (DHB), 9-aminoacridine (9-
AA), and 5-chloro-2-mercaptobenzothiazole (CMBT), was able to most efficiently desorb 
gangliosides from rat brain tissue in negative ion mode (manuscript in preparation). 
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Selecting the appropriate method of matrix deposition is of equal importance to 
selecting the matrix itself. Wet matrix deposition methods wherein the solid matrix is 
dissolved in an organic solvent, and deposited by pneumatic or automated sprayers or 
spotters, are particularly effective for the desorption of proteins and peptides as the liquid 
permeates the sample to allow for extraction of compounds and co-crystallization with the 
matrix. Although these techniques can also be used for lipid applications, analyte 
delocalization and uneven matrix crystal formations are common occurrences due to the 
high abundance and solubility of lipids in solvents, particularly in tissue (Thomas, 
Charbonneau, Fournaise & Chaurand, 2012; Murphy et al., 2011). Because lipids are 
readily ionized from tissue, dry matrix deposition techniques, such as sublimation, offer a 
simple, cost effective alternative to sprayers while circumventing many of the drawback of 
these techniques. The success of sublimation in MALDI IMS experiments is attributed to 
features such as microcrystalline matrix morphology which increases the surface area for 
matrix-analyte binding, increased matrix purity, and homogenous matrix deposition leading 
to increased reproducibility compared to wet matrix techniques (Hankin, Barkley & 
Murphy, 2007; Jaskolla, Karas, Roth & Steinert, 2009). 
Sublimation involves heating a powdered matrix under vacuum immediately below 
a cooled sample surface resulting in solid to gas-phase transition of the powdered matrix 
followed by deposition onto the tissue sample surface. During sublimation, matrix 
deposition can be controlled by varying factors such as time, temperature and pressure to 
provide highly reproducible results. A single sublimation experiment can take anywhere 
from 5 to 20 min depending on the type of matrix selected, which can be re-used several 
times before disposal. The apparatus can be purchased commercially at a fraction of the 
price of automated sprayers and is easily taken apart for cleaning and maintenance. The 
low cost and relative simplicity of this matrix deposition technique make it ideal for 
researchers beginning or expanding upon lipid imaging applications in MALDI IMS. 
Although information detailing protocols for sublimation of tissues for IMS have been 
reported (Rourke et al., 2015), few standardized protocols exist which focus on the basic 
workflow involved with carrying out a sublimation experiment for imaging high mass 
lipids in negative ion mode, making it difficult to establish the technique without extensive 
trial and error. The following is an experimental protocol aiming to fill that gap for the 
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sublimation of DAN matrix onto rat brain sections for high resolution imaging and 
detection of gangliosides (Figure 2). 
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Figure 2. Sublimation Apparatus. 
Photograph (A) and schematic diagram (B) of the sublimation apparatus. The vacuum 
pump is connected by rubber tubing to a cold trap filled with 300 mL of ethanol. The cold 
trap is then connected by rubber tubing to the sublimation apparatus. The apparatus is made 
up of two separate pieces of glassware that are sealed together with a metal U-joint. The 
top half of the sublimator contains the condenser which is filled with ice slush. The sample 
plate is taped onto the bottom of the condenser, inside the sealed glass apparatus. The 
bottom half of the sublimation apparatus contains the DAN matrix, spread out evenly 
facing the sample plate. During sublimation, the glass apparatus is placed on a sand bath 
heated to 140 °C by a hot plate directly below it. The temperature probe helps maintain a 
stable temperature throughout the sublimation experiment through feedback of the sand 
bath temperature compared to the preset temperature for the experiment. 
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Protocol 
All animal handling procedures described below adhere to the University of Western 
Ontario's animal care committee (2016-014). 
1. Tissue Preparation and Sectioning 
1.1. Extract brain tissue from the rat through a process known as "Fresh Frozen Extraction" 
(FFE). 
a. Euthanize the rat with an overdose of pentobarbital sodium and monitor reflexes 
in the limbs. Once all reflexes have ceased, sever the head of the rat using a 
guillotine. 
b. Carefully separate the muscles and other tissues from the skull using a scalpel. 
Use bone-cutting forceps to break the skull to expose the brain, starting from the 
base of the skull (foramen magnum) to the anterior portion. 
c. Once the brain is exposed, carefully scoop it out with a surgical spatula and 
immediately place on crushed dry ice for flash freezing. 
NOTE: The brain will be very malleable. Therefore, take extreme care when placing the 
brain on dry ice. If the brain is crushed or pressed against a surface, it will alter its shape 
and freeze in that position. 
1.2. Remove fresh frozen tissue (not perfused with formaldehyde or embedded in OCT) 
from - 80° C freezer and place on dry ice. 
1.3. Place several drops of water on a cryostat holder and place on either dry ice or cryostat 
freeze bar. Press tissue lightly onto cryostat holder as it begins to freeze and hold until 
water freezes around the base of the tissue and anchors it in place. Add additional water to 
further secure the tissue on the holder if necessary. 
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NOTE: Water is used instead of OCT media for mounting tissue in order to avoid 
contamination of the tissue with compounds which can affect the detection of the desired 
signal. 
1.4. Position tissue in cryostat. Section tissue up to the desired anatomical location. Ensure 
that the cutting thickness is between 8 - 12 μm. 
NOTE: When sectioning tissue in communal cryostat devices, it is imperative that separate 
materials such as blades, brushes, anti-roll bars, and holders be used in order to avoid 
contamination with embedding compounds. The inside of the cryostat should also be 
cleaned thoroughly with ethanol before use. 
1.5. Using the cryostat anti-roll bar, slowly section flattened tissue sections. Holes or 
markings on the tissue can occur if the roll bar placement is incorrect or blade is dull. Move 
the tissue to the center of slicing platform using clean paintbrushes. 
1.6. Mounting 
a. Freeze conductive slides or metal plates by placing them in the cryostat while 
slicing. When the slide is completely frozen, carefully move the sectioned tissue 
onto the conductive surface of the slide using clean paintbrushes. Once all tissue 
sections are positioned correctly on the slide, place a finger under the slide, opposite 
the tissue, and press until the section thaws. 
NOTE: Sections may fold or curl during the thawing process when using this mounting 
method. This can be reduced by keeping the slide in the cryostat when thawing the tissue. 
If these issues become problematic, an alternative, warm-mount method is listed below. 
b. Alternatively, take a room temperature Indium-tin Oxide (ITO) slide (or metal 
plate) and lightly press down on frozen tissue section on the slicing platform 
surface, conductive side down. This will lead to the tissue section thawing evenly 
onto the surface of the slide with little curling or folding of the tissue. 
NOTE: Condensation may appear below the section when mounting using this method 
which may lead to loss of certain proteins and lipids. 
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1.7. Place slides with tissue in a desiccator for 5 - 10 min. 
2. Sublimator Apparatus Set-up 
NOTE: Perform these steps in a fume hood. 
2.1. Place a sand bath in an aluminum container onto a hot plate, with the hot plate on a 
metal scissor lift of appropriate surface area (i.e. larger than the hot plate). Turn on the hot 
plate and set the temperature to 140 °C. 
NOTE: The melting point for DAN matrix is between 187 - 190 °C. Do not exceed this 
temperature on the hotplate. 
a. If the hot plate is equipped with a temperature feedback probe, use it to monitor 
sand temperature throughout the experiment and ensure temperature consistency. 
This feature can assist with experiment reproducibility across various sublimation 
experiments. 
NOTE: The sand bath should be contained within an aluminum container as a glass 
container may shatter at high temperatures. 
2.2. Place 300 mg of DAN matrix onto the bottom surface of sublimation apparatus. Place 
the matrix in the center of the apparatus and spread out in an even layer in the approximate 
width and length of the slide being sublimated. 
CAUTION: DAN matrix is toxic. Therefore, it is important wear gloves, masks, and safety 
goggles at all times when handling the powdered matrix. DAN should be stored in the dark 
as it is light sensitive. 
2.3. Tape a metal plate onto the inner surface of the apparatus with the plate making direct 
contact with the bottom of the condenser in order to ensure even distribution of temperature 
cooling across the entire surface of the slide during sublimation. Alternatively, sand the 
bottom of the condenser to ensure a flat surface. 
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a. Place the tape along the outer edges of the plate and adhere to the sides of the 
inner glassware. If the tape is placed under the plate and adheres to the bottom of 
the inner glass surface, the temperature distribution may not be even and could 
result in uneven matrix distribution across the surface of the slide. 
b. Tape a blank (test) slide diagonally across the surface of the metal plate with the 
tape again placed on the outer edges of the slide. 
2.4. Connect the top and bottom portions of the apparatus, with a rubber O-ring in the 
middle to ensure a complete seal. 
2.5. Place a metal U-joint around the center of the apparatus and tighten vices until the top 
and bottom half of the apparatus are sealed tightly together. Place in the metal O-ring 
above the sand bath. 
2.6. Take a handful of crushed ice and place it in the condenser. Fill condenser ¼ to ½ full 
with cold water to create ice slush. The ice slush will cool the metal plate on the inside of 
the apparatus and subsequently the slide adhered to it. Wait at least 5 min for the 
temperature to reach a steady state. 
2.7. Pour 300 mL of ethanol in the cold trap container and place the glassware into the 
container. Drop 2 - 3 small pieces of dry ice into the ethanol in the bottom of the cold trap 
container. The cold trap input has a glass tube running to the bottom of the cylinder, while 
the output does not. 
2.8. Connect the vacuum pump to the cold trap output using rubber tubing. Use another 
piece of rubber tubing to connect the cold trap input to the sublimation apparatus. Ensure 
that the tubing is tightly secured using metal clamps if available. 
2.9. Use the vacuum pump to deliver a vacuum of 30 - 50 mT. Allow the pump to run for at 
least 5 min for pressure equilibration. Vices on U-ring of sublimation apparatus may have 
to be tightened again once the vacuum pump is turned on because of decreased pressure in 
the apparatus. 
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NOTE: It is highly recommended that a vacuum gauge be attached to the pump to monitor 
the pressure of vacuum during the experiment and to test for leaks in pressure in order to 
achieve the highest possible reproducibility between experiments. However, most pumps 
are designed to maintain a constant pressure, therefore the gauge may not be essential for 
experienced users. Additionally, vacuum seal grease can be used to help maintain vacuum 
pressure. 
3. Sublimation 
3.1. Ensure that the sand bath temperature has stabilized at 140 °C and that the apparatus is 
secured in the metal O-ring above the sand bath with all tubing connected and the vacuum 
turned on. 
3.2. Set timer for 7 min but do not start timer. Slowly raise the scissor lift and sand bath up 
to the sublimation apparatus until the U-joint of the sublimator is well above the metal O-
ring. This extra space allows for adjustment of the apparatus on the sand. 
a. Quickly press the sublimator gently on the sand surface to ensure that the 
apparatus is sitting evenly on the sand, and then immediately start the timer. 
3.3. When the timer sounds, turn off the vacuum pump and carefully lower the scissor lift 
until the sublimator is no longer touching the sand bath and is sitting securely in the metal 
O-ring. 
a. Slowly loosen the micro-vent valve to release pressure in the apparatus. Loosen 
the metal clamp around the rubber tubing of the sublimation apparatus and slowly 
begin to loosen the tube. Once the rubber tube has been loosened slightly, bend the 
tube to one side to allow residual pressure to escape. 
b. When ambient pressure returns, carefully remove the rubber tubing from the 
sublimation apparatus. 
3.4. Loosen the vices on the U-joint of the apparatus and remove. Carefully separate the 
two halves of the sublimation apparatus and pull off the slide from the top of the inner 
glassware. Examine slide to confirm even matrix distribution. 
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NOTE: If matrix is uneven, the powdered matrix in the bottom of the sublimator can be 
repositioned or the sublimator apparatus can be repositioned in the sand for the next slide. 
The sublimation process can be repeated several times using the same matrix, however, the 
matrix will eventually become darker from repeated heat exposure and the quantity of 
powder will decrease such that the sublimation time will have to be adjusted slightly to 
compensate. For this reason, it is important to monitor the amount of matrix being 
sublimated after each experiment to ensure consistency in matrix deposition between slides 
3.5. If the distribution and amount of matrix sublimated is sufficient, tape a new slide with 
tissue onto the inside of the sublimator and repeat Section 3. 
NOTE: For quality control (QC) purposes, the amount of matrix sublimated can be 
measured after each experiment by weighing the slide before and after sublimation and 
dividing the weight of sublimated matrix with the surface area of the slide 2, it should be 
noted that due to the lack of precision of most scales beyond 4 decimal points and 
variability between scales, these measurements should be only be used a guide for optimal 
matrix deposition as opposed to a fully quantifiable means of QC unless a high precision 
balance is used (see Figure 3). 
4. Tissue Storage/Rehydration 
4.1. After sublimation, store slides in a sealed container or small cassette in sealed plastic 
bag. 
4.2. Incubate slides in -20 °C freezer for 2 h or overnight. 
NOTE: The goal of the freezing process is to act as a rehydration step for the desorption of 
tissue materials into the matrix. The freezing process has also been shown to prevent 
degradation of lipid signals for up to 1 week when stored at -80 °C (Patterson, Thomas & 
Chaurand, 2014). For this reason, the amount of time the samples are stored in the freezer 
can be varied to a certain degree to suit the needs of the experimenter without significantly 
altering signal detection (as observed in our lab). However, we have noticed some 
discoloration of matrix when samples are frozen for longer than 24 h at -20 °C. Thus, we 
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recommend imaging the sublimated tissue before that time or storing tissue at -80 °C for 
longer incubation periods. 
4.3. Remove slides from freezer (and container) and place in a desiccator for 5 - 10 min. 
5. Imaging and Analysis 
5.1. Remove slides from desiccator and apply instrument standards to ensure mass 
accuracy of MALDI instrument during imaging. The type of standards will vary depending 
on instrumentation. Standards are generally applied evenly across entire slide, surrounding 
tissue to be imaged (Figure 3 D). 
5.2. Insert slide into MALDI instrument and follow manufacturer's instructions for imaging 
experiments (instrument methods should be optimized for a 1,000 - 2,000 mass range). 
Representative result (Figure 4) was acquired in reflectron negative mode with a 70 μm 
raster and 20 shots/spectrum (acquisition time ~ 2 h). 
Representative Results 
Upon completion of the sublimation experiment, the two halves of the glass apparatus are 
separated in the fume hood and the slide, taped to the condenser, can be removed (Figure 3 
A). At this point, the slide should be examined for uneven matrix distribution and the time, 
temperature, or placement of the apparatus in the sand bath may have to be adjusted for the 
next slide. A successful DAN sublimation experiment will result in an even coating of 
grey/brown matrix along the surface of the slide where the anatomical features of the tissue 
can be clearly visualized and the amount of matrix on the glass slide is similar to the 
amount on the tissue (Figure 3 B). For example, if too much matrix has been sublimated 
on the tissue, the thickness of the matrix will cover the features of the tissue and only the 
general shape will be discernable. However, if too little matrix is sublimated, the tissue will 
have a darker appearance than the rest of the slide (Figure 3 C). Both too much and too 
little matrix will result in poor signal in the MALDI instrument. For quality control 
purposes, Thomas et al. weighed the amount of matrix deposited on the slide and divided 
the weight by the surface area of the slide. They reported an optimal amount of matrix 
deposition for several matrices including DAN (110 μg/cm²) 2. Although most balances 
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lack the precision needed to replicate such results, we have attempted this method of QC; 
however, due to a high degree of variability, we can only advise a suitable range of matrix 
deposition found to be associated successful versus unsuccessful sublimation experiments 
with DAN matrix as determined through signal detection in the instrument. A matrix 
measurement of below 100 μg/cm² was associated with "too little" matrix conditions while 
a measurement of above 140 μg/cm² was associated with "too much". Matrix deposition 
between 100 and 140 μg/cm² was found to be an optimal quantity for imaging with DAN 
matrix. Calibrating standards should be applied on the glass slide around the tissue samples 
to ensure the mass accuracy of the detected IMS signals (Figure 3 D) 
In a MALDI IMS experiment, the molecular image allows for the visualization of 
the spatial distribution of the analyte of interest along with any unknown species that may 
be present in a given mass range. The molecular images of gangliosides in this experiment 
were overlaid using ImageJ software to show the anatomical distribution of several 
ganglioside species across the cortical and subcortical regions of the rat brain (Figure 4 A). 
The most abundant gangliosides in the brain are the A-series species GD1a and GM1 but 
also contain gangliosides GM2 and GM3 which can all be found between the 1,000-2,000 
m/z mass range, a higher mass range than most common brain lipids, making these 
gangliosides easy to identify along the spectrum (Figure 4 B). The ionic abundance of each 
ganglioside species can be used to semi-quantify differences or changes in ganglioside 
species within the same image. Because a certain amount of variability in sample prep 
cannot be avoided in IMS, between scan comparisons are considered to be semi-
quantitative. 
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Figure 3: DAN Sublimation. 
Representative results of sublimation of DAN matrix on rat brain tissue. (A) Upon 
completion of sublimation, the two halves of the apparatus are separated and the slide is 
removed from the condenser. (B) DAN matrix spreads evenly across multiple rat brain 
tissue sections on the surface of the slide to allow for highly reproducible results (between 
100 - 150 μg/cm²). (C) Examples of failed sublimation experiments where too little matrix 
(left - <90 μg/cm²) or too much matrix (right - >150 μg/cm²) was deposited. Too little 
matrix will result in insufficient desorption of analytes, while too much matrix will not 
allow the laser to penetrate to the tissue during acquisition, resulting in low ion detection. 
(D) Slide containing rat brain tissue sections sublimated with DAN matrix and calibration 
standards applied is ready for insertion into MALDI instrument for imaging. 
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Figure 4: MALDI IMS of Gangliosides in the Rat Brain. 
Representative MALDI IMS molecular image and mass spectrum of gangliosides in the rat 
brain after sublimation with DAN matrix. The molecular image is a composite of multiple 
ganglioside species in the spectrum overlaid and pseudocolored using Image J software to 
show the unique anatomical distribution of ganglioside species throughout the brain. 
Species GM1d18:1 (red, mass ~1,547 Da), GM1d20:1 (green, mass ~1,573 Da), GM3d18:1 
(blue, mass ~1,178 Da), and GM3d20:1 (teal, mass ~1,207 Da) are represented. The mass 
spectrum displays ionic abundance of analytes within a 1,000 - 2,000 mass range. The 
major A-series gangliosides are labelled along the spectrum. 
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Discussion 
This work details a standardized protocol of matrix sublimation on tissue for the detection 
of negatively charged lipids, such as gangliosides, in MALDI IMS experiments. Sample 
preparation for MALDI IMS is highly variable and must be customized to suit the unique 
properties of the analyte of interest. The application of matrix onto the tissue sample 
surface is a crucial aspect of the sample preparation process with regards to the quality of 
results in IMS. Particular care should be taken when selecting matrices, ensuring that the 
matrix is compatible with the analyte of interest and is free of matrix-derived artifacts in 
the spectrum. Sublimation is a dry matrix deposition technique which provides a high 
degree of matrix crystal homogeneity with little delocalization of lipids on tissue. DAN 
matrix in particular shows a high degree of sensitivity for the desorption of a group of 
negatively charged membrane lipids called gangliosides, as demonstrated in rat brain 
sections, and is stable under vacuum for extended periods of time, allowing for 
compatibility with the majority of imaging applications. DAN matrix has the additional 
benefit of also having a high affinity for positively charged lipid species, thus increasing 
the versatility of this matrix for MALDI IMS applications (Thomas, Charbonneau, 
Fournaise & Chaurand, 2012). It should also be noted that multiple lipid species, including 
phospholipids, can be detected simultaneously when using this IMS protocol. 
A thorough examination of the properties of DAN matrix as compared to 9 other 
commonly used matrices has been previously published (Thomas, Charbonneau, Fournaise 
& Chaurand, 2012). In this article, the authors highlight the increased sensitivity of DAN 
matrix in negative ion mode as compared to the other matrices examined as well as the 
capability for high resolution imaging using DAN. DAN matrix was found to have the 
highest overall performance for negative polarity ions. Interestingly, it performed equally 
well for positive polarity ions. Other common matrices which have demonstrated high 
affinity for negative polarity ions include DHA, DHB, and 9-AA. The efficiency of DHA 
as a matrix is limited by its low stability under vacuum which makes it impractical for most 
imaging applications (Thomas, Charbonneau, Fournaise & Chaurand, 2012). 9-AA has the 
benefit of producing low background noise and demonstrated enrichment of sulfatide 
signals in the 750 - 950 mass range in negative mode compared to DHB matrix (Cheng et 
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al., 2010). Although DHB has been shown to be very effective in positive mode, it yields 
lower negative polarity ion signal as compared to DAN matrix (Thomas, Charbonneau, 
Fournaise & Chaurand, 2012). DAN matrix also demonstrated increased sensitivity in 
negative ion mode in the lower mass range (650 - 950) compared to DHB (Thomas, 
Charbonneau, Fournaise & Chaurand, 2012). Additionally, it has been reported that DHB 
can form significant matrix clusters in negative ion mode up to 750 Da 2. 
Another method of dry matrix deposition has been described by Puolitaival et al., in 
which ground matrix is passed through a fine sieve and deposited onto the sample surface. 
The authors compared this dry method of matrix deposition to a wet matrix manual spray 
technique and found that they gave comparable signal for phospholipids in the 450 - 1,200 
mass range (Puolitaival, Burnam, Cornett & Caprioli, 2008). One study used both 
sublimation and dry-coating with a sieve to examine phospholipid expression, however, the 
authors did not comment on how the two techniques compared in terms of image resolution 
or ion signal yield (Chaurand, Cornett, Angel & Caprioli, 2011). 
In order to ensure the widest possible range of applicability, the protocol presented 
was a basic workflow that will allow both new and more specialized users of MALDI IMS 
to achieve highly reproducible results for a wide variety of lipid imaging applications. 
However, sublimation protocols can be modified to meet the unique circumstances of the 
experiment. For example, the fine matrix crystal deposition provided by sublimation allows 
for the option to reverse the order of sample preparation by pre-coating slides/plates with 
matrix prior to mounting the tissue. The matrix can be sublimated onto the conductive 
surface in advance and stored in a dark environment for later use thus reducing sample 
preparation time post-sectioning while still maintaining high sensitivity for lipid detection 
(Grove, Frappier & Caprioli, 2011; Yang & Caprioli, 2011). Another modification that can 
be made to this protocol to enhance signal for the detection of lipids is a 2 min wash with 
ammonium formate (Angel, Spraggins, Baldwin & Caprioli, 2012). 
Although sublimation can circumvent many of the drawbacks of most wet 
deposition techniques, such as smaller, more homogenous matrix crystal deposition 
(Hankin, Barkley & Murphy, 2007), decreased delocalization of analytes, and low cost as 
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compared to automated sprayers, some variability in the sample preparation process is 
unavoidable. In the case of sublimation, there are several factors which may cause minute 
differences from one experiment to another and can include the following which have been 
observed in our lab. There can be differences in the position of the sublimation apparatus 
on the sand. When running several sublimation experiments back-to-back, the sand in the 
sand bath may begin to shift its position which can affect the dispersion of heat throughout 
the sand bath. Flattening the sand before each round of sublimation can also change the 
dispersion of heat as sand that has been displaced may take time to return to a uniform 
temperature. Sublimation time may have to be adjusted slightly between each round to 
compensate for shifting sand in the sand bath. Alternatively, use of an oil bath may lead to 
more homogenous heat dispersion. 
Secondly, the amount of matrix at the bottom of the sublimator can vary. DAN 
matrix has a clumpy grey appearance and has a tendency to form large clusters. These 
clusters can be manually broken up and arranged in the bottom of the sublimator but cannot 
be completely eliminated. Large clusters of matrix will take longer to heat and sublimate 
than smaller pieces which can affect the end product of the sublimation. 
The vacuum output on the sublimation apparatus is another critical factor. Most 
sublimators are made with a single vacuum output onto which tubing is attached to connect 
it to the vacuum pump during sublimation. Because the pressure is being regulated on that 
side of the apparatus, there may be a slight unevenness of the matrix deposition, with more 
being deposited on the side with the vacuum output. This can be somewhat compensated 
for by shifting either the position of the apparatus in the sand, the position of the matrix in 
the bottom of the sublimator, or by changing the position of the slide/plate on the 
condenser. These factors are the main drawbacks of the sublimation technique and for this 
reason it is crucial to run a test slide through the sublimation process before running 
experimental sample so that time can be adjusted to compensate for these variables. 
Another reported drawback of sublimation is that the detection of higher mass 
analytes is limited by insufficient analyte extraction and/or mixing with matrix. A 
rehydration step after sublimation can help pull out these higher mass analytes to 
224 
 
circumvent this issue. This is typically achieved using a humidity chamber (Gemperline, 
Rawson & Li, 2014). However, in this protocol, a freezing step is added after sublimation 
which achieves the same purpose. The freezing and subsequent thawing (in a desiccator) of 
the samples before insertion in the MALDI instrument causes condensation to form on the 
surface of the sample which temporarily rehydrates the sample to allow for the extraction 
of higher mass lipids while preserving the tissue for analysis (Patterson, Thomas & 
Chaurand, 2014; Yang & Caprioli, 2013). 
Overall, sublimation is a highly sensitive and cost effective method of matrix 
application for the detection of lipids in MALDI IMS experiments. Indeed, our group has 
noticed significant improvements to IMS results when we shifted from using an air-spray 
method 3 to a sublimation method 4 for matrix deposition. The present protocol is 
appropriate for a number of lipid imaging applications but can be modified to suit the needs 
of the experimenter. 
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Appendix iv: MS/MS identification of gangliosides 
Tandem mass spectrometry (MS/MS) is often performed in MALDI-based experiments in 
order to identify molecules of interest within a mass spectrum based on their fragmentation 
patterns. Although there are a number of challenges associated with on-tissue MS/MS 
fragmentation of ions in negative mode, mostly related to diminished signal as compared to 
positive mode, MS/MS was performed, where possible, in order to confirm the identity of 
some of the major A-series gangliosides examined in this work. 
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Appendix iiii. On-tissue negative mode MS/MS identification of the major ganglioside 
species. A. GM1 d18:1 (m/z 1547); B. GM1 d20:1 (m/z 1572); C. GM2 d18:1 (m/z 1384); 
D. GM3 d18:1 (m/z 1181). MS/MS spectra produced the diagnostic fragmentation ions 
which corresponded to the data reported by Dufresne et al., 2016 (PMID: 27873002). 
Generally, fragmentation confirmed that sialic acid produced an intense peak at m/z 290 
with additional characteristic fragmentation of various sugar units (m/z 564, 727, and/or 
888). Characterization of gangliosides was performed on-tissue using a SCIEX 5800 
MALDI TOF-TOF mass spectrometer. DAN matrix was applied onto tissue sections by 
sublimation and negative ion MS/MS spectra were acquired. The detector multiplier 
voltage was maximized at 2.25 kV and a total of 900 shots per spectrum was acquired in a 
continuous stage motion. Following the external calibration at ±50 ppm mass tolerance, the 
precursor ion was isolated within an m/z window of 40 FWHM (full width at half 
maximum) resolution and fragmented in a posts-source decay mechanism. MS/MS mode 
experiments were conducted using 10 to 20% higher laser energy compared to the MS 
mode, in order to promote fragmentation of the analytes of interest for structural 
identification. 
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Appendix v: GM3 species with varied carbon length increase in response to 
stroke injury and are decreased with CQ treatment. 
Several peaks corresponding to GM3 species with varied carbons in their ceramide 
moieties were detected along with the d18:1 and d20:1 species reported in Figures 5.2 and 
5.3 of chapter 5. The masses of these GM3 species match what is reported in the Lipidmaps 
database for the d16:1 (m/z 1151), d22:1 (m/z 1234), and d24:1 (m/z 1262) species of 
GM3.  
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Appendix v: GM3 species with varied LCB increase in response to stroke injury and 
are decreased with CQ treatment. Quantification of MALDI IMS data along with 
representative MALDI images showing the abundance of GM3 species with 16, 22, and 24 
carbons in control (left), stroke injured, and stroke injured CQ treatment groups 3 and 21 d 
post-stroke. (A) GM3 species were increased within the stroke region compared to control 
levels in stroke injured rats 3 d post-stroke. This significant increase was prevented with 
CQ treatment in stroke injured rats. (B) GM3 species remained significantly elevated 
compared to controls within the stroke region 21 d post-stroke, however, CQ treatment was 
associated with a reduction in this increase compared to stroke injury alone. Group with 
different letter represent a statistical difference with p < 0.05 via Two-way ANOVA, Tukey 
post-hoc. 
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